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A third of epilepsy patients are resistant to anti-epileptic drug (AED) treatment leading to 
reduced quality of life, increased treatment costs and complexities surrounding polytherapy. 
The overall aim of this project was to explore dynamic network changes in the excitability and 
efficacy of AEDs in: acute models of epileptiform activity, chronic models of epileptogenesis 
and in resected human tissue, in vitro.  
Initial studies investigated the differences in the neuronal network excitability induced by 
0[Mg]2+ in rat brain slices prepared using either a standard NaCl-based aCSF or a sucrose-
based aCSF. Standard prepared slices were more excitable in comparison to sucrose-based 
aCSF prepared slices. Immunohistochemical investigations for parvalbumin demonstrated a 
reduction of interneurons in slices prepared in the standard way. There was little difference in 
response to combination AEDs, but this could be due to increased latency to first seizure in 
sucrose prepared slices. LTP was suggested to play a role in the resistance to AEDs. These 
results suggest sucrose prepared slices better preserve the neuronal network in vitro, and 
serve as a better acute model for assessing AEDs and mechanisms of resistance. 
Sucrose perfused slices were prepared from rodents that had undergone a refined chronic 
Li-pilocarpine-based model of epileptogenesis (RISE) to investigate the effects of six AED 
combinations on network excitability (24 hrs and 1, 5 and 12 weeks post status). Ictal-like 
discharges (IDs) were seen in significantly greater numbers in slices from RISE animals 
compared to age-matched controls. Additionally, RISE slices showed a consistently shorter 
latency to first seizure across all time points. Investigations exploring the efficacy of different 
AED combinations during epileptogenesis showed that the tiagabine and carbamazepine 
combination was most effective in reducing measures of ictal activity whilst the combination 
of lamotrigine and gabapentin was least effective. The resistance of different drug 
combinations was also variable depending on the stage of epileptogenesis. These findings 
suggest that vulnerable networks show underlying hyperexcitability even at stages when 
chronic behavioural seizures are not yet developed, and that the RISE model may provide 
insights into the variable efficacy of AEDs.  
In comparison to chronically epileptic rodent tissue, epileptic human tissue from the temporal 
lobe was not as excitable, and often required stronger ID inducing manipulations. Once IDs 
were initiated in vitro, inter-event intervals between seizures were longer in comparison 
rodent epileptic tissue. Discrepancies in excitability could be attributed to the likelihood that 
damage within human tissue is likely to be subtle, hence require more stimulation to induce 
ictal-like activity (Gabriel et al., 2004). 
There was a developmental trend for excitability, in response to low concentrations of the 
NMDA antagonist MK801 (100-300 nM), to decrease in controls and remain elevated in 
epileptic animals. The NOS inhibitor, 7-nitraindazole, failed to stop the induction of IDs by low 
concentrations of MK801. Additionally, low concentrations of MK801 had no significant 
effects on the frequency and amplitude of field IPSPs in control and SE latent period slices. 
Further investigations are required to elucidate the mechanisms of how altered excitatory 
drive of inhibition may promote network excitability in epilepsy. 
Overall, my findings suggest network changes in excitability occur at stages when chronic 
behavioural seizures are not yet developed, and that the RISE model may provide insights 
into the variable efficacy of AEDs and underlying mechanisms of epileptogenesis. 
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1.1 The Hippocampal Formation 
The temporal lobe has a variety of functions and has been implicated with auditory, olfactory, 
vestibular and visual sensory processing, as well as having roles in speech, memory and 
emotion (Kiernan, 2012).  Pathologically, the hippocampal formation has been associated 
with Alzheimer’s disease, temporal lobe epilepsy (TLE), schizophrenia, depression and 
anxiety disorders (Small et al., 2011).   
Definitions of the neuroanatomical organisation of the temporal lobe structures have varied 
considerably, depending on whether a cytoarchitectural or hodological viewpoint is adopted. 
In terms of cytoarchitecture, the cortex can be divided into the allocortex (3-4 cell layers) and 
the iso- or neocortex (6 cell layers). A translational layer, the mesocortex, exists between the 
allocortex and isocortex. This mesocortex can further be divided into the periallocortex 
(bordering the allocortex) and the pro-isocortex (bordering the isocortex). The periallocortex 
consists of five cell layers and has a densely packed layer two, but the laminar differences 
are not as clear as those in the pro-isocortex and isocortex (Witter, 1989; Lopes da Silva, 
1990). Cytoarchitectonically, the limbic cortex (infralimbic cortex, ventral anterior cingulate 
cortex, granular retrosplenial cortex, pre- and parasubiculum, medial perirhinal cortex and 
the entorhinal cortex) belongs to the periallocortex.  
From a hodological viewpoint the limbic cortex is strongly connected to the hippocampal 
formation (Witter, 1989). The hippocampal formation includes the dentate gyrus (DG), 
hippocampus, subiculum, presubiculum, parasubiculum and the entorhinal cortex (EC), as 
shown in figure 1-1. This neuroanatomical definition has withstood the test of time, and was 
first highlighted by Ramon y Cajal (1902) who emphasised the physiological significance of 
the hippocampus must be related to the EC as they were strongly connected. The EC serves 
to mediate inputs and outputs to the hippocampus, and hence represents a nodal point in 
cortico-hippocampal circuits (Canto et al., 2008).  
The circuitry of the hippocampal formation, starting from layer 2 of the EC, projects to the DG 
and CA3 via the perforant pathway and layer 3 of the EC projects to CA1 and the subiculum. 
The DG gives rise to mossy fibres which terminate in CA3. The CA3 pyramidal cells, in turn, 
project to CA1 via the Schaffer collaterals. The subiculum and CA1, both project to deep 
layers of the EC and the deep layers of the EC return projections to cortical areas which 
originally projected to the EC (Shepherd, 2004).  
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Figure1-1. The hippocampal formation. A. The anatomy and positioning of the hippocampal formation. B. A schematic representation of the 
morphology MEC cells (adapted from Canto et al., 2008). 
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1.1.1 The Entorhinal Cortex 
The EC plays a pivotal role in the processing of information in cortico-hippocampal 
interactions. Brodmann (1909) defined the EC as area 28, and subsequently further divided 
the EC into the lateral entorhinal cortex (LEC) (area 28a) and the medial entorhinal cortex 
(MEC) (area 28b). Using retrograde and anterograde tracers, it has been demonstrated that 
the main cortical inputs to the LEC come from the piriform cortex, insular regions and frontal 
regions (Burwell & Amaral, 1998). The connections are reciprocated back from the LEC, with 
the strongest output connection to the piriform cortex (Agster & Burwell, 2009). The main 
cortical input to the MEC comes from the piriform cortex. The MEC also receives cortical 
inputs from insular, occipital, parietal and cingulate regions. The strongest cortical output 
connection is to the piriform cortex.  
The main subcortical inputs to the LEC and MEC comprise of olfactory areas, the claustrum 
and the amygdala. These subcortical afferents project equally to the different layers of the 
LEC but not as equally to the different layers of the MEC. In the MEC, the olfactory areas 
strongly innervate the intermediate and medial layers, whereas the claustrum strongly 
innervates the lateral layers and the amygdala strongly innervates the medial layers. Other 
subcortical inputs to the EC include the septal nuclei, basal ganglia, dorsal thalamus, ventral 
thalamus and the hypothalamus (Kerr et al., 2007). The LEC provides strong output 
projections to the amygdala and olfactory areas of the subcortex, and both the MEC and LEC 
provide strong output connections to the basal ganglia. 
1.1.1.1 Entorhinal cortex intrinsic organisation 
The EC structure consists of six layers, which are clearly defined by the relative lack of cells 
in layer 1 and 4 (lamina dissecans). This type of lamination is characteristic of translational 
structures that connect the three-layered allocortex and the six-layered isocortex.  Exploring 
the electrophysiological functions of different EC laminations, Greenhill et al. (2014) 
investigated background synaptic activity of the rodent entorhinal cortex via spontaneous 
inhibitory and excitatory currents, as this activity modulates responsiveness to inputs and 
outputs, and alterations are perhaps important in synchronization. Using a combination of 
whole cell patch clamp recordings, VmD and charge transfer (CT) measurements, to account 
for presynaptic as well as post-synaptic conductances, it was demonstrated, spontaneous 
excitatory conductances were greatest in L3 and equal in L2 and L5. Inhibitory conductance 
was greatest in L2, slightly smaller in L3 but substantially lower in L5. However, overall there 
was a dominance of inhibition over excitation in all three EC layers investigated.  
These findings support earlier investigations showing a dominance of inhibition in the 
superficial EC layers (Gloveli et al., 1997b; Gloveli et al., 2001). Additionally, Woodhall et al. 
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(2005) demonstrated the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) 
in layer II occurred at four times the frequency of those recorded in layer V. The underlying 
mechanisms for this difference have been attributed to the presence of more inhibitory 
terminals in layer II cells. In support of this notion other studies have shown that layer II 
contained the highest number of GABA and GAD immunoreactive neurons in the EC (Kohler 
et al., 1985). However this observation cannot fully account for differences of inhibition in 
layer II and V, because the contribution of action-potential driven release was the same in 
both layers, which would be expected to be greater in layer II due to the larger number of 
inhibitory cells. Given this evidence, the likelihood of other possibilities such as differences in 
the release mechanisms or the control release of GABA terminals in the two layers maybe 
different. Complimentary to these investigations, Berretta and Jones (1996) illustrated layer V 
cells showed larger spontaneous excitatory postsynaptic currents (sEPSCs) which could 
occur in high frequency bursts and had a higher contribution from NMDA receptors, in 
comparison to layer II cells. 
Many of the axonal projections from deep to superficial layers have been suggested to be 
excitatory and serve both excitatory and feed-forward inhibition purposes (van Haeften et al., 
2003). There are also, greater morphological and electrophysiological differences between 
LEC and MEC layers 1 and 2 cells in comparison to layer 3 and 5 (Canto et al., 2008). 
1.1.1.2 Layer II 
Layer II of the MEC is densely packed with stellate cells (SCs), which are the most abundant 
cells in layer II, and pyramidal-like or non-SCs (Klink & Alonso, 1997a). Both types of cells 
have been considered as projection cells. Layer II SCs occasional project to layers III-VI, but 
their main targets are the DG and CA3 (Tamamaki & Nojyo, 1993).  The cell bodies of SCs 
are ovoid or trapezoid in shape and are preferentially located in the superficial part of layer II. 
SCs are further characterised by the presence of thick primary apical dendrites (5.6-7.5 μm), 
whilst the basal dendrites are thinner (2.3- 4.5 μm). Primary dendrites mostly arise from 
apical and basal locations of the soma, and when they do arise from the sides they tended to 
curve upwards, giving these cells and hour-glass shape appearance. Dendrites frequently 
ended with a bouquet of three to six spines.  
Non-SCs are smaller than the SCs and project to layers I and III (Klink & Alonso, 1997b). 
These cells are preferentially located in the deeper part of layer II, and cell bodies are ovoid 
or triangular in shape. Non-SCs present a radial distribution of dendrites. Many of these cells 
have one primary thick apical dendrite and several secondary apical dendrites which show a 
high density of dendritic spines. Basal dendrite projection was equal to apical dendrite 
projection and basal dendrites could be identified in the superficial part of layer III, this is one 
third the projection distance of SCs (Klink & Alonso, 1997a). 
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In terms of functionality, cells in layer II of the MEC display different electro-responsive 
properties and consequently different integrative properties that project to the hippocampal 
formation. SCs are highly electro-responsive, and application of subthreshold depolarising or 
hyperpolarising current pulse injections lead to the membrane potential obtaining an early 
peak followed by low sag. The presence of inward rectification during depolarising and 
hyperpolarising ranges indicates SCs are characterised by a non-linear voltage-current 
relationship. SCs seem to hold strong pacemaker properties which participate in the 
generation of theta and/or beta oscillations. In comparison to SCs, non-SCs display a less 
pronounced time-dependent inward rectification. Non-SCs also have longer action potential 
durations and do not generate subthreshold oscillatory activity, or spike clustering as SCs do 
(Alonso & Klink, 1993).  
Similarly, Jones (1994) also described two cell types (type I: 69 % and type II: 31 %) of the 
MEC layer II, of SC morphology. In response to hyperpolarising currents, type I cells 
displayed pronounced time-dependent inward rectification, and rebound depolarisation when 
stepped back to rest.  Inward rectification was abolished by bath application of Cs+, which 
also induced a negative shift in membrane potential, thus implying this hyperpolarising 
inward rectification is activated at resting potential. The rebound depolarisation was 
diminished by extracellular application of Cs+, Ca2+ channel blockers and TTX, suggesting 
this activity resulted from multiple conductances. 
In response to depolarising currents, type I cells demonstrated early peaks followed by a 
steady decline, and inward rectification was evident. Type I neurons showed spike frequency 
adaptation but there was no convincing evidence of intrinsic bursting, as suggested by 
Alonso and Klink (1993). Finally, rebound hyperpolarisations were apparent in response to 
positive current steps, even when action potentials were not evoked, and could be blocked 
by Cs+ which blocks Ih. 
In response to hyperpolarising currents, type II cells did show inward rectification, but only at 
very large negative deviations from the membrane potential, which would probably not be of 
significance with regard to normal cellular activity. Type II cells did not show anode break 
rebound depolarisations, like type I cells. Inward rectification in type II cells, was blocked by 
Cs+, but was not accompanied by Cs+ associated membrane potential changes, as was 
evident with type I cells, thus indicating this type of inward rectification is unlikely to be 
activated at resting potential and therefore lacks depolarising influence. 
In response to depolarising currents, type II cells displayed inward rectification, which could 
be reduced by TTX, and to a lesser extent Ca2+ channel blockers, indicating mediation by a 
subthreshold Na+ and Ca2+ currents. If action potentials were evoked, they were followed by 
slow and fast after-hyperpolarisations. Type II cells did not show intrinsic bursting properties. 
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Initial studies exploring the morphology, intrinsic membrane properties and pharmacology of 
layer II MEC cells, have clearly identified the main difference between these two types of 
principle cells is the presence of a pronounced inward rectification in abundant type I cells 
(Alonso & Llinas, 1989; Alonso & Klink, 1993; Jones, 1994; van der Linden & Lopes da Silva, 
1998). Since inward rectification in type I cells is present at rest, it is likely to drive rebound 
excitation, hence increased excitability in type I cells in comparison to type II. Jones (1994) 
further explored the pharmacology of the synaptic response of these two types of cells and 
found at low frequencies responses were controlled largely by inhibitory inputs, mediated by 
GABAA and GABAB receptors and at higher frequencies responses were dominated by 
excitatory inputs mediated by NMDA and non-NMDA receptors. Similarly, Gloveli et al. 
(1997b), demonstrated when layer II cells are stimulated with frequencies less than 5Hz no 
action potentials are produced, but when stimulated with frequencies more than 10Hz action 
potentials can be triggered during later stages of the stimulus train. As acetylcholine can 
modulate intrinsic EC conductances, it was further investigated whether cholinergic 
transmission effects on potential threshold during stimulation, but the muscarinic antagonist, 
atropine, had no effect on the frequency dependent induction of action potentials or on the 
firing threshold. Other explanations for the activation of layer II cells during high-frequency 
stimulations was suggested to include the down regulation of K+ currents in response to 
synaptic input and/or the removal of inactivation of sodium channels as a result of net 
hyperpolarisation induced by repetitive stimulation, thus lowering the firing threshold. In 
support of this explanation it has been shown that layer II cells possess K+ channels that are 
under strong metabolic control (Eder et al., 1991). 
Alonso and Klink (2003) compared layer II MEC and LEC cells, and demonstrated LEC cells 
had a higher input resistance and MEC cells had a much more pronounced rectification, 
probably due to larger Ih currents. MEC neurons also displayed larger depolarising after 
potentials and the ability to fire action potential doublets, presumably from larger low-voltage-
activated (LVA) calcium and sodium currents. 
More specifically, Tahvildari and Alonso (2005) identified three types of principal cells of layer 
II of the LEC: fan cells, pyramidal cell and multiform cells. Fan cells had the most depolarised 
resting membrane potential (-66 ± 0.58 mV), the highest input resistance (57.3 ± 4.9 MΩ) 
and the shortest action potential duration (1.28 ± 0.03 ms) of the three cell types.  Fan cells 
are the most abundant cells in layer II of the LEC and are relatively similar in morphology to 
layer II MEC SCs, as they displayed primary dendrites that branched over layers I and II. 
Like SCs, fan cells also showed time dependent inward rectification, but this was less robust 
in fan cells. Fan cells displayed inward rectification in the depolarising direction, indicating 
the presence of a persistent Na+ current. Despite similarities between fan cells and SCs, fan 
cells did not develop subthreshold oscillations, as evident in SCs.  Pyramidal cells of layer II 
LEC, display prominent dendritic trees that extend over layers I and II. Layer II MEC 
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pyramidal-like cells do show a less pronounced inward rectification in comparison to SCs, 
however, layer II LEC pyramidal cell did not show any presence of inward rectification. 
Multipolar cells had distinct morphology as dendrites of these cells were orientated in all 
directions, in comparison to the semi-circle orientation of fan cells. Dendrites of multiform 
cells extended over cell layers I, II and III. The electrophysiology of multiform cells was not 
significantly different from fan cells or pyramidal cells, and generally represented an 
intermediate of the other two types of layer II LEC cells. 
Layer II of the EC also consists of a variety of interneurons such as multi-polar-neurons 
(MPNs) (Kohler et al., 1986), bipolar cells (Germroth et al., 1991), fast-spiking basket-like 
cells (Jones & Buhl, 1993) and chandelier cells (Soriano et al., 1993). Despite the difficulty 
associated with obtaining reliable intracellular recordings from EC interneurons, Jones and 
Buhl (1993) evoked responses from layer II fast-spiking basket cells and further determined 
they predominantly exhibit prolonged NMDA-mediated synaptic excitation. Assuming these 
interneurons are GABAergic in nature, they provide inhibitory control over SCs and output to 
the DG. 
1.1.1.3 Layer III 
The wider layer III of the EC consists predominantly of loosely arranged pyramidal cells, the 
morphology and electrophysiological properties, of which, appear to be consistent across the 
LEC and MEC (Lorente de Nó, 1933; Tahvildari & Alsonso, 2005). Layer III pyramidal cells 
project to EC layers II and V, and the subiculum. 
Gloveli et al. (1997a) distinguished between four types of cell in layer III MEC. In terms of 
morphology type I and II were considered projection cells. Type I cells were the most 
commonly identified and displayed large-pyramidal-shaped cell bodies and extensive apical 
and basal dendrites. The apical dendrites always extended as far as the cortical surface and 
the basal dendrites extended twice as far in the horizontal direction in comparison to the 
vertical direction. Basal dendrite axons from this type of cell were detected in the deep layers 
of the EC and hippocampal CA1 area. Type II cells possessed non-spiny dendrites, whereas 
type I cells displayed spiny dendrites. Type II apical dendrites also projected to the cortical 
surface, but the first bifurcation was closer to the cell body. Type II basal dendrites were also 
presented as projecting to deep EC layers. 
Electrophysiologically, both types of projection cells displayed antidromic action potentials 
with deep layer stimulation and showed slow hyperpolarisation following short subthreshold 
trains. Differences between type I and type II cells manifested, as type I cells had higher 
input resistance and slow time constants (estimated time taken to reach 63 % of the steady 
state voltage deflection during -0.1 nA, 160-250 ms current pulses), whereas type II cells has 
lower input resistance and faster time constants. These cells differed in synaptic response 
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too, as type I cells did not present fast IPSPs and type II cells did not present long-lasting 
EPSPs.  
The two other types of cells identified were local circuit cells and could not be activated 
antidromically, by deep EC layer stimulation, nor did they display prolonged hyperpolarisation 
with stimulation of the LEC, MEC and subiculum. Type III cells were similar to type I cells; 
except the apical dendrites of this type did not reach the cortical surface, and apical and 
basal dendrites were non-spiny. Type III cells possessed local arborisation within layer III but 
also projected to the deep layers of the EC. Type III cells could further be differentiated from 
type I cells, by the presence of a lower firing rate and late occurring action potentials in 
response to current injection. Type IV cells projected predominantly to the superficial layers 
of the EC, but dendrites had been shown to also reach the cortical surface. Type IV cells 
possessed few apical dendrites but numerous basal dendrites. Deep layer stimulation did not 
activate these cells, antidromically, but instead evoke a fast IPSP which was not followed by 
a slow inhibitory component. Repetitive LEC stimulation did stimulate a depolarising 
response. 
Morphological and electrophysiological properties of layer III cells, clearly demonstrate their 
suitability in transferring information. The excitability of these cells in the presence of 
bicuculline (GABAA antagonist) emphasise the importance of inhibition preserving control 
within the network, and malfunction of this control may contribute to cognitive impairments 
associated with Alzheimer’s disease (Braak & Braak, 1991), epilepsy (Du et al., 1995) and 
schizophrenia (Jakob & Beckmann, 1994).  
1.1.1.4 Layer V 
Layer V of the EC receives input connection from the hippocampus and subiculum (Swanson 
& Cowan, 1977; Sorensen and Shipley, 1979), and provides long range output back to the 
neocortex (Insausti et al., 1997). In addition to connections outside the hippocampus, layer V 
also innervated the superficial layers of the EC (Lorente de No, 1933; Dolorfo & Amaral, 
1998). Exploring the morphological and electrophysiological properties of layer V cells, 
Hamam et al. (2000, 2002) identified three cell types of neurons: pyramidal, horizontal and 
polymorphic cells. Pyramidal cells were characterised by a primary apical dendrite which 
mostly branched at the distal extreme end, in layers I and II. Basal dendrites branched 
radially within layer V and VI. Horizontal cells are similar to pyramidal cells, as both have a 
primary apical dendrite and prominent basal dendritic tree, but the dendritic tree of horizontal 
cells projects mainly in the horizontal plane. Horizontal cells did not have a pyramidal-shaped 
soma, and the apical dendrites branch further down in comparison to pyramidal cell, in layer 
III and deep layer II. All dendrites of horizontal cells are sparsely covered with spines. In 
contrast to pyramidal and horizontal cells, polymorphic cells did not have a primary apical 
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dendrite, and instead displayed numerous primary dendrites that are radially distributed and 
also consist of short spines along the length of dendrites. 
Electrophysiologically, it is difficult to distinguish between the different cell types as they are 
similar in several parameters including: inward-rectification, spike-frequency adaptation and 
intrinsic oscillations. Subthreshold membrane potential oscillations were present, but this is 
unlikely to involve Ih, as layer V neurons displayed subthreshold membrane potential 
oscillations but not have Ih. Furthermore, time-dependent inward-rectification is minimal in 
layer V neurons (15 %) compared to layer II SCs (50 %). Subthreshold oscillatory activity is 
generally associated with pace-maker properties of layer II SC theta generation, but it is 
known that during prolonged periods of cortical activity the basal forebrain cholinergic system 
is activated, which significantly innervates layer V of the EC (Milner et al., 1983; Alonso & 
Kohler, 1984; Lysakowski et al., 1989).  
1.2 Epilepsy 
The EC is implicated with some of the earliest and most severe pathological changes in 
Alzheimer’s disease (Braak & Braak, 1991; Jansen et al., 1990). Additionally, 
neuropathological disruption of the EC has also been associated with the development of 
Parkinson’s disease and Down’s syndrome (Hirano & Zimmerman, 1962), schizophrenia and 
manic depression (Jakob & Beckmann, 1986), and temporal lobe epilepsy (TLE) (Rutecki et 
al., 1989; Deutch et al., 1991; Spencer and Spencer, 1994). 
Epilepsy has been recognised as one of the most common neurological disorders, affecting 
50 million people worldwide (Kwan & Brodie, 2006). Many different types of epilepsies can 
be distinguished based on affected areas, but 41 % of cases suffer from temporal lobe 
epilepsy (Curia et al., 2014). Although significant pharmacological advances have been 
made, one third of patients remain resistant to two or more antiepileptic drugs (AEDs), and 
are therefore drug refractory (Kwan & Brodie, 2006; French, 2007). Three main types of drug 
resistance can be observed clinically: Refractory de novo (patient never enters remission 
from the onset of epilepsy), progressive refractoriness (patient becomes seizure free initially 
but seizures recur and become uncontrollable), and wax-and-wane pattern (epilepsy 
alternates between being controlled and uncontrolled) (Schmidt & Loscher, 2005). Factors 
that can be used to predict responsiveness to antiepileptic drugs (AEDs) include: the type of 
epilepsy, aetiology and patient’s history of seizure frequency. Environmental factors that 
affect AED therapy include: trauma, drug exposure, genetics and metabolism. Resistance to 
AEDs is therefore multifactorial (French, 2007). 
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Epilepsy is a collection of conditions which have a range of underlying aetiologies and 
pathologies. The common feature amongst this cluster of conditions is recurrent seizures. 
Seizures are abnormal, excessive and synchronous excitation of neuronal populations. The 
Commission on Classification and Terminology of the International League Against Epilepsy 
(1981), states seizures can be broadly classified into partial seizures, which originate from a 
focal area of the cortex, or generalised seizures, which are widespread and involve bilateral 
cortical regions. As illustrated in figure 1-2, partial seizures can be further divided into simple 
partial (remain conscious) and complex partial seizures (impaired consciousness). There are 
several subclasses of generalised seizures: tonic, atonic, clonic, tonic-clonic, myoclonic and 
absence seizures. Generalised seizures which are preceded by partial seizures are known 
as secondary generalised seizures. The aetiologies of seizures can be broadly classified into 
several groups too: Idiopathic (mono-or poly-genetic origin), Symptomatic/ Secondary 
(known cause) and Cryptogenic (unidentified underlying abnormality).  
 
Figure 1-2. Seizure classification. Seizures can be classified into two broad categories 
partial and generalised seizures depending on brain regions involved. These two broad 
classes of seizure can be further subdivided depending on level of impaired consciousness 
and severity of symptoms. 
 
Seizure-like EEG events can vary considerably depending on the age of the individual or 
animal, the type of epilepsy, the stage of epileptogenesis, and so forth. These complexities 
make it difficult to temporally define seizure like events (SLE). EEG seizure activity can 
usually be classified into interictal and ictal like discharges. As illustrated in figure 1-3 inter-
ictal discharges (IIDs) consists of a single population burst of approximately 100 ms duration, 
whereas ictal discharges (IDs) consist of a series of population bursts and often lasts several 
seconds (Anderson et al., 1986; Avoli et al., 2002). Although seizure activity typically follows 
from inter-ictal through to ictal discharges, in vitro investigations have shown that often tonic-
clonic activity that characterises ictal-discharges (IDs) develops into late-recurring-
discharges (LRDs) which only display short bursts of tonic activity with prolonged exposure 
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to seizure inducing agents and extracellular ionic manipulations.  In contrast to IDs, LRDs 
have been shown to be resistant to several AEDs (Drier & Heineman, 1990; Sokolova et al., 
1998; Zhang et al., 1995). LRDs have been suggested by Zhang et al. (1995) to mimic status 
epilepticus (SE) development seen in vivo, in humans (Trieman et al., 1990) and animals 
(Lothman et al., 1989). 
 
Figure 1-3. Inter-ictal and ictal like discharges recorded in vitro from layer II mEC of a 
chronically epileptic Wistar rat. Tonic and clonic phases of the ictal event are indicated 
and the red arrow highlights inter-ictal events. Scale 1000 µV x 20 seconds. 
 
Refractory epilepsy has devastating effects for patients and their families. Many individuals 
suffer bodily injuries, psychiatric and social impairments that limit employability, likelihood of 
marriage and significantly decrease the quality of life (Brodie, 2005). Additionally, the cost of 
treating epileptic patients, and even more so for drug-resistant patients, represents a great 
burden to the healthcare system (Curia et al., 2014). Given these caveats, it remains an 
important challenge of epilepsy research to understand the pathophysiogenesis of TLE.  
1.2.1 Epileptogenesis 
One way in which research has attempted to gain insight into the mechanisms of epilepsy is 
to employ different kinds of animal models (see section 1.4 for further details). A particular 
advantage of some types of models is the ability to replicate, to some extent, the 
development of epilepsy, also known as epileptogenesis. Under these circumstances, 
researchers can investigate modifications that occur within the network at different stages of 
pathology which promote seizure activity, rather than just the mechanisms present once 
recurring seizures are established. Epileptogenesis has been defined as injury initiated, finite 
changes, which cause surviving neurons to generate abnormal, synchronous and recurring 
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epileptiform discharges, and which can be precipitated as clinically non-obvious epileptiform 
event or clinically obvious focal or generalised seizures (Sloviter & Bumanglag, 2013; Curia 
et al., 2014). The typical time course of epileptogenesis is as follows: initial neuronal injury 
followed by a seizure free latent period and finally the presence of recurring seizures (Dudek 
& Staley, 2012; Sloviter & Bumanglag, 2013). 
An important question surrounding epileptogenesis, is whether it is a continuous process. 
The step-function hypothesis suggests the mechanisms responsible for seizure generation 
are mature at the time of the first seizure, after the latent period. On the other hand, the 
continuous-function hypothesis suggests the mechanisms responsible for seizure generation 
are not complete at the time of the first seizure, and seizure frequency increases as 
epileptogenesis progresses. There is evidence to support both sides of the argument which 
highlights the complexity surrounding the temporal progression of epilepsy. In support of the 
continuous-function hypothesis many studies have highlighted that most rats do not reach a 
steady seizure frequency for many months (Hellier et al., 1998; Nissinen et al., 2000), 
although not all rodents show progressive activity (Gorter et al., 2001). 
Furthermore, it is likely many individuals will demonstrate non-convulsive seizure activity, 
during the latent period, before the first convulsive seizure (Bertram & Cornett, 1993; Bertram 
& Cornett, 1994). However, due to the clustering of seizure activity and lack of continuous 
recording during the latent period these preclinical features are unlikely to be detected. 
Clearly, some important epileptogenic mechanisms are active during and even after the 
latent period, with circuit alterations enough to induce epilepsy. Two mechanisms that have 
been proposed are: death of GABAergic interneurons and axon sprouting with consequential 
increases in excitation (Ben-Ari & Dudek, 2010). 
The latent period has been highlighted as a crucial stage in epileptogenesis, and has taken 
the focal spotlight of epilepsy research. The idea that “seizures beget seizures” (Gowers, 
1881) was one of the earliest proposed mechanisms of epileptogenesis. Since then, 
numerous supporting studies has shown seizures induce a cascade of events including 
neuronal damage (Crepel et al., 1989; Cossart et al., 2001; Dinocourt et al., 2003; Dudek & 
Shao, 2003; Kobayashi & Buckmaster, 2003) and formations of mossy fibres that establish 
aberrant glutamatergic synapses (Epsztein et al., 2005; Sutula et al., 1988; Tauck & Nadler, 
1985) (see Ben-Ari et al., 2008 and Nadler, 2003 for reviews). However, this view of latent 
period mechanisms of epileptogenesis has been contested by evidence from animal and 
clinical studies which show the occurrence of a seizure does not influence the longer term 
predisposition to more seizures, and whilst seizure frequency or seizure density may have 
some contribution to future predisposition of seizures given that many patients enter 
remission and discontinue medication other mechanisms must be contributing too (Berg & 
Shinnar, 1997; Evans et al., 2006; Hauser & Lee, 2002). 
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Moreover, others have questioned whether the latent period is an obligatory stage of disease 
progression. Slovitier and Bumanglag (2013) suggest hyper-excitability, disinhibition, loss of 
interneurons and entorhinal cortex neurons have direct epileptogenic mechanisms which are 
independent of secondary mechanisms that lead to disease progression. Based on such 
evidence it would seem apparent that the definition of latent period needs modification rather 
than the questioning of its existence. Furthermore, the model of epilepsy used and the 
temporal development span associated with it should be carefully considered when 
addressing research questions on the epileptogenesis process. As Slovitier and Bumanglag 
(2013) have suggested research can be divided into disease prevention (immediately after 
injury) and disease modification (once recurrent seizures begin, attempts are made to silence 
them). 
1.2.2 Seizure initiation and propagation 
Many temporal lobe seizure initiation and propagation studies have demonstrated the 
importance of the EC. In particular, it has been shown that IIDs are initiated in the CA3 
hippocampal area, and thereafter propagate to the EC via CA1 and the subiculum, and 
return to CA3 via the DG (Barbarosie & Avoli, 1997; Barbarosie et al., 2000; D’Antuono et al., 
2002). This has been confirmed by the laceration of the Schaffer collaterals which reduces 
the spread of CA3 initiated IIDs. Conversely, temporal analysis of the effects of 4-AP, 
pilocarpine, elevated K+ and Mg2+ free medium, alongside laceration of the perforant path, 
illustrate that IDs are initiated in the EC (Nagao, Alonso & Avoli, 1996; Avoli et al., 1996; 
Barbarosie & Avoli, 1997; Barbarosie et al., 2000; Walther et al., 1986; Wilson et al., 1988; 
Dreier & Heinemann, 1991; Bear & Lothman, 1993).  More specifically, the deep layers of the 
EC have been highlighted in the generation of IDs (Lopantsev & Avoli, 1998b; Jones & 
Heinemann, 1988; Jones & Lambert, 1990). In support of animal electrophysiological 
research, human studies (Rutecki et al., 1989; Deutch et al., 1991; Spencer and Spencer, 
1994) and intrinsic optical signalling studies (D’Arcangelo et al., 2001) have also implicated 
EC dysfunction.  
Jones and Heinemann (1988) further explored the synaptic and intrinsic responses of deep 
MEC cells in normal and magnesium-free mediums to gain insight into the cellular properties 
that give rise to the ictogenic region. Three cell types were characterised: non-bursting, 
bursting and fast spiking cells.  
Non-bursting cells displayed minimal late AHPs following repetitive firing, and 
accommodation of spike firing frequency was not prominent. AHPs and accommodation of 
spike firing frequency, are presumed to be dependent on a calcium-dependent-potassium 
conductance (Brown & Griffith, 1983; Hotson & Prince, 1980). Evidently, intrinsic inhibition in 
the form of spike frequency adaptation during repetitive firing and AHPs are not well 
expressed in the deep layers of the MEC.  
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Bursting cells displayed intrinsic bursting properties which was suggested to be due to 
activation of a persistent Ca2+ conductance that is often seen in other brain regions 
(Deschenes et al, 1982; Wong & Prince, 1978). Synchronous discharges of these cells, 
promoted by reciprocal excitation could drive epileptic activity in non-bursting cells.  
Generally the investigation of current voltage relationships in cells displayed ohmic 
characteristics (linear voltage-current relationship) but inward rectification in depolarising and 
hyperpolarising directions was seen. The hyperpolarising rectification was suggested to 
indicate the presence of inward K+ or mixed Na+/K+ conductance. Depolarising rectification 
was suggested to be a result of Na+ and/or Ca2+ conductance. Bursting and/or non-bursting 
cells displayed high threshold Ca2+ spikes, which may be synaptically activated, when 
penetrated with Cs/QX-314 containing electrodes, which blocks K+ and Na+ conductances. 
Such Ca2+ or Na+ inward currents would promote ictal activity. Following subiculum 
stimulation, deep layer EC cells did not display long-latency, long-duration IPSPs, as seen in 
neocortical cells, therefore suggesting feed-forward or recurrent inhibition is weak, or masked 
by powerful excitation. Evidently, the intrinsic and synaptic properties of MEC cells support 
the generation of seizure activity, and its location and function within the limbic system 
makes it an ideal candidate in seizure propagation. 
Several lines of investigation have further elucidated the active mechanisms during ictal 
activity. For example, pharmacological investigations have associated NMDA receptors in 
EC ID generation, as antagonists such as CPP (3,3(2-carboxypiperazine-4-yl)propyl-1-
phosphonate) abolish NMDA receptor mediated seizure activity in the EC, but have no effect 
on slow GABA receptors or CA3 IIDs (Avoli  et al., 1996). Although, NMDA independent 
paths of ID initiation in the EC, do appear to be present in younger rodent brains 
(Calcagnotto et al., 2000). More specifically, the potent AMPA/Kainate antagonist CNQX (6-
cyano-7-nitro-quinoxaline-2, 3-dione) abolishes IIDs and IDs.   
Additionally, intracellular recordings from EC cells, during ictal activity have reversal 
potentials which suggest the involvement of GABAA receptor mediated conductance 
(Lopantsev & Avoli, 1998a). Similarly, residual deep EC activity can be extinguished with the 
application of the GABAA receptor antagonist, bicuculline methiodide (D’Arcangelo et al., 
2001).  
The neuronal mechanisms active during ictal and interictal activity are to some extent 
understood, however the mechanisms underlying the transition from IIDs to IDs remain 
obscure (Avoli et al., 2002). Nevertheless, IIDs have been postulated to control rather than 
sustain IDs. When the Schaffer collaterals are cut, ictal activity in the EC and DG is 
accompanied by large elevation in K+, which precedes the ictal events. These elevations are 
not seen in CA3, suggesting this area inhibits IDs (Barbarosie et al., 1997). Moreover, these 
findings are not replicable in younger animals, further suggesting age-dependent 
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mechanisms (Calcagnotto et al., 2000). Seizure activity is not only accompanied by 
extracellular elevation of K+, but also decreases in Ca2+ (Antonio et al., 2016; Gloveli et al., 
1995). 
1.3 Models of seizures and epilepsy 
The pioneering work of Yamamoto and McIlwain (1966) with the development of the brain 
slice preparation, permitted a more thorough, multidisciplinary, understanding of 
neurobiological processes and activity. Like many scientific techniques, the in vitro brain slice 
preparation has many advantages and disadvantages (see chapter 3 for further discussion), 
that researchers should take into consideration when forming a hypothesis. However, in 
terms of research on seizures and epilepsy, advantages of the in vitro brain slice preparation 
include: the ability to investigate seizure initiation and propagation in combined hippocampal-
entorhinal slices, apply pharmacological manipulations to understand the mechanisms of 
seizure generation and cessation and test the efficacy of different antiepileptic drugs.  
In vitro investigations of seizures and epilepsy have typically taken two approaches with the 
use of either acute or chronic models. Acute models require ‘normal’ brain slices to be 
prepared, thereafter manipulations are carried out to induce seizures. In chronic models, 
brain slices are prepared from chronically epileptic rats which have undergone procedures 
that initiate the process of epileptogenesis. Slices produced from these processes have the 
advantage of a modified network architecture which more closely represents the pathological 
condition. Despite the impressive range of protocols available to carry out such 
investigations, cautions regarding the interpretation of results should be made. For example, 
as the brain slice preparation method severs many intrinsic and extrinsic connections, it is 
not surprising that, generally, seizures do not occur spontaneously and require 
pharmacological manipulation to induce them. Additionally, acute in vitro studies have 
demonstrated interneurons play a fundamental role in the after-discharge of ictal-like events, 
but chronic models have demonstrated that interneurons are lost as a result of the epileptic 
condition, therefore conclusions and generalisations about epilepsy and seizure mechanisms 
made from such studies, although very insightful, should be treated with caution or only firmly 
made when combined with other techniques such as in vivo studies. Although there a 
numerous types of acute and chronic models of epilepsy (as illustrated in figure 1-5), only the 
main acute models (0[Mg]2+, low calcium, high potassium, 4-AP and electrical stimulation) 
and main chronic models (the pilocarpine, kainate and kindling models) shall be considered 
in further detail. 
 
 
 
32 
 
 
Figure 1-5. Animal models of epilepsy (Adapted from Fisher, 1989). There are many 
different types of animal models, use is dependent on the hypothesis. 
 
1.3.1 Acute Models 
1.3.1.1 Magnesium free model of acute seizures 
Since the development of magnesium-free model of seizure induction in the early 1980s, the 
model has been widely used in the testing of antiepileptic drugs (Albus et al., 2008; Anderson 
et al., 1986; Coulter & Lee, 1993; Walther et al., 1986). The magnesium-free model of 
seizures also has clinical relevance as there is evidence that patients with generalised tonic-
clonic seizures have Mg2+ deficits in serum and cerebrospinal fluid (Afzal et al., 1985; Govil 
et al., 1981), and has even been suggested as the cause of seizures in some humans 
(Arnold et al., 1983; Nuytten et al., 1991). Additionally, anticonvulsant properties of Mg2+ 
have been demonstrated by intravenous injection in animal models of epilepsy (Borges & 
Gucer, 1978).  
Under normal physiological conditions Mg2+ ions serve to maintain a block on NMDA 
receptors (see figure 1-6). When extracellular Mg2+ is reduced this block is removed and a 
potent increase in excitability is initiated, and SLEs precipitate. The mechanism through 
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which the magnesium-free model of seizures works is through the facilitation of NMDA 
receptors and a decrease in the surface charge screening near voltage activated channels 
as a result of a reduction of positively charged Mg2+ ions in the extracellular solution 
(Heinemann et al., 2006; Iseav et al., 2012).  
There are seven subunits of NMDA receptors: GluN1, GluN2A, GluN2B, GluN2C, GluN2D, 
GluN3A and GluN3B. NMDA receptors are tetramers which are commonly composed of 
GluN1 and GluN2 subunits (Candy et al, 2001; Clarke et al, 2013). NMDA receptors play 
important roles in excitotoxicity, excitatory synaptic transmission and plasticity, as a 
consequence of their unique features which include: slow activation-deactivation kinetics, 
high permeability to Ca2+ and a voltage-sensitive block by extracellular Mg2+ (Candy et al., 
2001). The importance of increased NMDA conductance in seizure activity initiation has been 
demonstrated by SLEs induced by the magnesium-free model, being stopped initially (<2 hrs 
after first SLE) with application of NMDA receptor antagonists or by restoration of Mg2+ in the 
extracellular solution. However, cessation of SLEs with such agents at later phases often fail 
to have the same effects, suggesting the presence of a long lasting synaptic potentiation has 
formed (Anderson et al., 1986; Derchansky et al., 2004; Dichter & Pollard, 2006; Stanton et 
al., 1987).  
 
Figure 1-6. A schematic representation of a NMDA receptor. Modulatory (green) and 
glutamate binding sites (yellow) are shown, where polyamine, glycine and NMDA antagonists 
are effective, respectively. The Mg2+ site is shown in blue. The site where channel blocking 
agents, such as PCP, are effective is marked in red.  
The role of surface charge screening in the magnesium-free model of seizure generation is 
evident but not as well understood (Isaev et al., 2012). Cell membrane surface charge is 
produced by phosphates, sialic acid, charged amino acids, charged lipids and other 
hydrophilic residues of channel proteins (Messner et al., 1985; Iseav et al., 2007). The 
electrical double layer ‘is the array of charged particles and orientated dipoles which is 
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thought to exist at every interface’ (Grahame, 1947). As illustrated in figure 1-7, the cell 
surface is predominantly negatively charged, and so attracts a layer of positive ions (Stern 
layer). As positive ions are large, the cell surface charge is not completely neutralised and 
more positive ions and a few negative ions are attracted (Gouy-Chapman layer). This 
additional layer of ions is further from the cell surface and can be displaced. The diffuse 
double layer theory has traditionally been applied to non-biological substances such as 
mercury and clay, but a comprehensive description of electrochemical potentials at the 
surface of biomolecules has been given by Dukhin (1993). There are two types of 
electrostatic interactions between the negatively charged cell surface and cations. Firstly, the 
cations can bind to cell surface when hydration has been removed. In this instance the cation 
complex is immobile. Secondly, hydrated cations, found a few angstroms from the cell 
surface can screen the cell surface to repel opposing charges. Here, cations remain mobile 
and unbound (Bara et al., 1989).  
 
Figure 1-7. A schematic representation of the diffuse double layer theory and surface 
charge screening and binding. A. The head groups of phosphatidylserine and 
phosphatidylinositol (two phospholipids of plasma membrane) are negatively charged, hence 
a predominance of negative charge on the cell surface. This negative charge attracts a well 
ordered layer of positive ions, also known as the stationary or Stern layer. As positive ions 
are large they do not fully neutralise the surface charge, and the residual anionic charge 
attracts more positive ions. Additional positive ions are further away from the cell surface and 
therefore weakly attracted. This of additional layer of positive ions is known as the diffuse 
layer or Gouy-Chapman layer and is less ordered and more moveable. B. The graph 
demonstrates potential differences at the cell surface (green dot), Stern layer (purple dot) 
and Gouy-Chapman layer (orange dot). The potential at the slipping plane (where the Gouy-
Chapman layer and bulk solution meet, is also known as the zeta potential. Ions at the 
diffuse layer can often be displaced, and the change in potential measured. C. A schematic 
representation of surface charge screening (top) and binding (bottom). 
 
Whilst the opening of NMDA receptors in low Mg2+ is a key determinant of hyperexcitability, 
so too, is the altered charge screening, which creates conditions where the membrane is 
much more excitable because the Stern and Gouy layers are not there to screen/shield the 
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membrane and this can shift voltage dependences (activation and inactivation) of many ion 
channels toward hyperpolarized potentials (Frankenhaeuser and Hodgkin, 1957; Hille, 2001). 
Divalent cations such as Mg2+ and Ca2+ are negative regulators of excitability and so their 
loss directly excites cells as well as altering NMDAr function. 
Early investigations demonstrated how the Mg2+ binding effects on the NMDA receptor 
affects its kinetics. The membrane depolarisation evoked by NMDA receptors was 
accompanied by an increase in resistance, when neurons were bathed in a Mg2+ containing 
medium. The channel blocking effects provided by the presence of Mg2+ is highly dependent 
on membrane potential, as antagonist effects were strong at -60 mV but practically absent at 
+20 mV.  In contrast, when neurons were bathed in Mg2+ free medium, NMDA evoked 
depolarisation was accompanied by a decrease in resistance (Mayer et al., 1984). Removal 
of the Mg2+ block, promotes the influx of Ca2+ and Na+ ions (Kandel et al., 2012; Malenka & 
Nicoll, 1999).  
To further investigate the origin of Mg2+ conductance effects, voltage-clamp experiments 
were conducted. Examinations of current-voltage relationships provide insight into 
conductance of different channels. Typical ohmic conductors display a positive linear I-V 
relationship. However, many channels have non-linear I-V relations as membrane 
conductance changes depending on voltage, a property called rectification (Hille, 2001). The 
current-voltage relationship of the NMDA response has a negative slope over the -70 to -
35mV potential range, indicating the conductance activated by NMDA becomes smaller on 
membrane hyperpolarisation. Conversely this negative slope is not present in a low Mg2+ 
medium, indicating the removal of Mg2+ reduces the voltage sensitivity of the conductance 
activated by NMDA (Mayer et al., 1984). Overall, deviations from physiological 
concentrations of Mg2+ are potent modulators of neuronal excitability, as is evident from 
differences in conductance curves. Additionally, replacement of depleted Mg2+ with Ca2+ has 
been shown to decrease the amplitude of ictal events, thus supporting the notion that 
reduced surface charge screening contributes to the epileptic-like effects seen in the 
magnesium-free model (Jones & Heinemann, 1988).  
Despite the importance of the EC highlighted by the Mg2+ free model, SLEs have been 
reported to have differential properties in different parts of the brain. For example, the 
epileptiform pattern seen in the frontal cortex is much shorter and does not include after-
discharges commonly seen on temporal lobe regions, and activity seems to spread much 
faster than in limbic regions (Armand et al., 1998a). SLEs in the EC, subiculum and temporal 
neocortex are characterised by negative potential shifts of up to 30mV, which are 
superimposed by high-frequency, small amplitude bursts, after which clonic after-discharges 
follow. In combined hippocampal-entorhinal slices SLEs can often be seen to start in the EC, 
but spread to other areas at a slower rate in comparison to low Ca2+ induced SLEs 
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(Buchheim et al., 2000). Additionally, different patterns of seizure spread can be seen when 
a low Mg2+ medium is used to initiate SLEs in chronically epileptic tissue. For example in 
pilocarpine treated animals, seizure spread can be initiated by the DG or subiculum, whereas 
in kindled animals seizure spread is preferentially through the DG (Behr et al., 1998). 
Moreover, SLEs induced by low Mg2+ show age-dependent differences as latency to first SLE 
has been shown to be shorter in immature rodents in comparison to adult rodents (Gloveli et 
al., 1995). These effects can be explained by less efficacious GABAergic inhibition. In the 
immature brain, GABA can act in an excitatory rather inhibitory manner. Increased 
expression of the sodium-potassium-chloride cotransporter, (NKCC2), and reduced 
expression of the chloride exporter (KCC2) during early development leads to an increased 
intracellular Cl- concentration, therefore when GABAA receptors are activated an efflux of Cl- 
ions occurs which produces depolarisation rather than hyperpolarisation (Ben-Ari et al., 
1989; Rakhade & Jensen, 2009). It has also been highlighted that NMDA expression in the 
immature brain is higher (Chahal et al., 1998) and less responsive to Mg2+ block (Kleckner & 
Dingledine, 1991). Levels of Na+, K+ ATPase levels are sufficiently low in the immature brain, 
further contributing to increased susceptibility of ictal discharges (Fukunda & Prince, 1992). 
1.3.1.1.1 Long Term Potentiation 
The induction of LTP fundamentally relies on the activation of postsynaptic NMDA receptors. 
Glutamatergic activation of postsynaptic AMPA receptors allows intracellular entry of Na+ and 
K+ ions and glutamatergic activation of postsynaptic NMDA receptors promotes influx of Ca2+ 
and Na+ ions once the Mg2+ block has been removed. Metabotropic glutamate receptors 
have also been shown to enhance LTP via activation of protein kinase C (PKC) (McGuinness 
et al., 1991).  
As described in section 1.4.1.1, the removal of Mg2+ from the extracellular environment, 
removes the NMDA receptor block and facilitates NMDA receptor conductance. The critical 
rise in intracellular Ca2+ as a result of NMDA receptor activation, triggers LTP through a wide 
range of cellular signal transduction pathways. Despite this number of protein kinases 
involved in LTP, overwhelming evidence has a suggested an important role of Ca2+ activated 
α-calcium-calmodulin-dependent protein kinase II (CamKII) in initiating LTP effects. CamKII 
is one the most abundant proteins in neurons and is expressed pre- and post-synaptically, 
but expression has been found to be higher in postsynaptic cells where it would be ideally 
located to respond to changes in calcium concentration (Flink & Meyer, 2002; Lynch, 2004). 
Activation of CamKII leads to AMPA receptor phosphorylation which ultimately increases 
AMPA receptor conductance (Barria et al., 1997). 
Brief, controlled periods of Ca2+ elevations occur during physiological processes associated 
with plasticity changes of LTP in learning and memory (Gnegy, 2000; Malenka & Nicoll, 
1999; Tzounopoulos & Stackman, 2003; West et al., 2001). However, at the other of the 
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spectrum pathological, uncontrolled and irreversible elevations in Ca2+ lead to neuronal 
death. The middle ground, appears to be a characterised by a less severe epileptogenic 
injury whereby exposure to prolonged but reversible elevations in Ca2+ trigger pathological 
plasticity changes, leading to chronic epilepsy and DRE (DeLorenzo et al., 2005). 
1.3.1.2 The low calcium model 
The first in vitro demonstration of low extracellular Ca2+ leading to the induction of SLEs, was 
carried out by Jefferys and Hass (1982). The CA1 area of the hippocampus seemed to be 
particularly sensitive to the low Ca2+ model. Seizure events become apparent as 
simultaneous synaptic activity is blocked and elevation in extracellular K+ (9-10 mM) occurs. 
The mechanisms through which these effects can be seen are reduced surface charge 
screening and a reduction in Ca2+ dependent K+ conductance, as indicated by increased 
input resistance (Haas & Jefferys, 1984; Heinemann et al., 2006). Similar seizure inducing 
effects can be seen in vivo with Ca2+ chelating agents, such as EGTA (Feng & Durand, 
2003). Furthermore, seizure inducing effects of low Ca2+ can be reversed by restoring 
extracellular calcium. Unlike the Mg2+ free model of seizures, which display tonic-clonic firing, 
SLEs of the low Ca2+ model only display tonic activity (Heinemann et al., 2006). 
The rate at which seizure activity spreads in the low Ca2+ model, is relatively slow (Konnerth 
et al., 1984). Like the low Mg2+ model, the low Ca2+ model shows age-dependent effects, with 
a lower threshold for induction of SLEs in younger rodents (Heinemann et al., 2006). This 
model is not as effective in human or in other brain regions unless accompanied by further 
ionic concentration modifications, such as the increase in extracellular K+ (Schweitzer et al., 
1992). Such differences may possibly be a result of less compact cellular spatial 
arrangement, in comparison to CA1. 
1.3.1.3 The high potassium model 
As many early studies on seizure activity identified extracellular rises in K+ accompany 
seizure activity, it is not surprising such modifications were later used as a model of acute 
seizure induction. Jensen and Yaari (1988), first, mimicked in vitro SLEs by raising the 
concentration of extracellular K+ from 3.5 mM to 8 mM. As highlighted by Traynelis and 
Dingledine (1988), mechanistically high extracellular K+ causes: a decrease in K+ mediated 
AHPs amplitude, a decrease in GABAergic IPSP amplitude as a consequence of increase 
intracellular Cl-, depolarisation of pyramidal cells, reduced spike threshold. A reduction in the 
amplitude of IPSPs and pyramidal cell firing, activate NMDA receptors. As more cells are 
recruited, extracellular K+ raises further, producing swelling and reducing the extracellular 
space, resulting in concentrated effects of high K+. As IIDs arrive at CA1, and high 
extracellular K+ is not effectively removed from the extracellular space, seizures are initiated. 
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The high K+ model produces ictal events with durations of 20-90 seconds, at regular intervals 
of 1-8 minutes. Ictal events showed tonic and clonic patterns of firing (Traynelis & Dingledine, 
1988). The high K+ model has been reported to preferentially induce SLEs in CA1 (Traynelis 
& Dingledine, 1988), and IIDs initiated in CA3 have been suggested to contribute to the 
initiation of IDs in CA1. It has been proposed reason for preferential CA1 activity include: 
increased susceptibility to hypoxia in the CA1 (Aitken & Schiff, 1986), lower Na+K+ ATPase in 
CA1 (Haglund et al., 1985) and higher NMDA receptor density in CA1 in comparison to CA3 
(Monaghan & Cotman, 1985). On the other hand, the investigation of SLEs hippocampal and 
parahippocampal regions have shown both CA1 and the EC are the most susceptible to high 
K+ induced SLEs, whereas the DG is least susceptible (Bear & Lothman, 1993). 
Nevertheless, induced SLEs occur in the DG when high K+ is combined with low Ca2+ 
(Schweitzer et al., 1992). 
1.3.1.4 The 4-Aminopyridine model 
4-aminopyridine, has been shown to induce SLEs in vitro in the temporal lobe (Avoli et al., 
1996; Rutecki et al., 1987; Voskuyl & Albus, 1985) and in humans (Lundh et al., 1984). 
Mechanistically, 4-AP blocks voltage-gated K+ channels (Llinas et al., 1976). As a 
consequence of K+ blockade, direct or indirect Ca2+ influx is facilitated. This has been the 
proposed explanation for augmentation of inhibitory and excitatory neurotransmitter release 
by 4-AP (Tapia & Sitges, 1982). 
Profile analysis of ictal discharges in combined hippocampal-entorhinal slices shows 4-AP 
induced ictal events are initiated in the deep layers of EC (Avoli et al., 1996). This finding is 
congruent with other models such as: low Mg2+, GABAA antagonists (Jones & Lambert, 
1990), high K+ (Bear & Lothman, 1993) and pilocarpine (Nagao et al., 1996). Ictal discharges 
in this model have been shown to last between 20-480 seconds, with intervals of 71-1000 
seconds and displays both tonic and clonic patterns of firing during IDs (Avoli et al., 1996). 
Once again, IIDs are initiated in the CA3 and propagate to CA1 but not to the EC. In this 
model, short recurrent discharges dominate in CA1 and CA3. Short recurrent discharges are 
thought to be similar to IIDs, but are not associated with increases in extracellular K+ 
(Bruckner & Heinemann, 2000; Sokolova et al., 1998). Additionally, short recurrent 
discharges do not respond as effectively as IDs to AEDs (Bruckner & Heinemann, 2000). 
1.3.1.5 The electrical stimulation model 
Electrical stimulation trains (60 Hz, 2 seconds) at 10 minute intervals have been applied to 
combined hippocampal-entorhinal slices and used as an acute model of seizures (Rafiq et 
al., 1993). Stimulation intensity of trains were four times the voltage required to trigger field 
potentials, at 8-10V. Initial electrical stimulation of the Schaffer collaterals in CA1 prompted 
an after-discharge of around 10 seconds. This initial activity was comprised of rapid tonic 
discharges, but following an additional 2-4 stimulations, elicited activity began to show clonic 
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discharges too. Additionally, after-discharges increased in duration, with successive 
stimulation trains, before plateauing at 40 seconds with 5-9 stimulations.  
Following the initial after-discharge, secondary discharges began to appear. Both, primary 
and secondary discharges could be recorded at hippocampal and parahippocampal sites. 
Latency of secondary discharges was the shortest in the DG, followed by CA3, CA1 and the 
EC. Lesions of the mossy fibre and subicular region demonstrated secondary discharges 
were dependent in the hippocampal-entorhinal connections. Discharges were sensitive 
NMDA antagonists. An advantage this model has over other acute models, is the 
mechanisms of seizures can be assessed without overtly obvious modifications to the 
inhibition and ionic medium of slices. 
1.3.2 Chronic Models of Epilepsy 
1.3.2.1 The pilocarpine model 
The pilocarpine model of epilepsy belongs to the SE group of models and was developed 
shortly after the kainate model (Nadler et al., 1978) and the kindling model (Goddard et al., 
1969). These models represent three of the most widely used models in epilepsy research 
(Pitkänen et al., 2006). The pilocarpine model can be regarded as a model of both, acute and 
chronic seizures, and was first described by Turski et al. (1983). Turski et al, administered 
methyl scopolamine nitrate (1 mg/kg s.c) 30 minutes prior to all doses of pilocarpine to 
reduce peripheral cholinergic effects along with diazepam (10 mg/Kg i.p.). Methyl 
scopolamine is used to block the peripheral cholinergic effects of pilocarpine, and as it does 
not cross the BBB, it does not interfere with the development of SE. Diazepam is used to 
reduce SE duration. 
Turski et al. (1983), thereafter, administered different pilocarpine doses (100/200/400 mg/Kg 
i.p.) into male Wistar rats (200-220 g), and the progression of seizures were classified 
according to the Racine scale (1972). Behavioural changes were time and dose dependent, 
with rodents who had received lower doses of pilocarpine, taking longer to show behavioural 
effects. Similarly, in animals who had received lower doses (100 mg/Kg) of pilocarpine, 
damage was confined to the piriform cortex and anterior olfactory nuclei, but in animals that 
had received larger doses of pilocarpine, further profound neuropathological damage was 
observed. 
Animals that received 300-400 mg/Kg of pilocarpine were motionless for 5-10 minutes after 
pilocarpine administration and displayed oral-facial movements, salivation, eye-blinking, 
twitching of vibrissae, and yawning. This activity persisted for 18-45 minutes. Thirty minutes 
after injection limbic motor seizures with intense salivation, rearing, upper extremity clonus, 
and falling were observed every 5-15 minutes and lasted up to 2 hours. Around 60 % of the 
rats successfully developed SE (Cavalheiro et al., 1991). Animals entered a post-ictal 
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unconscious state for 1-2 days following remittance of SE, which occurred 5-6 hours after 
pilocarpine administration. Following SE, body weight decreased (10–20%), but returned to 
pre-treatment states after 1 week (Turski et al., 1989). Mortality rates were reported to be 
around 30–40%. 
Since the initial description of the pilocarpine model, various improvements and 
considerations have been made, consequently leading it to be considered a relevant animal 
model of the human disease years after its initial characterisation (Curia et al., 2008). 
Nonetheless, as researchers develop different aims in epilepsy research, differences occur in 
several variables of the pilocarpine model which ultimately affects findings. For example, 
route of pilocarpine administration, species, strain, gender and age of animals add variability 
in the induction and development of epilepsy and findings associated with such changes 
(Curia et al., 2008). Additionally, different doses of pilocarpine affect the length of the latent 
period (Cavalheiro et al., 1991; Liu et al., 1994). The length of SE and the induction of 
various arresting drugs (e.g. diazepam, 10 mg/Kg and pentobarbital, 30 mg/Kg) also affects 
the length of the latent period with the literature showing considerable variability (Lemos & 
Cavalheiro, 1995 cf Biagini et al., 2006). Similarly, the extent of damage and activation of 
epileptogenic mechanisms varies with SE duration (Biagini et al., 2006, 2008; Du et al., 
1995; Wozny et al., 2005). 
Pilocarpine has also been used in combination with other drugs such as: lithium (Honchar et 
al., 1983), N omega-nitro-L-arginine methyl ester (Starr & Starr, 1993), picrotoxin (Hamani & 
Mello, 1997), cycloheximide (Longo & Mello, 1997) and MK-801 (Hughes et al., 1993). 
However, the lithium-pilocarpine has been the most extensively used. Lithium is administered 
24 hours before pilocarpine administration and reduces the dose of pilocarpine (30 mg/Kg) 
required to induced SE, presumably by increasing sensitivity to pilocarpine (Clifford et al., 
1987). The addition of lithium pre-treatment has also increased success of inducing SE. 
Moreover, further improvement of mortality rates has been made, without affecting 
electrographic seizures, by administering the central muscle relaxant, xylazine, after SE 
induction (Yang et al., 2006; Thompson et al., 2007). Evidently, there are many variations 
within the pilocarpine model of epilepsy; however the refinements have significantly 
increased the quality and ethical standards of animal research. 
In our laboratory, further refinements to the lithium-pilocarpine model have been made, 
leading to the development of the Reduced-Intensity-Status-Epilepticus (RISE) model 
(Modebadze et al., 2016). Two major innovations of this model are the use of xylazine during 
the early development of SE, and the use of a ‘stop’ cocktail which comprised of a mGluR5 
antagonist (MPEP), the non-competitive NMDA receptor antagonist (MK-801) and diazepam 
being administered an hour after SE had been induced. Together these improvements led to 
a substantial reduction in mortality, below 1 %, and retained epileptogenic morbidity. This 
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model was developed with the aim to improve the quality of epilepsy research and increase 
efforts to implement the research ethics principles of 3R’s (reduction, refinement and 
replacement) more effectively. The refinements to the induction procedure led to a reduction 
in animal suffering and a reduction in the number of animals required, as more animals 
survived the induction process. These findings exemplify the strengths of this pilocarpine 
model over others whereby mortality can be as high as 90 % (Curia et al., 2008). Moreover, 
by limiting the time period of SE, the intensity of SE was reduced which consequently 
reduced the level of neuronal damage. As highlighted by Sloviter (2005), prolonged periods 
of SE lead to global cortical damage, inflammation and cerebrovascular damage which do 
not accurately imitate the natural progression of epilepsy.  
Pilocarpine has been suggested to induce SE through activation of M1 and M2 muscarinic 
receptors subtype. M1 receptor knockout mice do not develop seizures from pilocarpine 
administration (Hamilton et al., 1997). Additionally, the muscarinic antagonist, atropine, can 
block pilocarpine induced SE, but only before seizures have been initiated. After seizure 
initiation the maintenance of seizure activity relies on other mechanisms (Clifford et al., 
1987). Activation of these receptors modifies several signalling pathways through a cascade 
of reactions which ensure excitability and epileptic pathology is initiated and maintained. 
Activation of M2 receptors, leads to a decrease of neuronal excitation as adenylate cyclase is 
inhibited which in turn reduces the release of ACh (Smolders, 1997). The activation of M1 
receptors, in contrast leads to a much more complex set of reactions (See Figure 2 from 
Cavalheiro et al, 2006 for overview). Firstly, phospholipase C is activated with leads to 
production of diacylglycerol and inositol triphosphate (IP3), this in turn alters Ca2+ and K+ 
conductance resulting in increased excitability (Segal et al., 1988).  
Additionally, the reduction in ATPase activity alters the homeostasis of ionic environments to 
promote excitability and seizure activity. For example, Fernandes et al. (1996) noted a 
reduction of Na+ K+ ATPase during SE and the latent period but and increase during chronic 
epilepsy. Glutamate toxicity induces abnormal NMDA conductance which increase 
intracellular levels of Ca2+ which activates the formation of free radicals which in turn alters 
ATPase activity. Compensatory upregulation of cytosolic Ca2+, through Ca2+ ATPases 
(SERCA and PMCAs) can be seen at initial insult, but 5 hours post SE reductions in ATPase 
activity is evident, thus promoting loss of Ca2+ homeostasis and cell death (Funke et al., 
2003). High concentrations of Ca2+ lead to increases in glutamate release, which in turn 
activate AMPA and kainate receptors leading to increased intracellular Na+ and Ca2+, which 
in turn influence the Mg2+ block on NMDA receptors, allowing glutamate conductance to 
further increase and exacerbate excitability (Cavalheiro et al., 2006). Glutamate conductance 
at NMDA receptors also encourages expression of GAP-43, which leads to mossy fibre 
sprouting and plasticity (McNamara & Routtenberg, 1995). Status epilepticus has further 
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been associated with increases in noradrenaline and serotonin, and decreases in dopamine 
utilisation (Cavalheiro et al., 1994). Metabolic processes associated with the use of these 
neurotransmitters, release free radicals which have been associated neurodegeneration 
(Bellissimo et al., 2001). Evidently, all these alternations lead to modified neurotransmission, 
and cellular sprouting which promote cell death and seizure activity. 
1.3.2.2 The kainate model  
Kainic acid (KA) is a potent analogue of the excitatory neurotransmitter, glutamate. In the late 
1970s it was used to develop a model of epilepsy, as it was demonstrated to induce 
repetitive seizures and neuronal damage in the hippocampus (Nadler et al., 1978) and 
amygdala (Ben-Ari et al., 1979). Like the pilocarpine model, the KA model is characterised by 
three stages of epileptogenesis: 1) an ‘initial precipitating incident’ which in this model is 
proposed to be the damage induced during recurring seizures in status epilepticus, following 
KA administration, 2) the seizure free latent period and 3) the development and increase in 
the frequency of recurrent spontaneous seizures, which characterises chronic epilepsy. The 
KA model closely resembles domoic acid poisoning, and in 1987 a severe outbreak of 
domoic acid poisoning through shellfish was reported. Individuals who had suffered SE from 
domoic acid poisoning, had a seizure-free period of about a year before developing TLE 
(Cendes et al., 1995). Superimposed with the temporal progression of recurring seizures, are 
the anatomical changes which include: neuronal loss, mossy-fibre sprouting (Buckmaster & 
Dudek, 1997), metabolic (Ebisu et al., 1994) and genetic changes (Nedivi et al., 1993; 
Hevroni et al., 1998).  
Early work of the KA model of epileptogenesis demonstrated preferential neuronal loss and 
damage to the CA3 area, which probably reflects the greater expression of KA receptors in 
the CA3, and susceptibility to excitation and damage (Monaghan & Cotman, 1982; Nadler, 
1978; Tremblay et al., 1984). However, this pattern of pathology is different to patterns seen 
in human TLE, whereby CA1 is usually more damaged than CA3. Although, such difference 
may be explained by the differences in neuroanatomic structure between human and rodent 
brains. On the other hand, sclerosis is not necessarily required for the generation of seizures, 
as resected tissue does not always shows neuronal loss in human TLE patients (Williamson 
et al., 1993). 
The KA induction of SE, typically follows one of two protocols, either a single large systemic 
injections (9-12 mg/Kg) (e.g., IV, SC) (Cronin et al., 1992; Tauck & Nadler, 1985; Tremblay et 
al., 1984) or single low-volume intracerebral injections (1 - 3.75 nM) (e.g. intraventricular or 
intrahippocampal) (Bragin et al., 1999; Tauck & Nadler, 1985). Limitations of the former 
include high mortality rates following treatment, but this has been partially overcome by 
stopping SE with diazepam after a specified amount of time (Tremblay & Ben-Ari, 1984). 
However, this led to fewer animals developing recurring spontaneous seizures as 
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characterised by chronic epilepsy. It is also important to consider the shelf life of drugs such 
as KA, as differences in the potency of effect is likely to be seen depending on whether it is 
new or old (Dudek et al., 2006). Furthermore, significant improvements to this protocol have 
been made by titrating the dose of KA (Hellier et al., 1998).  
In contrast to systematic injection, intracerebral injections require anaesthesia and 
stereotaxic techniques and are therefore time consuming, but importantly are more likely to 
develop focal injury. Administration of KA intracerebrally has been suggested to not 
consistently shown as much damage as seen when administered IV (Nadler et al., 1985). 
Additionally, with intracranial injection, seizures are initiated at the site of injection. In 
comparison, IV administration of KA initiates seizures in hippocampal and amygdala areas, 
which propagate to other limbic areas and the neocortex, which drives motor seizures 
(Nadler, 1981). Evidently such differences in seizure initiation and propagation is the reason 
why systemic injections are considered to produce more realistic forms of pathology and 
therefore the preferred method of administration of kainate. Moreover, Bragin et al. (1999) 
demonstrated through video-monitoring that only 40% of animals who received intracranial 
KA injections developed spontaneous recurring seizures 3-8 months post SE, presumably 
such limited progression of epileptogenesis occurring as a result of the focal nature of injury 
produced by intracerebral injections.  
1.3.2.3 The kindling model of epilepsy 
The kindling model of epilepsy was first recognised by Goddard et al. (1969) and is 
commonly initiated by repetitive electrical stimulation which leads to a gradually evolving 
seizure-induced plasticity which promotes epileptogenesis and the emergence of 
spontaneous recurrent seizures (SRS) characterised in chronic epileptic states. Following 
electrode implantation and postoperative recovery, biphasic 1 msec pulses at 60-100 Hz are 
delivered for a duration of 1-2 seconds. Behaviour is observed and electrographic recordings 
taken for each daily stimulus. Goddard et al. (1969) noticed there was no obvious 
behavioural response initially, and no after-discharge present on EEG recordings, but after 
one week of daily stimulation behavioural response included arrest, closing of the ipsilateral 
eye and chewing movements. At this time point after-discharges also became apparent. The 
after-discharge consisted of high amplitude rhythmic spikes which lasted several seconds 
and altered in frequency. Progression of stimulation induced effects continued thereafter. At 
the end of two weeks with daily stimulation, the first bilateral clonic convulsion (7 seconds) 
was observed, 15 seconds after stimulation, and involved rearing, loss of balance, facial 
contractions and forelimb clonus. Thereafter successive days of stimulation continued to 
induce convulsions with shorter latencies and longer durations. It is noteworthy to mention, 
however, whilst consecutive stimulation induced convulsions spontaneous seizures in the 
absence of stimulation did not occur. On the other hand, Sayin et al. (2003) demonstrated 
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spontaneous seizures were apparent when paired-pulse inhibition was reduced or lost after 
90-100 evoked seizures. The sensitivity to stimulation once induced seemed to be 
permanent, as intervals of 2, 3, 4 or 6 weeks without stimulation did not reverse kindling 
effects (Goddard et al., 1969). The slower progression of epileptogenesis in the kindling 
model has been seen as great advantage over pilocarpine and kainate models whereby SE 
is induced rapidly, because there is much more control and minimal mortality, along with the 
ability to investigate more detailed network changes (Galanopoulou & Moshe, 2006). 
The timing of intervals between stimulations is also of importance to kindling effects. 
Goddard et al. (1969) highlighted the ‘massed stimulation effect’ which refers to a reduction 
in the response to stimulation when stimulus trains were applied with inter-stimuli intervals 
less than 24 hours. For optimal kindling effects intervals between stimulation should be 24 
hours or longer. This massed stimulation effect shows age dependent effects, as it appears 
in adult rats but not rat pups (Moshe & Albala, 1982). Moreover, massed stimulation effects 
can be overcome by increasing the stimulation duration, such as 10 second trains at 30 
minute intervals over 6 hours (Lothman & Williamson, 1994) or 20 Hz pulses for 10 seconds 
delivered per minute over 24 hours (Sloviter, 1983). Such differences in stimulation 
protocols, undoubtedly, lead to differences seizure activity and progression of 
epileptogenesis (Nairsmagi et al., 2004; Pitkanen et al., 2002). Additionally, differences in the 
development of seizures can be seen when kindling is applied to different pathways. Limbic 
pathways develop stage 5 seizures quicker in comparison to neocortical and sub-cortical 
areas (Goddard et al., 1969). 
In comparison to other chronic models of epilepsy, the kindling model shows similar 
functional and structural alterations. Following the first evoked seizure, there are reports of 
increase in NMDA conductance, increased inhibition, apoptosis, neurogenesis and gliosis. In 
the dentate gyrus, granule cells normally only fire single action potentials, even when 
inhibition is reduced or blocked, and these properties contributes to the filtering properties. 
However, when NMDA conductance is increased by kindling induced seizures, filtering 
properties are reduced and spike discharges are more likely to occur in CA3 (Lynch et al., 
2000; Sayin et al., 1999). 
Following five evoked seizures axonal sprouting has been shown form recurrent excitatory 
circuits (Scharfman et al., 2003). Following 30 evoked seizures, presence of hippocampal 
sclerosis and memory loss is apparent (Sutula et al., 1995), and following 90-100 evoked 
seizures there appears to be reduced inhibition as a result of interneuron loss (Sayin et al., 
2003). Evidently, kindling starts with activation of NMDA receptors, and a further cascade of 
events leading to functional and structural network changes.  
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1.3.3 Models of epilepsy as screening tools for antiepileptic drug discovery  
The discovery of AEDs originally occurred by serendipity, and later the need for preclinical 
testing of potential AEDs became apparent, hence the common use of pentylenetrazole 
(PTZ) and maximal electric shock (MES) screening models. The MES model induces tonic 
hind limb seizures through corneal or transauricular electrical stimulation. The PTZ model 
induces generalised clonic and myoclonic seizures via systematic administration of PTZ 
(Klitgaard, 2005). As early as 1881 Gowers highlighted “abnormal discharges are due to 
potentiation of excitatory mechanisms or to a failure of intrinsic cerebral inhibitory systems”. 
Since then epilepsy research has illustrated that the brain’s equilibrium can be disrupted in 
several ways (e.g. GABA antagonists, 4-AP, alterations to the aCSF concentrations of Na+, 
K+ and Mg2+) to induce seizures (Köhling & Avoli, 2006; Margineanu & Klitgaard, 2009). 
Additionally, other studies have suggested initial seizure activity promotes recurring seizures 
by inducing network changes, such as cell loss and formation of novel mossy fibre synapses, 
which disrupt the balance between excitation and inhibition (Ben Ari & Cossart, 2000). Many 
AEDs focus on restoring, the excitation-inhibition balance, by reducing excitation or 
enhancing inhibition (Klitgaard, 2005).  
Significant improvements have been made from first generation to second generation AEDs, 
such as: improved ease of use and tolerability, lowered risk of hypersensitivity and 
detrimental drug interactions. However, AED discovery investigations have received strong 
criticism as development of new AEDs have not attenuated drug-refractory epilepsy, or 
improved treatment in terms of prevention and cure for the disease (Simonato et al., 2012). 
Evidently, the emphasis of the excitation-inhibition imbalance in epilepsy is of limited value, 
as this over simplistic view, of a clearly multi-factorial disease, ignores the mechanisms that 
render an epileptic brain resistance to AEDs (Margineanu & Klitgaard, 2009). Many have 
recognised the most important step in AED discovery is the choice of animal model, which 
should accurately mimic human drug-refractory epilepsy in order to elucidate the 
mechanisms that lead to resistance and screen for new AEDs which are superior to currently 
available AEDs (Kupferberg, 2001; Potschka, 2012).  
Intractable epilepsy has been defined as a failure to respond to two or more drugs, with more 
than one seizure per month, for a specified time period (e.g. 12-18 months) (Berg et al., 
2001; Cowan, 2002). Given the various types of epilepsy, drug resistance is likely to be 
multifactorial, hence the need for several types of animal models. Nevertheless, several 
suggestions as to the mechanism of drug-refractory epilepsy have been indicated. For 
example the target (or pharmacodynamics) hypothesis suggests alterations of cellular targets 
leads to reduced sensitivity to AEDs (Remy et al., 2003; Loup et al., 2000). On the other 
hand the transporter (or pharmacokinetics) hypothesis proposes that cerebral endothelium of 
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the blood brain barrier (BBB) overexpress efflux drug transporters, hence reduces the AEDs 
at intended sites (Loscher & Potschka, 2002; Sisodiya, 2003). Chronic models that imitate 
the epileptogenesis process have been recognised as adding significant value to the 
discovery of AEDs and elucidating the mechanisms of drug-refractory epilepsy, but protocols 
are often elaborate and time consuming, therefore the need for improved acute models also 
exists. 
1.4 Antiepileptic Drugs 
The first effective AED was potassium bromide, introduced by Charles Locock in 1957 
(Eadie, 2012; Sieveking, 1861). Locock was an obstetrician, who described patients suffering 
from ‘hysterical epilepsy’, a disorder of seizures in women which were prominent around 
menstruation. Locock reported 93% of patients obtained seizure control following treatment 
with potassium bromide. Sixty years later, Alfred Hauptmann (1912) described the 
antiepileptic effects of phenobarbital given to epileptic patients for sedation. Preclinical 
evaluation of bromides and barbiturates were not conducted; nevertheless, the importance of 
screening antiepileptic agents was recognised leading to the development of the MES and 
PTZ models (Kupferberg, 1989; Loscher and Schmidt, 1988). 
Since the advent of bromides and barbiturates, several other first generation AEDs became 
available, such as benzodiazepines (BZD), ethosuximide (ESM), carbamazepine (CBZ), 
phenytoin (PHT), and valproate (VPA) (Klitgaard, 2005). After 1965, several second 
generation AEDs became available, such as lamotrigine (LTG), felbamate (FBM), vigabatrin 
(VGB), tiagabine (TGB), topiramate (TPM), gabapentin (GPT), zonisamide (ZNS) and 
levetiracetam (LEV). Second generation AEDs have been associated with fewer side effects 
and interaction effects, therefore are more tolerable than classical AEDs, but have not made 
significant advances in terms of antiepileptic efficacy; therefore there remains a continued 
need for new medical therapies (Loscher and Leppik, 2002). To maintain ethical standards 
new AEDs have been tested as add-on treatments in drug-resistant epileptic patients, 
consequently this trend has been maintained once drugs have been licenced (Perucca, 
1996). The variety of AEDs available has allowed greater propensity to tailor treatment to the 
characteristics of the patient. Drug selection requires professionals to evaluate type of 
seizures, pharmacokinetic properties, co-morbid conditions, age, ease of use and cost 
(Perucca, 2005). 
Ideally, AEDs should decrease the spread of excessive abnormal neuronal firing, without 
interfering with normal physiology. AEDs are typically not categorised based on mechanistic 
action due to several reasons. Firstly, the molecular mechanisms of AEDs are not fully 
understood and many have more than one mode of action. Secondly, knowledge of the 
pathophysiology of epilepsy is incomplete, therefore categorising AEDs is of limited value 
(Peruuca, 2005). Despite these limitations many AEDs have been demonstrated to control 
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seizures by modulating voltage-dependent Na+ channels, Ca2+ channels, and potentiating 
GABAergic inhibition (Macdonald & Kelly, 1995; Perucca, 2005; Rogawski & Loscher, 2004), 
as illustrated in Table 2.
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Table 1.2 Mechanisms of first and second generation antiepileptic drugs (Adapted from Perucca (2005) and Rogawski & Loscher (2004)) 
 
 Abbrev. Sodium 
channels 
Calcium channels GABA 
system 
Other Partial 
Seizures 
GTC 
seizures 
Absence 
seizures 
Myoclonic 
Seizures 
Infantile 
Spasms 
Lennox- 
Gastaut 
First Generation AEDs            
Benzodiazepines BDZ   ++  + + + +  + 
Carbamazepine  CBZ ++ + (L-type) ? + + + - -   
Ethosuximide ESM  ++ (T-type)   - - +    
Phenobarbital PHB  ? + ++ (Cl-)(AMPA) + + -    
Phenytoin PHT ++ ?  + + + - -   
Valproic Acid VPA ? + (T-type) ? ++ + + + +  + 
Second Generation 
AEDs 
           
Felbamate FBM ++ + (L-type) + + (NMDA) + + +   + 
Gabapentin GPT ? ++ (N-,P/Q-type) ?  + + - -   
Lamotrigine LTG ++ ++(N-,P/Q, R-,T-type) + + + + + ?  + 
Levetiracetam LEV  + (N-type) + ++ (SV2A) + + + +   
Oxcarbazepine OXC ++ + (N-, P-type)  + + + - -   
Pregabalin PGB  ++(N-, P/Q-type)         
Tiagabine TGB   ++        
Topiramate TPM ++ +(L-type) + + (KA/AMPA) + + + + + + 
Vigabatrin VGB   ++  + + - - +  
Zonisamide ZNS ++ ++(N-,P-,T-type) ? + + + + + + + 
Table 1.2. Mechanisms of first and second generation antiepileptic drugs. (Adapted from Perucca (2005) and Rogawski & 
Loscher (2004)) 
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1.4.1 Voltage-gated sodium channels 
Voltage-gated sodium channels (VGSCs) play an important role in regulating the electrical 
excitability of many cells. VGSCs can rapidly cycle through resting, open and inactivated 
states, promoting high-frequency actions potentials required for normal physiological function 
and epileptic activity. As a result serval AEDs target the modulation of VGSCs (Rogawski & 
Loscher, 2004).   
VGSCs consist of an α-subunit which consists of four homologous domains and each domain 
is made of six transmembrane segments (S1-S6). Between segments S5 and S6 there is a 
P-loop which comprises part of the channel pore. The α-subunit is covalently linked with an 
accessory β subunit (β1, β2, β3) in some tissues (Ragsdale & Avoli, 1998; Catterall, 2000; 
Goldin, 2003). The physiological functions of VGSCs are fundamentally dependent on 
voltage, which controls the opening and closing or inactivation of the channel. Once a 
threshold voltage has been reached within the cell the channel will become activated and the 
channel will open allowing positive ions to flow into the cell (depolarisation). At the peak of 
the action potential, the channel closes or becomes inactivated and the cellular potential 
decreases back to its resting potential as the neuron repolarises and thereafter 
hyperpolarises itself. During hyperpolarisation the membrane’s voltage becomes sufficiently 
low and removal of inactivation or de-inactivation occurs, rendering the cell ready to 
participate in another action potential. 
Inactivation closes the channel until sufficient recovery time has elapsed, hence inactivation 
determines the refractory period, which determines the frequency of firing (Goldin, 2003). 
There are two main kinetic classes of inactivation, fast and slow. Inactivation that is fast, has 
been described as a ‘ball-and-chain’ mechanism, in which the inactivating particle (IFMT (a 
four amino acid stretch consisting of isoleucine, phenylalanine, methionine and threonine)), 
which consists of a cytoplasmic linker between domains 3 and 4, and docks at domains 3 
(between S4 and S5) and 4 (between S4 and S5 and at the end of S6) (Rohl et al., 1999; 
Goldin, 2003). The molecular mechanism governing slow inactivation is not clearly defined, 
but it has been suggested to involve structural rearrangement (Mitrovic et al., 2000; Ong et 
al., 2000; Vilin et al., 2001; Goldin, 2003). 
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Figure 1-8. A schematic representation of voltage-gated sodium channels.  
 
Many AEDs block high-frequency firing and the spread of seizure activity by enhancing 
sodium channel inactivation, such as: PHT (Quandt, 1988), LTG (Leach et al., 1986; Kuo & 
Lu, 1997), CBZ (Willow et al., 1983; Kuo et al, 1997), OXC (Schmutz et al., 1994), ZNS 
(Schauf, 1987), and possibly FBM (Taglialatela et al., 1996), TPM (Taverna et al., 1999) and 
VPA (Van den Berg et al., 1993). The inhibitory potency of these drugs is strongly use-
dependent; therefore at pronounced levels of depolarisation, the block is strengthened. This 
mechanism, explains why normal neuronal activity is spared and only pathological seizure 
discharges are inhibited. AEDs which exert antiepileptic effects by enhancing sodium 
channel inactivation have been suggested to be useful in treating partial and secondarily 
generalised tonic-clonic seizures (Perucca, 2001) but not very effective and possibly 
aggravating in treating myoclonic and absence seizures (Perucca et al., 1998). 
Additional subtle differences can be identified when affinity and drug kinetics are explored. 
For example, Kuo (1998) found that, mechanistically, CBZ and LTG are only effective 
extracellularly and only one drug molecule can bind to one channel; hence there are no 
significant additive effects by using two or more of these types of drugs. Despite striking 
similarities in modes of action, AEDs acting on sodium channels are structurally rather 
different, but PHT, CBZ and LTG do all contain two phenyl groups separated by one or two 
C-C or C-N single bonds, which are probably essential for binding (Kuo, 1998; Rogawski & 
Loscher,2004). Additionally, Kuo et al. (1997) found the affinity of CBZ to sodium channels 
was three times less than that of PHT, but the binding rate of CBZ was five times faster. 
These differences have been suggested to explain treatment efficacy differences, as CBZ is 
likely to be better at treating shorter ictal events.  
There has also been further debate regarding whether certain AEDs effect fast or slow 
sodium channel inactivation. The normal firing of action potentials triggers fast inactivation, 
but sustained firing triggers slow inactivation. Xie et al. (1995) proposed LTG works by 
enhancing slow inactivation. This conclusion was based on findings that LTG did not show 
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inhibition of Na+ currents when a train of short pulses were applied, which would activate fast 
inactivation not slow inactivation. Additionally, when the duration of pulse applied was 
increased, to activate slow inactivation, the inactivation curve shifted with LTG application. In 
contrast, Kuo and Lu (1997) demonstrated Xie et al’s findings could also be explained by 
LTG binding to fast inactivated Na+ channels but with slower binding kinetics, by comparing 
recovery kinetics. If recovery from fast inactivation of Na+ channels is 1 ms and recovery from 
slow inactivation is 10 ms or more then if LTG is bound to slow inactivating Na+ channels the 
recovery time would be expected to increase more than 10ms however this was found not be 
the case, and instead recovery time of LTG-bound Na+ channels was faster than non-LTG-
bound slow inactivating Na+ channels, supporting the notion LTG binds to fast inactivating 
Na+ channels but at a slower rate. 
1.4.2 Voltage-gated calcium channels 
Voltage-gated calcium channels (VGCCs) influx in response to action potentials and sub-
threshold depolarisation signals. Calcium ions are also important second messengers that 
initiate intracellular events such as secretion, contraction, synaptic transmission and gene 
expression (Catterall, 2000). VGCCs were first reported by Hagiwara et al. (1975). VGCCs 
can be broadly divided into two categories: high-voltage activated (HVA) (-40 to -10 mV) and 
low-voltage activated (LVA) (-60 to -70 mV). HVA Ca2+ channels can further be divided into 
L-type, N-type, P/Q-type and R-type and LVA Ca2+ channels only consist of T-type channels 
(Yamakage & Namiki, 2002). Seven genes have been identified for HVA calcium channels 
and three for LVA calcium channels (Moreno, 1999). As demonstrated in figure 1-9, calcium 
channels consists of an α1 protein that forms the channel pore and voltage sensor, and 
additional β and γ subunits (Curtis & Catterall, 1984,1985). Later, a α2δ subunit was also 
discovered (Takahasi et al., 1987). 
Figure 1-9. A schematic representation of the structure of VGCC. 
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Several studies using acute models of seizure initiation, through application of various 
convulsants or stimulation, have demonstrated decreases in extracellular Ca2+ just before the 
onset of an ictal event, indicating Ca2+ entry into the intracellular environment (Heinemann et 
al., 1977; Heinemann & Louvel, 1983; Heinemann et al., 1984; Pumain & Heinemann, 1985; 
Hablitz & Heinemann, 1987). In support, chronic models of epilepsy have also suggested 
seizure activity is associated with rises in extracellular K+ and decreases in Ca2+ (Heinemann 
et al., 1981; Pumain 1981; Pumain et al., 1985; Heinemann et al., 1986). Calcium plays a 
pivotal role in maintaining neuronal homeostasis therefore, decreases in extracellular Ca2+ 
further promote neuronal excitability by reducing the threshold for activation of inward current 
(Frankenhaueser and Hodgkin, 1957). Also, as IPSPs fail to generate at extracellular Ca2+ 
concentrations of 0.7mM and EPSPs are blocked at extracellular Ca2+ concentrations of 
0.4mM so the balance between inhibition and excitation is shifted in support of excitation 
(Konnerth & Heinemann, 1983; Jones & Heinemann, 1987).   
Several studies have utilised different models of chronic epilepsy to demonstrate that calcium 
levels are altered during epileptogenesis (Rice & DeLorenzo, 1998; Pal et al., 2000; Raza et 
al., 2004). Based on these studies the Ca2+ hypothesis of epileptogenesis suggests at the 
time of initial brain insult, intracellular calcium concentrations are elevated, but not sufficient 
to cause cell death. During the latency phase of epileptogenesis intracellular Ca2+ levels 
remain elevated and cause long-term-plasticity changes which later aid the maintenance of 
SRS during the chronic phase (Meyer, 1989; DeLorenzo et al., 2005). 
Considering the prominent role of Ca2+ in seizure initiation and maintenance it is not 
surprising many AEDs target Ca2+ channels. GABA analogues, GPT and pregabalin (PGB) 
were originally synthesised in the hope of acting at GABA sites, but have been shown to 
exert AED effects by binding to the Ca2+ channel auxiliary subunits, α2δ-1 and α2δ-2 
(Suman-Chauhan et al., 1993; Gee et al., 1996; Piechan et al., 2004). Although the 
functional effects of this binding are not fully understood, it has been demonstrated that GPT 
inhibits HVA Ca2+ current at clinical concentrations (Bryans et al., 1998; Marais et al., 2001; 
McClelland et al., 2004) which ultimately reduces excitation through regulation of 
neurotransmitter release. In support, studies from rat neocortex (van Hooft et al., 2002) and 
resected human epileptic tissue (Fink et al., 2002) have shown GPT and PGB reduce 
presynaptic Ca2+ influx. In addition to producing Ca2+ dependent reductions in glutamate 
release, GPT and PGB have also been shown to act on other neurotransmitters such as 
norepinephrine (Dooley et al., 2000, 2002). Furthermore, GPT and PGB have also been 
implicated in modulating Ca2+ independent neurotransmitter release, potentially through 
interactions with P/Q type VGCCs (Cunningham et al., 2004). Other AEDs such as LTG have 
also been shown to inhibit N- and P/Q-type HVA Ca2+ channels (Stefani et al., 1996; Wang et 
al., 1996). LEV also acts on inhibits N-type Ca2+ channels (Lukyanetz et al., 2002). 
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Phenobarbital (PB) primarily acts at GABAA receptors, but has also been shown to inhibit 
HVA Ca2+ channels too (Ffrench-Mullen et al., 1993). 
In contrast to HVA calcium channels, LVA T-type Ca2+ channels regulate activity by 
participating in bursting and intrinsic oscillations (Perez-Reyes, 2003). These channels play a 
significant role in seizure activity of the thalamus (Suzuki & Rogawski, 1989; Steriade, 2006). 
Two AEDs which are effective in treating absence seizures, by inhibiting T-type Ca2+ 
channels are ESM (Coulter et al., 1989; Gomora & Daud, 2001) and ZNS (Kito et al., 1996; 
Matar et al., 2009). Interestingly, LTG is also effective at treating absence seizures, but does 
not affect T-type Ca2+ channels (Rogawski & Loscher, 2004). Additionally, ESM has a ureide 
ring structure, like PHT, which acts on Na+ channels, but ESM is not effective in partial or 
generalized tonic-clonic seizures (McLean & McDonald, 1986). Evidently, AEDs cannot be 
easily compartmentalised according to structure, site of activity and type of seizure. 
1.4.3 GABA 
The major inhibitory neurotransmitters are γ-aminobutyric acid (GABA) and glycine. Inhibitory 
neurons make up around 20% of CNS neurons. GABA activates two types of receptor, 
GABAA (ligand-gated ion channels) and GABAB (G-protein coupled) (Farrant & Nusser, 2005; 
Bettler et al., 2004). The most common subunit stoichiometries are α1β2γ2, α2β3γ2 and 
α3β1-3γ2 subunits. 
 
 
 
 
 
 
Figure 1-10. The structure of GABAA receptors. 
 
Despite the imbalance between number of inhibitory and excitatory neurons, inhibitory 
neurons play a vital role in preventing epileptiform discharges and maintaining neuronal 
homeostasis as demonstrated by Galaretta and Hestrin (1998). In this study, dual recordings 
from excitatory pyramidal and fast-spiking inhibitory neurons were taken in response to 
stimulation. It was demonstrated that excitatory synaptic currents showed a stronger 
depression in comparison to inhibitory ones. As a consequence of this difference, synaptic 
impact will peak at higher frequencies at inhibitory synapses in comparison to excitatory 
synapses, and therefore promote stability.  
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Genetic studies (Kang & Macdonald, 2004) have further demonstrated the role of GABA 
receptor mutations supporting neuronal instability and promotion of seizure events. Likewise, 
pharmacological studies have shown GABAA blockade, with bicuculline, leads to pathological 
discharges (Jones & Lambert, 1990a, b). In contrast, when excitatory transmission is 
blocked, the convulsant, 4-AP, induces GABA-mediated ictal discharges by raising 
extracellular K+ (Avoli et al., 1996).  
Seizure events can also initiate long term circuitry changes which impact inhibitory control. 
For example, hilar GABAergic cells are much more susceptible to seizure-induced damage, 
in comparison to dentate basket cells (Houser, 1999; Obenaus et al., 1993). Furthermore, 
rather than loss of inhibitory neurons, seizures may lead to the disconnection of inhibitory 
and excitatory neurons, as proposed by dormant interneuron hypothesis (Sloviter, 1987; 
Bear et al., 1996; Fountain et al., 1998; Sloviter, 2003). However, support for this hypothesis 
is questionable as reviewed by Bernard et al. (1998). Moreover, Ascady et al. (1997) 
demonstrated granule cells of the fascia dentate provide strong excitatory drive onto hilar 
interneurons. Additionally, it has also been found that anatomical and electrophysiological 
markers of inhibition are increased and pyramidal cells are hyperexcitable (Prince et al., 
1997). These paradoxical findings demonstrate the role of inhibition is by no means straight-
forward to decipher. 
AEDs that aim to enhance inhibition by acting on GABA receptors, do so by affecting GABA 
transport, metabolism or receptor kinetics. One of the earliest AEDs discovered to work by 
acting at GABAA receptor are BZDs (Gastaut et al., 1965). The BDZ receptor forms part of 
the GABAA receptor complex and exists in number of forms (e.g. BZD1, BZD2 and BZD3). 
BZDs bind to its GABAA receptor complex binding site to increase channel opening 
frequency (Vicini et al., 1987; Rogers et al., 1994). Similarly, TPM has also been shown to 
increase GABAA opening frequency, but appears to have a different binding site in 
comparison to BZDs, as the BZD receptor antagonist, flumazenil, failed to inhibit TPM 
induced activity (White et al., 1995). Alternative modulatory GABAA binding sites for TPM 
include: butyrolactone, neurosteroid, inverse agonist site or another novel site (Turner et al., 
1989; Majewska et al., 1990). Barbiturates also impact GABAA receptor kinetics but instead 
of effecting opening frequency like BZD and TPM, barbiturates act by increasing the duration 
of time the channels is open (Study & Barker, 1981; Macdonald et al, 1989). Two enzymes 
that control GABA levels are glutamate decarboxylase (GAD) and GABA transaminase 
(GABAT).VGB affects GABA metabolism by irreversibly binding to the enzyme responsible 
for GABA metabolism, GABAT, leading to increased levels of GABA and consequently 
increased inhibitory activity (Jung et al., 1977; Schecter et al., 1977). TGB affects GABA 
transport by inhibiting neuronal GABA uptake (Braestrup et al., 1990).  
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Besides benzodiazepines, many AEDs that influence GABA inhibition, also promote 
antiepileptic effects by acting through other mechanisms. For example, TPM also has effects 
on Na+ channels (White, 1997) and PB inhibits HVA Ca2+ channels (Ffrench-Mullen et al., 
1993). Additionally, FBM has shown to be effective by inhibiting Na+ channels (Taglialatela et 
al., 1996), glycine binding site of the NMDA receptor (McCabe et al, 1993; Wamsley et al., 
1994) but also enhancing GABA currents (Rho et al, 1994). Similarly, VPA has been shown 
to reduce Na+ currents (Zona & Avoli, 1990) and Ca2+ currents (Kelly et al., 1990), but also 
elevate GABA levels (Loscher, 2002). AEDs that are multi-mechanistic in modes of action 
are favoured among clinicians as drug interactions are less likely and tolerability is better 
(White, 1997). Generally, multi-modal AEDs are useful in treating a wide range of types of 
seizures however, there are some exceptions. For example, PB is not effective in treating, 
and may even provoke, absence seizures (Rogawski & Loscher, 2004; Perucca, 2005). 
Other AEDs acting on GABA, such and VGB and TGB are also not effective in treating 
absence seizures. Additionally, VGB is also not effective in treating myoclonic seizures.  
Whilst, AEDs acting on GABA maybe useful in treating a wide variety of seizures there are 
also detrimental side effects to consider. For example, serious side effects of aplastic 
anaemia and fatal liver toxicity have been associated with FBM (Leppik & Wolff, 1995). VGB 
is also associated with detrimental irreversible visual defects (Kalviainen & Nousiaine, 2001). 
As a result, these AEDs are only used as a last resort or when treatment is justified, as in the 
case of VGB in the treatment of infantile spasms due to tuberous sclerosis (Chiron et al., 
1997). 
1.5 Aims and Objectives 
The EC has been implicated with some of the earliest and most severe pathological changes 
in a variety of diseases, including temporal lobe epilepsy. Several studies have demonstrated 
the intrinsic and synaptic properties of MEC cells support the generation of seizure activity, 
and its location and function within the limbic system makes it an ideal candidate in seizure 
propagation. Despite significant pharmacological advances in the treatment of epilepsy, one 
third of patients remain resistant to two or more AEDs, and are therefore drug refractory 
(Kwan & Brodie, 2006; French, 2007). One fundamental possibility for the lack of 
understanding and treatment options for drug refractory patients, is due to the focus on the 
excitation-inhibition balance within the brain which has been suggested to be a secondary 
effect of underlying pathology. For example investigations of epileptogenesis mechanisms 
often focus on network circuitry changes as a result of death of GABAergic interneurons and 
axonal sprouting. Similarly, many AEDs focus on enhancing inhibition and/or reducing 
excitation. 
It remains an important challenge of epilepsy research to understand the pathophysiogenesis 
of TLE. Several acute and chronic models have been developed in order to explore the 
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mechanisms of seizures and epileptogenesis, however these models have also been 
criticised on the basis they induce severe damage and do not accurately imitate human 
pathology. Based upon these issues within epilepsy research the following project aims and 
objectives are proposed: 
 To explore how improved brain preparations act as acute models of drug-resistant 
seizures, and mechanisms behind resistance. 
 To explore excitability and AED response during epileptogenesis in the refined lithium 
pilocarpine model of epilepsy, in vitro. 
 To compare the excitability and AED response of resected human tissue to 
chronically epileptic rodent tissue, in vitro. 
 To explore the role of LTP induced effects in chronic epileptogenesis. 
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Chapter 2 Methods 
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2.1 Brain slice preparation 
Transverse hippocampal-EC slices (450 μm) were prepared from male Wistar rats (45-600 
g). Each rat was anaesthetised with 3% isoflurane in N2 and O2 for 2-3 minutes for smaller 
animals and up to 5 minutes for larger animals. Once the heartbeat had reduced until it was 
no longer visible, a subcutaneous (s/c) injection of pentobarbital (600 mg/Kg) was 
administered along with an intramuscular (i/m) injection of combined ketamine (100 mg/Kg) 
and xylazine (10 mg/Kg). Once the pedal reflex had ceased to be active, smaller animals 
(45-150 g) were held in an ice bath for 30-45 seconds to reduce metabolic rate. Thereafter, 
animals were transcardially perfused with ice-cold sucrose aCSF, which contained (mM): 206 
sucrose, 2 KCl, 1.6 MgSO4, 26 NaHCO3, 1.25 NaH2PO4, 2.25 CaCl2, 10 glucose, and 5 
sodium pyruvate. Neuroprotectants (mM): 0.04 indomethacin, 0.4 uric acid and 0.19 
ketamine were added and the solution was saturated with carbogen (95% O2, 5% CO2) (see 
EC preparation in Table 2.1). 
Following the perfusion, the brain was carefully extracted and placed into the sucrose aCSF. 
Thereafter, the brain was prepared for slicing by dissecting and fixing the dorsal surface onto 
a platform using cyanoacrylate adhesive (super-glue, RS components, UK) before being 
placing it into a small bath of cold sucrose aCSF which was continuously bubbled with 
carbogen. Transverse hippocampal-EC slices (450 μm) were then cut using a Vibroslicer 
(Campden Instruments, UK). Slices were then placed into an interface holding chamber, 
which contained a NaCl based aCSF (mM): 126 NaCl, 3 KCl, 1.6 MgSO4, 26 NaHCO3, 1.25 
NaH2PO4, 2 CaCl2, 10 glucose. Neuroprotectants, indomethacin (0.4 mM), uric acid (0.4 mM) 
and ketamine (0.19 mM) were also added. The holding chamber solution was stored at room 
temperature and also continuously bubbled with carbogen. After slices had been prepared 
they were transferred into an interface chamber (Scientific System Design Inc., Canada), and 
left to rest for 1 hour. The perfusate was temperature maintained to 30-31 °C using a PTCO3 
proportional temperature controller (Scientific System Design Inc., Canada) and was bubbled 
with carbogen. Carbogen was also bubbled through distilled water underneath the interface 
recording chamber in order to maintain humidity between 95-100 %.  
The majority of slices were prepared using the method outlined above (see chapter 4 and 5), 
but as chapter 3 explored the effects of brain slice preparation differences on excitability in 
0[Mg]2+, different brain slice preparation methods were employed, the main differences are 
outlined below. In chapter 3 transverse hippocampal-EC slice (450 μm) were prepared from 
male Wistar rats (100 g) in one of two ways:  
Firstly, animals were anaesthetised as highlighted above and decapitated, without 
transcardial perfusion. The brain was carefully and swiftly extracted and placed in ice-cold 
NaCl based aCSF, and cut and stored in the same solution. The only difference between 
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cutting and holding solutions being the temperature. No neuroprotectants were added. This 
method is a standard method of slice preparation and still used by many laboratories.  
Secondly, animals were anaesthetised as explained above, and transcardially perfused with 
and cut in a sucrose based solution, which comprised of (mM): 180 sucrose, 2.5 KCl, 10 
MgSO4, 25 NaHCO3, 1.25 NaH2PO4, 0.5 CaCl2, 10 glucose, 1 L-ascorbic acid, 2 N-acetyl-L-
cysteine, 1 taurine, 20 ethyl pyruvate, 0.04 indomethacin, 0.4 uric acid, 0.01 aminoguanidine, 
0.19 ketamine and saturated with carbogen. The holding chamber contained the NaCl based 
aCSF with neuroprotectants, indomethacin (0.4 mM) and uric acid (0.4 mM) (see M1 
preparation in Table 2.1).  
All experiments were carried out in accordance with the Animals (Scientific Procedures) Act 
1986, European Communities Directive 1986 (86/609/EEC) and Aston University ethical 
review documents. Male Wistar rats were housed in groups of 1-10 depending on size, in 
temperature and humidity controlled cages with a 12/12 light/dark cycle. Access to food and 
drink was provided ad libitum. 
Finally, all human tissue and piriform cortex slices (see chapter 4) were cut in a choline 
based aCSF, which contained (mM): 110 choline chloride, 26 NaHCO3, 10 D-Glucose, 11.6 
ascorbic acid, 7 MgCl2, 3.1 sodium pyruvate, 2.5 KCl, 1.25 NaHPO4 and 0.5 CaCl2. The 
solution had neuroprotectants: indomethacin (0.4 mM), uric acid (0.4 mM) and ketamine 
(0.19 mM) added to the ice-cold solution which was saturated with carbogen. An agar ‘seat’ 
was fixed onto the standard metal platforms. Resected human tissue was then glued onto 
the agar, to prevent the tissue from becoming detached during slicing. 
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Table 2.1. Summary of different brain slice preparation methods   
 EC Preparation M1 Preparation Standard 
Preparation 
Piriform and 
Human Tissue 
Preparation 
Perfusion Yes Yes No PC: Yes, HT: No 
cutting solution 206 sucrose, 2 
KCl, 1.6 MgSO4, 
26 NaHCO3, 
1.25 NaH2PO4, 
2.25 CaCl2, 10 
glucose, and 5 
sodium pyruvate 
180 sucrose, 2.5 
KCl, 10 MgSO4, 
25 NaHCO3, 
1.25 NaH2PO4, 
0.5 CaCl2, 10 
glucose, 1 L-
ascorbic acid, 2 
N-acetyl-L-
cysteine, 1 
taurine, 20 ethyl 
pyruvate 
126 NaCl, 3 
KCl, 1.6 MgSO4, 
26 NaHCO3, 
1.25 NaH2PO4, 
2 CaCl2, 10 
glucose 
110 choline 
chloride, 26 
NaHCO3, 10 D-
Glucose, 11.6 
ascorbic acid, 7 
MgCl2, 3.1 
sodium 
pyruvate, 2.5 
KCl, 1.25 
NaHPO4 and 0.5 
CaCl2 
 cutting solution 
neuroprotectants 
0.04 
indomethacin, 
0.4 uric acid and 
0.19 ketamine 
0.04 
indomethacin, 
0.4 uric acid and 
0.19 ketamine 
N/A 0.04 
indomethacin, 
0.4 uric acid and 
0.19 ketamine 
storage solution 126 NaCl, 3 KCl, 
1.6 MgSO4, 26 
NaHCO3, 1.25 
NaH2PO4, 2 
CaCl2, 10 
glucose 
126 NaCl, 3 KCl, 
1.6 MgSO4, 26 
NaHCO3, 1.25 
NaH2PO4, 2 
CaCl2, 10 
glucose 
126 NaCl, 3 
KCl, 1.6 MgSO4, 
26 NaHCO3, 
1.25 NaH2PO4, 
2 CaCl2, 10 
glucose 
126 NaCl, 3 KCl, 
1.6 MgSO4, 26 
NaHCO3, 1.25 
NaH2PO4, 2 
CaCl2, 10 
glucose 
storage/experimental 
solution 
neuroprotectants 
indomethacin 
(0.4 mM), uric 
acid (0.4 mM) 
and ketamine 
(0.19 mM) 
Indomethacin 
(0.4 mM) and 
uric acid (0.4 
mM). 
N/A indomethacin 
(0.4 mM), uric 
acid (0.4 mM) 
and ketamine 
(0.19 mM) 
Chapters 4, 5 3 3 4 
 
2.2 Reduced intensity lithium pilocarpine model of epilepsy 
2.2.1 Model protocol 
The reduced intensity lithium pilocarpine model (Modebadze et al., 2016) was employed in 
experiments aimed at exploring effects of epileptogenesis on neuronal network excitability. 
One to three days post weaning (postnatal day 21 - 24) rats were marked for identification 
and a dose of LiCl (127mg/Kg) was administered s/c, 24 hours before the protocol was fully 
initiated. Pre-treatment with LiCl has been shown to increase sensitivity to pilocarpine 
(Clifford et al., 1987). The following day, the rats were weighed and the protocol was initiated 
with a dose of α-methyl scopolamine (1 mg/Kg, s/c), which reduces the peripheral effects of 
muscarinic cholinergic receptor activation. Thirty minutes later, a low dose of pilocarpine (25-
30 mg/Kg) was administered s/c. Thereafter rats were carefully monitored for signs of seizure 
activity, which was classified according to the Racine scale (see Table 2.2). After 45-60 
minutes, if animals had not developed stage 4 seizures, they were given another dose of 
pilocarpine. A maximum of 3 doses were administered. Once two stage 4 seizures were 
observed, the central muscle relaxant, xylazine (2.5 mg/Kg, i/m) was administered, to reduce 
seizure severity. Rats were permitted to stay in this SE state for 1 hour, after which a ‘stop’ 
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solution (1 ml/Kg, s/c) was administered to halt intense repetitive seizures. The ‘stop’ solution 
was comprised of MK801 (0.1 mg/Kg), diazepam (2.5 mg/Kg) and MPEP (20 mg/Kg). 
Seizures ceased to occur around thirty minutes after the stop solution had been given, and 
animals remained in a sleep-like state for 3-4 hours.  
Table 2.2. The Racine Scale. 
Stage Activity 
1 Facial/mouth movement, chewing and salivation 
2 Head nodding and eye twitching 
3 Forelimb clonus 
4 Clonic rearing (sitting up on hind limbs, forelimbs shaking) 
5 Clonic rearing and falling over with loss of postural control 
 
Animals were kept on heat pads and carefully monitored and given 0.5 ml (saline/glucose) 
s/c every 2 hours for 8 hours after induction. Whilst the animals were sleeping, their nails 
were also trimmed to prevent cutaneous damage at later stages from excessive grooming 
which is often seen in epileptic behaviour. Regular checks were made for 3 days, whereby 
animals were weighed daily to ensure dramatic weight loss had not occurred, and break-
through seizures were not severe (e.g. running-bouncing-seizures) or prolonged.  An end-
point limit of 20 % weight loss from pre-induction weight was set to ensure prolonged 
suffering was not endured. Minimal weight loss was overcome by giving rats treats (e.g. 
sweetcorn, peanut butter, muesli and milkshake) or oral gavage in certain cases. Following 
full recovery animals were returned to temperature and humidity controlled environments 
with a 12-12 light-dark cycle. 
2.2.3 Experimental timeline and SRS development 
Animals were killed at 24 hours, 1 week, 5 weeks and 12 weeks+ post induction. As 
illustrated in figure 2-1, 1 week and 5 weeks after SE induction are representative of latent 
period time points in epileptogenesis, whereas 12 weeks+ post SE induction is typically when 
SRS is observed, characterising chronic epilepsy. Often comparisons with age-matched 
controls were made, whereby weight was used as an indication of age. 
 
 
 
Figure 2-1. A schematic timeline representation of epileptogenesis. The time points at 
which SE and aged matched controls were sacrificed is noted. 
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2.2.4 The post-seizure behavioural battery test 
The post-seizure behavioural battery (PSBB) test, developed by Moser et al. (1988) and 
adapted by Rice et al. (1998), was employed, to confirm the development of the SRS that 
characterises the chronic epileptic stage. The test involved a touch task and a pick-up task. 
The touch task involved the animal being gently prodded in the rump with a blunt object (e.g. 
permanent marker). The pick-up task required an attempt to pick-up the animal. Behavioural 
response to both tasks were rated on a scale from 1-7 for the touch task and 1-6 for the pick-
up task, as highlighted in Table 2.3.  The two scores were then multiplied together. Once an 
animal had obtained 4 consecutive scores higher than 10 it was confirmed as epileptic. It has 
previously been demonstrated that animals who have undergone variations of the pilocarpine 
model of epilepsy induction show behavioural modifications such as hyperexcitability and 
aggression in comparison to controls (Huang et al., 2012; Modebadze et al., 2016; 
Polascheck et al., 2010). 
Table 2.3 Post seizure behavioural battery test responses and scores 
Touch task Pick-up Task 
1 No Reaction 1 Very easy pickup 
2 Rat turn toward instrument 2 Easy pickup with vocalisation 
3 Rat moved away from instrument 3 Some difficulty in pickup (rears and faces hand) 
4 Rat freezes 4 Rat freezes 
5 Rat turns toward the touch 5 Difficult pickup (rat moves away) 
6 Rats turns away from the touch 6 Very difficult pickup (defensive/attacks hand) 
7 Rat jumps (with or without vocalisation)   
 
The PSBB task was initiated 1 week post SE induction, and was completed twice a week 
(Tuesday and Friday) by three individuals on a rotational basis, to avoid bias. Some animals 
that had been confirmed epileptic by the PSBB task, were video recorded in the ‘big brother 
system’. The ‘big brother system’ was set up by Astra Zeneca, and recordings helped in the 
development of software to detect seizures. As illustrated in figure 2-2, animals that had 
undergone SE induction scored consistently higher on the PSBB task in comparison to 
control animals. The majority of SE animals had been confirmed epileptic, with 4 consecutive 
scores above 10, by 28 weeks (~6 months). 
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Figure 2-2. PSBB scores over time in SE (n= 44) and control (n=6) animals. 
 
2.3 Human tissue electrophysiology 
A collaboration with Birmingham Children’s Hospital allowed informed consent to be obtained 
from parents and paediatric patients who were undergoing resective brain surgery due to 
intractable epilepsy. Ethical approval specified by the Black Country LREC (protocol 'Cellular 
studies in epilepsy' 10/H1202/23), and the Birmingham Children's Hospital NHS Trust 
(RECREF 10/H1202/23) can be found in Appendix 1. Pre-surgery electrocorticography 
methods determined site of resection. Brain tissue was surgically removed and placed into 
cold choline-based aCSF, which had been saturated with carbogen, as described in section 
2.1. Patient data, from which human tissue experiments are based, is outlined in Table 2.4. 
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Table 2.4. Site of resection in human tissue  
Patient Human tissue with induced IDs 
1 Motor cortex 
2 Temporal gyrus and amygdala 
3 Sensory motor cortex 
4 Medial temporal gyrus and amygdala 
5 Inferior frontal gyrus 
6 Left parietal gyrus 
7 Sensory motor cortex 
8 Temporal lobe 
9 Medial temporal gyrus 
 Human tissue unable to induce IDs 
10 Frontal cortex 
11 Temporal lobectomy 
12 Frontal cortex 
14 Left temporal gyrus and amygdala 
 
2.4 Extracellular recording 
Extracellular recording techniques were used to assess the neural network activity of LFPs. 
Microelectrodes were prepared from borosilicate glass which was pulled using a Flaming/ 
Brown micropipette puller (P-97, Sutter instrument Co, U.S.A.). The resistance of electrodes 
was 1-3MΩ. Microelectrodes were then filled with a NaCl based aCSF and inserted into the 
microelectrode holder, which has attached a silver piece of wire which was coated with silver 
chloride. Once the microelectrode was securely fitted to the holder it was mounted on the 
manually operated micromanipulators (Narishige MM-3, Japan). As discussed in detail in 
section 1.2, LFP emerge from multiple sources but are mainly generated by the summation 
of current sinks and sources distributed along neuronal aggregates, which when 
geometrically aligned often give rise to oscillations. Microelectrodes can detect activity within 
250 m of the electrode tip (Xing et al., 2009). 
Using an optical stereomicroscope Olympus SZX16 (Leica Wild M3Z, Leica UK), 4 
microelectrodes were placed in layer II of the MEC of 4 different slices, and simultaneously 
recorded from. Signals were passed through an EXT amplifier headstage (NPI electronics 
GMBH, Germany) and then further amplified x100 and low-pass filtered at 1 KHz using an 
EX10-2F amplifier (NPI Electronics GMBH, Germany). Low amplitude 50 Hz noise was 
reduced using Hum Bug noise eliminators (Quest Scientific, North Vancouver, Canada) and 
the signal was filtered between 1 Hz and 1000 Hz. Thereafter, signals were digitized to a PC, 
at a 10 KHz sampling rate, using an analogue to digital converter (CED micro-1401 mkII; 
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Cambridge Electronic Design, UK). On-line recordings were made using Spike2 software 
(CED, UK). 
Different types of noise (e.g. vibrations and electrical noise from lights and power supplies) 
can interfere with the accurate recording of biological signals. As mentioned, the use of Hum 
Bug noise eliminators reduces some of the electrical noise, by cancelling out interferences in 
real time. Electrical noise is further reduced by the presence of a Faraday cage around the 
experimental set-up, which is connected to a common ground (e.g. the microelectrode 
amplifier). Vibrational noise is reduced by the vibration isolation table, on which the 
experimental set-up is located. 
2.5 Drugs 
Stock solutions of drugs were prepared at known concentrations by diluting drugs with water, 
DMSO or ethanol depending on solubility and stored at -20 °C before use, for no longer than 
6-9 months (all drugs were purchased from Sigma, Abcam or Tocris, see table 2.5). The 
drugs were directly applied to the perfusing aCSF, and the effects on neuronal activity 
observed for 30-45 minutes depending on experimental design. 
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Table 2.5 Drugs used in this thesis 
Drug Purchased 
from 
Stock concentration 
and solution 
Concentration used 
(-)-scopolamine methyl 
bromide 
Sigma 1 mg/ml water 1 mg/kg 
7-nitraindazole Abcam 20 mM ethanol, 100mM 
DMSO 
200 µM 
D-AP5 Abcam 100mM, water 50 µM 
bicuculline Abcam 5 mM ethanol, 100mM 
DMSO 
20 µM 
cannabidiol GW Pharma 60 mM, DMSO 30 µM 
carbachol Abcam 50 mM, water Variable 
carbamazepine Abcam 100 mM, DMSO 50 µM 
CNQX Abcam 100 mM, DMSO 20 µM 
cycloheximide Abcam 25 mM water 60 µM 
diazepam Hameln 2.5mg/ml, ethanol 2.5 mg/kg 
gabapentin Abcam 100mM, water 20 µM 
gabazine R&D systems 2.5 mM, DMSO 250 nM & 2.5 µM 
GF109203X Abcam 100 mM, DMSO 100 µM 
kainate Abcam 1mM water variable 
lamotrigine Abcam 20 mM DMSO 20 µM 
MK-801 Abcam 20 mM, water, in vitro, 
0.1 mg/ml in RISE 
model 
0.01 - 30 µM in vitro, 
0.1mg/kg in RISE 
model 
MPEP Abcam 100mM, DMSO, in vitro,  
20 mg/ml, ethanol, RISE 
model 
20 µM in vitro, 20mg/kg in 
RISE model 
pentobarbital R&D systems / 
JML 
10 mM in vitro, 200 
mg/ml in terminal 
procedure 
10 µM in vitro, 
600mg/kg in terminal 
procedure 
pilocarpine Sigma 20-25mg/ml water 20-75 mg/kg (repeated 
doses) 
tiagabine Abcam 25 mM, water 50 µM 
valproate Abcam 100 mM water 500 µM 
xylazine Bayer 20 mg/ml terminal 
procedure, 2.5 mg/ml, 
water, RISE 
100 mg/kg terminal 
procedure, 2.5mg/kg RISE 
zonisamide Abcam 100 mM, DMSO 100 µM 
 
2.6 Data collection and analysis 
2.6.1 Seizure activity data  
All data were analysed in Spike2 (version 7.0). To be considered for analysis seizure-like 
events (SLEs or ‘seizures’) had to be between 15-500 seconds in length, and have a 
characteristic shape which was accompanied by an increase in the power of activity, and the 
IEI between seizures needed to be less than 1000 seconds for accurate monitoring of AED 
effects. For accuracy, data regarding the following variables was manual extracted and input 
in matrices in Excel (2013): percentage of slices showing IDs, latency to first seizure, inter-
event-intervals (IEIs), duration of IDs and frequency of IDs. Many of these variables are 
illustrated in figure 2-4. For the analysis of power of seizures 90 seconds epochs of 3 
seizures per experimental manipulation was extracted and pooled together. For each seizure 
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activity segment, the highest power value at each frequency band was extracted by a model 
built in Excel (2013).   
 
Figure 2-3. Representation of ID variables: frequency, IEI, duration and power. 
 
In addition, to exploring how different ID parameters change in different acute and chronic 
models of epileptogenesis, resistance to AEDs was also explored using two different 
definitions. The measurement of resistance to AEDs in clinical studies as well as 
physiological in vivo / in vitro investigations have often been flawed. For example, in many 
clinical trials the ‘last observation carried forward’ measure includes patients who completed 
and dropped out of the trial, leading to the false inflation of seizure-free rates as patients who 
become seizure free and then drop-out are included in the seizure-free population (Gazzola 
et al., 2007). Similarly, many studies assess resistance towards a single AED treatment, but 
the definition of DRE clearly identifies a failure to respond to two or more AEDs (Berg et al., 
2001; Cowan 2002; Kwan & Brodie, 2006).  
The first definition of DRE clearly identifies a failure to respond to two or more AEDs (Berg et 
al., 2001; Cowan 2002; Kwan & Brodie, 2006) and so resistance was calculated using the 
criteria of percentage of slices which continue to show seizures following application of 2 
AEDs. Secondly, healthcare providers acknowledge a 50 % reduction as a measure of 
efficacy, but the clinical relevance over the patient’s health status is thought to be limited as 
patients are not seizure-free and therefore cannot drive (Beyenburg et al., 2010; Birbeck et 
al., 2002). Although seizure-freedom is the ultimate goal, it is not currently a realistic goal in 
patients with refractory epilepsy and a 50 % reduction can be seen as a significant 
improvement. The second analysis of resistance uses the clinical criteria in which a less than 
50 % reduction in seizure frequency is evidence of resistance and a 50 % reduction, or more, 
in seizure frequency is evidence of no-resistance. 
Depending on the complexity of questions hypothesised and the type of data collected (e.g. 
categorical vs continuous) a range of statistical analyses were adopted such as: t-tests, chi-
square analyses, log linear analyses, regressions and ANOVAs (Field, 2009; Gravetter & 
Wallnau, 2009; Pallant, 2010). As hypotheses were often multifactorial, different types of 
ANOVA and regression analyses were carried out for which there are limited non-parametric 
alternatives. Before analysis the distribution of data for different variables was determined. If 
data significantly deviated from normal distribution, log10, box-cox transformations or ranking 
operations were applied to make sure assumptions of normality were not violated and 
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conclusions drawn from analyses were accurate. Additional assumptions of homogeneity of 
variances and multicollinearity were checked before results were interpreted. All statistical 
analyses was carried out using SPSS and R. All data are expressed in terms of mean and 
standard error of the mean (SEM). Where analysis has been conducted on transformed data, 
this data is presented, but illustrations of the raw data can be found in appendices.  
2.6.2 GABAergic LFP activity 
The presence of unitary inhibitory field potentials (UIFPs) has been illustrated by Bazelot et 
al., (2010). To explore the effects of various manipulations on UIFPs) data were imported 
from Spike2 to the Mini-Analysis programme (Synaptosoft, U.S.A.). At least 50 events were 
taken from each recording, and the amplitude and frequency of events was calculated. 
Statistical analysis was carried out as described in section 2.6.1. 
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Chapter 3 Brain slice preparations as acute models of seizure-like 
events and the differential effects of antiepileptic drugs 
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3.1 Introduction 
3.1.1 The history of the in vitro brain slice preparation 
The pioneering development of the brain slice preparation by Henry McIlwain in the 1950s, 
was one of the most important historical landmarks in the neuroscience discipline. To 
validate the preparation, electrophysiological techniques were used to demonstrate that 
slices were metabolically viable (McIlwain et al., 1951), neurons displayed healthy resting 
membrane potentials (Li & McIlwain, 1957) and synaptic responses could be recorded from 
electrical stimulation (Yamamoto & McIlwain, 1966). Since these demonstrations, popularity 
of the technique has attracted researchers from multiple disciplines (e.g. biologists, 
pharmacologists, physiologists and anatomists) to investigate physiological and 
pharmacological properties of the different brain areas. 
The brain slice preparation is an excellent method of exploring local neuronal networks and 
has led to insights on the dynamics of physiological and pathological neuronal activity that 
would otherwise be difficult due to practicalities and ethical considerations. However, it is 
important to recognise some of the limitations of this technique. For example, many input and 
output connections are severed through the process of slicing and such stress inducing 
processes can trigger a cascade of excitotoxic and neuro-inflammatory reactions. As a result 
of network modifications from these processes the translational abilities of findings from in 
vitro research is not completely compatible with in vivo findings.   
Since the innovation of the brain slice preparation, various improvements have been made to 
reduce the trauma induced effects of the slicing process and increase oxygenation of the 
tissue. For example, considerations to the way in which the brain is removed, how it is sliced, 
what sort of equipment is used to glue the brain, what angle the brain is cut at, thickness of 
slices, oxygenation and temperature of chambers and the length of the preparatory process 
have been made to increase slice viability and thus improve the quality of research 
(Dingledine et al., 1980). Various tests have been utilised to assess the healthiness of slices, 
such as: metabolic tests (e.g. measuring levels of energy-rich phosphates), histological 
assessment of cell live/dead ratio and the response measurement to electrical stimulation, as 
the presence of multiple population spikes in response to weak stimulation indicates the slice 
has become anoxic (oxygen deprived). 
In the original description of brain slice preparation a hand-held razor blade was used, but 
since then mechanical choppers and vibratomes have been employed for greater precision 
and control. In addition, some potential improvements have actually been found to decrease 
viability, but have nonetheless improved our knowledge of the neuronal tissue. For example, 
it was previously thought using higher concentrations of K+ (5-6 mM) reduces cell swelling 
and maintains intracellular concentration of K+ to a similar level as found in vivo (Franck, 
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1972). However, subsequent research actually demonstrated increased extracellular K+ 
concentration depolarised neurons and reduced input resistance (Schofield, 1978). 
Additionally, profound epileptiform activity was also demonstrated to occur in hippocampal 
slices with elevated extracellular K+ (Schwartzkroin & Prince, 1978). Evidently, the 
composition of the extracellular environment has important implications in maintaining 
neuronal homeostasis (Nicolson, 1979; Schmitt & Samsom, 1969), and it therefore 
unsurprisingly remains a target of research to improve slice viability.  
One particular improvement to aCSF during slice preparation, has been the replacement of 
NaCl with sucrose or glycerol, which prevents cell swelling and lysis (Aghjanian & 
Rasmussen, 1989; Ye et al., 2006). The use of NaCl promotes passive Cl- entry and 
associated water transport which leads to neurotoxic effects (Aghajanian & Rasmussen, 
1989). This substitution for a sucrose-based aCSF has been shown to be particularly useful 
in cellular electrophysiology studies of the perigeniculate nucleus (Kim and McCormick, 
1998), inferior colliculus (Li et al., 1998) and hippocampus (Urban et al., 1998; Xiang and 
Brown, 1998). 
Moreover, within our laboratory the addition of several neuroprotectants (NAC, 
aminoguanidine, taurine and ascorbate) to aCSF have been shown to considerably improve 
motor cortex slice viability (Prokic, 2012). Furthermore, Prokic (2012) also demonstrated, 
whilst small improvements could be seen with the addition of such neuroprotectants to the 
aCSF, the biggest improvement to slice viability was actually evident when decapitation of 
the animal was replaced by transcardial perfusion with the modified sucrose based aCSF.  
Despite many improvements being suggested since the late 1980’s, many laboratories 
continue to prepare slices with decapitation, followed by slicing with NaCl based aCSF 
(standard methods). Whilst, differences in oscillatory activity and intracellular properties have 
been demonstrated between standard and modified methods of brain slice preparations 
(Kuenzi et al., 2000; Modebadze, 2014; Prokic, 2012), it is important to question how this 
brain slice preparation affects results when used in acute models of seizure-like-events in 
comparison to more viable slices.   
3.1.2 Effects of antiepileptic drugs in acute models 
Many studies which have used standard slicing methods and promoted SLEs with the 
application acute models (e.g. 0[Mg]2+, 4-AP, KA etc), have often found sensitivity to a wide 
range of antiepileptic drugs (AEDs) ( e.g. CBZ, VPA, PHT, BZDs and barbiturates) in the 
entorhinal cortex (EC) (Drier & Heinemann, 1990; Zhang et al., 1995). Although there are 
variations in response to AEDs from model to model (Sokolova et al., 1998) these types of 
findings have provided the fundamental basis of criticism of AED discovery studies, as they 
simply promote the development of ‘me too’ drugs that do not offer insight into the 
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mechanisms of drug resistance or effective treatment. Furthermore, this point has been 
exacerbated by the findings that demonstrate drugs such as LEV do not show anticonvulsant 
activity in acute MES and PTZ models, but show potent protection against seizures in a 
variety of chronic animal models of epilepsy (Loscher & Honack, 1993). 
Tonic-clonic activity that characterises ictal-discharges (IDs) has been demonstrated to 
transition (> 2 hours) into late-recurring-discharges (LRDs) which only display short bursts of 
tonic activity with prolonged exposure to seizure inducing agents and extracellular ionic 
manipulations.  This transitional behaviour is thought to be due to a reduction in synaptically 
available GABA (Mody et al., 1994). 
In contrast to IDs, LRDs have been shown to be resistant to several AEDs (Drier & 
Heinemann, 1990; Sokolova et al., 1998; Zhang et al., 1995). LRDs have been suggested by 
Zhang et al. (1995) to mimic status epilepticus (SE) development seen in vivo, in humans 
(Trieman et al., 1990) and animals (Lothman et al., 1989). As LRDs have been shown to be 
sensitive to NMDA receptor antagonism, but resistant to AEDs, it has been suggested drug 
resistance may be dependent on long-term-potentiation (LTP) (Drier & Heinemann, 1990; 
Zhang et al, 1995). However, others have suggested LRDs are similar to inter-ictal-
discharges (IIDs), but are not associated with increases in extracellular K+ (Bruckner & 
Heinemann, 2000; Sokolova et al, 1998). There is also the possibility that LRDs occur more 
prominently as a result of poor viability of slices and harsh seizure inducing modifications. 
Whilst it has been recognised that chronic models will undoubtedly provide the best insight 
into mechanisms of drug-resistant epilepsy, these models are often elaborate and time 
consuming. Moreover, the efforts of implementing such models could be argued to be 
wasted by poor brain slice preparation, which promotes neurotoxic effects and so may not 
accurately capture network alterations induced by epileptogenesis. Adding such confounds 
through inaccuracies produced by poor brain slice preparation, further raises ethical issues 
surrounding the use of animals. 
As outlined above, slice preparation could potentially act as a confounding variable when 
investigating AED efficacy and mechanisms. Our primary investigation aimed to investigate 
AED responsiveness and drug-refractory epilepsy (DRE) in the reduced-intensity-status-
epilepticus (RISE) pilocarpine model of chronic epilepsy. However, before this can be 
accurately investigated, the effects of slice preparation acting as a confounding variable on 
the susceptibility to IDs needed to be evaluated.  
The 0[Mg]2+ model is a commonly used, subtle in vitro model of epileptiform activity in 
entorhinal-hippocampal slice used to establish the effects of drugs in seizure activity and 
mechanisms of antiepileptic activity. Using the 0[Mg]2+ model, the current study aimed to 
investigate the effects of 3 different brain slice preparations on the excitability and viability of 
layer II of the MEC. Layer II of the MEC is highly sensitive to epileptogenesis (see section 
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1.3.2). The current study additionally aimed to investigate the possibility of DRE as a 
consequence of slice preparation. The method which produces the most viable slices from 
these investigations can then be used in the preparation of slices from chronically epileptic 
animals, to accurately assess AED efficacy and resistance. 
 
3.2 Results 
3.2.1 Excitability and parameter characteristics of two different brain slice 
preparations 
Transverse hippocampal-entorhinal slices were prepared using standard and modified 
sucrose brain slice preparation methods. Standard methods required the animal to be 
anaesthetised, decapitated and then the brain was extracted and sliced in a cold NaCl based 
aCSF. Modified methods required the animal to be anaesthetised and transcardially perfused 
with a modified sucrose based aCSF, which contained neuroprotectants: taurine, 
aminoguanidine, ethyl pyruvate, uric acid and ketamine (See section 2.1 for more details). 
Acute SLEs were modelled in layer II of the MEC in both types of slice preparations, by 
applying a 0[Mg]2+ aCSF perfusate.  
There was a significant difference between the two preparations, in terms of the number of 
slices that displayed IDs χ² (1, n = 189) = 7.17, p < 0.01. As illustrated in figure 3-1, there 
was a greater number of standard prepared slices (57/87) that showed IDs in comparison to 
sucrose prepared slices (47/102). 
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Figure 3-1. Percentage of slices which displayed IDs in two different slice 
preparations. A. A typical ID from a sucrose prepared 100 g control rat (Scale: 1000 μV x 25 
secs), i, ii, iii and iv correspond to different time points of the ID on a smaller scale (500 μV x 
1 sec). Expansion of the tonic portion of the ID is illustrated in Ai and Aii. Expansion of clonic 
phase bursts illustrated in Aiii and Aiv. B. Number of slices showing IDs following 0[Mg]2+ 
application in standard and sucrose prepared slices. 
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Additionally, there were significant differences between the two types of brain slice 
preparation in terms of latency to first ID, t (51.67) = -4.41, p < 0.01. As illustrated in figure 3-
2, sucrose slices had a significantly longer latency to first ID (3824.53 ± 316.46 seconds) in 
comparison to standard (2268.87 ± 155.91 seconds). 
 
 
Figure 3-2. Latency to first ID in two different brain slice preparations.  Latency to first 
ID in sucrose slices in comparison to standard slices.  
 
Different parameters of seizure activity, such as: frequency of IDs, the inter-event-intervals 
(IEIs) between IDs and the duration of IDs were characterised in the different preparations 
(Figure 3-3). In terms of frequency of IDs there were significant differences between the two 
slice preparations t (68.73) = 3.89, p < 0.01. The frequency of IDs in the sucrose preparation 
(3.38 ± 0.33 frequency per 45 minutes) was significantly lower in comparison to standard 
slices (5.48 ± 0.43 frequency per 45 minutes). IEIs showed the converse relationships.   
There were significant differences between the two slice preparations in terms of IEIs 
between IDs, t (71) = - 3.74, p < 0.01. Specifically, IEIs between IDs in the sucrose 
preparation (1106.68 ± 106.58 seconds) were significantly longer in comparison to standard 
(608.02 ± 82.75 seconds).  
There were also significant differences between the two slice preparations in terms of 
duration of IDs, t (75) = - 4.07, p < 0.01. Specifically, the duration of IDs in the standard 
preparation (65.62 ± 3.38 seconds) was significantly shorter in comparison to sucrose (89.85 
± 4.79 seconds) prepared slices, p < 0.01. There were no significant differences between the 
two slice preparations in terms of power of IDs, p > 0.05. 
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Figure 3-3. Parameter characteristics of induced IDs in two brain slice preparations. A. 
IDs of standard preparation (Scale: 500 μV x 200 secs). B. IDs of sucrose preparation. C. 
Comparison of frequency of IDs in two slice preparations (frequency per 45 minutes). D. 
Comparison of IEIs between IDs in two slice preparations. E. Comparison of durations of IDs 
in two slice preparations. F. Comparison of power (SW frequency: 0.7-2 Hz) of IDs in two 
slice preparations. 
 
3.2.2 Expression of parvalbumin interneurons in the entorhinal cortex of standard and 
sucrose slices 
The results presented thus far demonstrate increased excitability of standard prepared slices 
in comparison to sucrose prepared slices. These findings led us to question what may be 
causing heightened excitability in standard prepared slices.  
Interneurons have profound effects on the excitability of slices, and abnormalities in the 
GABAergic circuitry of animals and humans has been proposed to underlie the hyper-
excitability seen in epilepsy (de Lanerolle et al., 1989; Kumar & Buckmaster, 2006; Peterson 
& Ribak, 1989). Moreover, levels of inhibition in vitro and in vivo are not always consistent 
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(Buckmaster & Schwartzkroin, 1995). Whilst such differences can, to some extent, be 
accounted for by the removal of inhibitory axon collaterals induced during slicing procedures, 
another source of this variability in inhibition maybe due to poor slice preparation. It has been 
previously demonstrated that LTP, induced by field excitatory potentials (fEPSPs), is 
significantly reduced in the CA1 area of sucrose prepared slices in comparison to standard 
aCSF prepared slices. This LTP deficit in sucrose slices was reversed by blocking GABAA 
receptor function with picrotoxin, thus suggesting sucrose aCSF prepared slices better 
preserve GABA mediated transmission (Kuenzi et al., 2000).  
To investigate the possibility that interneurons in the EC are poorly preserved in standard 
preparations in comparison to sucrose preparation, and therefore potentially lead to 
increased excitability, our colleagues at Newcastle University (Hazra et al., 2015) carried out 
parvalbumin (PV) interneuron staining on the two types of slices. As shown in figure 3-4, 
there are appears more PV interneurons in slices which have been sucrose perfused in 
comparison to slices which have been prepared by standard protocols. Additionally, the 
presence of IDs may further reduce PV interneurons in both types of slices, supporting the 
notion that seizure-like activity promotes loss of GABAergic network input, which could 
potentially lead to increased excitability and increased likelihood of more SLEs (Kumar & 
Buckmaster, 2006).  
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Figure 3-4. Preservation of parvalbumin interneurons in the entorhinal cortex of 
sucrose perfused and standard prepared slices. (Scale: 100 μm) (See Hazra et al., 2015 
for further analysis) 
 
3.2.3. Persistence of ictal-like events 
As a result of network architecture differences between standard and sucrose aCSF 
prepared slices, consequent differences may also exist in the efficacy and resistance of 
AEDs. However, before this can be effectively tested, the persistence of IDs needed to be 
accounted for to ensure AED effects seen over the course of such experiments are true and 
not confounded by instability in excitability. It has been well documented, for example, that 
slices prepared from standard protocols exhibit the presence of LRDs after prolonged 
exposure to seizure inducing agents, and have often been shown to be resistant to AEDs 
(Drier & Heinemann, 1990; Sokolova et al., 1998; Zhang et al., 1995). LRDs have been 
suggested to represent more IID activity (Bruckner & Heinemann, 2000; Sokolova et al, 
1998). 
As shown in figure 3-5, both types of brain slices had the capacity to display persistent ID 
activity. However, both types of slices also showed the capacity to transform regular ID to 
recurring IIDs/LRDs, as illustrated in figure 3-6. Whilst this raises some concerns over the 
reliability of results, it was reassuring to find the occurrence of this transformation in sucrose 
slices was relatively low, and generally occurred when: the flow rate of the perfusate was 
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more than 2.5ml/minute, when IDs took 2.5 hours or more to be induced and when slices 
were placed directly into the 0[Mg]2+ aCSF perfusate rather than being gradually washed out. 
On the few occasions, this transformation of activity occurred in sucrose slices, it arose 
during the initial few IDs and could consequently be disregarded. 
 
 
Figure 3-5. The persistence of ID activity in two brain slice preparations. A. The 
persistence of ID activity standard brain slice (scale: 200 μV x 1000 secs). B. The 
persistence of ID activity sucrose brain slice (scale: 200 μV x 1000 secs). 
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Figure 3-6. The transformation from ID activity to IID/LRD activity in two brain slice 
preparations. Tonic-clonic activity that characterises ictal-discharges (IDs) has been 
demonstrated to transition (> 2 hours) into late-recurring-discharges (LRDs) which only 
display short bursts of tonic activity with prolonged exposure to seizure inducing agents and 
extracellular ionic manipulations.  This transitional behaviour is thought to be due to a 
reduction in synaptically available GABA (Mody et al., 1994). A. The transformation of ID 
activity to IID/LRD activity in a standard prepared slice (scale: 500 μV x 250 secs). B. The 
transformation of ID activity to IID/LRD activity in a sucrose prepared slice (scale: 500 μV x 
250 secs). Underneath IID/LRD type activity at shorter time scale (scale: 250 μV x 20 secs). 
 
3.2.4 Efficacy of antiepileptic drugs in two brain slice preparations 
Here, the antiepileptic activity of several combinations of AEDs was characterised in 
standard and sucrose prepared slices. The combinations of AEDs used are presented in 
table 3.1. A combination of two AEDs were used to assess resistance, as the definition of 
DRE is defined as a failure to respond to two or more drugs, with more than one seizure per 
month, for a specified time period (e.g. 12-18 months) (Berg et al., 2001; Cowan, 2002; 
Kwan & Brodie, 2006). As poly-therapy is generally not endorsed amongst patients, due to 
complications surrounding drug interactions, and relatively few studies use combinations 
AEDs, the choice of combination of AEDs was generally based on the use of a primary AED 
followed by a secondary AED as is commonly done with patients, as secondary AEDs have 
been tested and approved as add-on therapy. 
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Table 3.1 Combinations of antiepileptic drugs. Combination of AEDs was generally based 
on the use of a primary AED followed by a secondary AED as is commonly done with 
patients, as secondary AEDs have been tested and approved as add-on therapy. 
1st AED  2nd AED  
Tiagabine 20 µM Carbamazepine  50 µM 
Valproate 500 µM Carbamazepine 50 µM 
Carbamazepine 50 µM Zonisamide 100 µM 
Carbamazepine 50 µM Gabapentin 20 µM 
Lamotrigine 20 µM Gabapentin 20 µM 
Cannabidiol 30 µM Carbamazepine 50 µM 
 
3.2.4.1 Resistance to AEDs in two brain slice preparations. 
The following analysis explores changes in resistance to AED combinations in different slice 
preparations, according to two measurements of resistance.  
Firstly, to test the difference between the two slice preparations and resistance to several 
combination AEDs, a chi-square test for independence was conducted, and showed no 
significant difference χ² (1, n = 69) = 0.94, p > 0.05, as illustrated in figure 3-7A.  
Based on the first definition of AED resistance (continued presence of IDs following 
application of two AEDs), chi square tests of independence were conducted for each AED 
combination to assess differences between the two brain slice preparations. As illustrated in 
figure 3-7B, the only significant difference is between the two brain slice preparations when 
treated with CBD + CBZ χ² (1, n = 14) = 4.67, p < 0.05. The percentage of resistance was 
the highest in standard slices (85.71 %) in comparison to sucrose slices (28.57 %). 
Based on the second definition of resistance (< 50 % reduction of IDs following application of 
2 AEDs), chi square tests of independence were conducted for each AED combination to 
assess differences between the two brain slices preparations. An initial comparison of overall 
resistance between the brain slice preparations, showed no significant differences χ² (1, n = 
77) = 0.61, p > 0.05. As illustrated in figure 3-7C, there were no significant difference in 
resistance between standard and sucrose slices in response to different AED combinations, 
p > 0.05. 
 
Table 3.2 The resistance of different brain slice preparations and combined resistance 
to AEDs. 
 Standard  Sucrose Combined 
Number of slices 20/37 21/40 41/77 
Proportion (%) 54.05 52.5 53.25 
 
82 
 
 
Figure 3-7. Resistance to combination AEDs in layer II of the MEC in two brain slice 
preparations. A. Percentage of slices from two different preparations that show resistance to 
combination AEDs. B. Percentage of slices from two different preparations that show 
resistance to specific combinations of AEDs where resistance is the presence of IDs after 2 
AEDs. C. Percentage of slices from two different preparations that show resistance to 
specific combinations of AEDs where resistance is < 50 % reduction in ID frequency after 2 
AEDs. 
 
3.2.4.2 The effects of AEDs on different ID parameters in two brain slice preparations  
To assess AED efficacy, the frequency of IDs and latency to first ID are often used in clinical 
settings (for examples see Brodie et al., 1999b; Buchanan, 1994; de Silva et al., 1996; 
Sivenius et al., 1994). However, there is a need to consider other parameters (Baker et al., 
83 
 
1991) such as: the IEI between IDs, the duration of IDs and the power of IDs. Further 
assessment of such parameters when investigating AED effects could provide useful 
insights, and was therefore conducted here to further assess responses to AEDs in the two 
brain slice preparations (see Appendices 3-6 for representation of raw data). 
3.2.4.2.1 Frequency 
In terms of the frequency of IDs, a mixed model ANOVA demonstrated there was no 
significant difference between different brain slice preparations and the effects of AED 
combinations, p > 0.05. There was a main effect of drug combination F (5, 65) = 4.70, p < 
0.01. Irrespective of brain slice preparation, the TGB+CBZ combination showed a lower 
frequency of IDs in comparison to CBD+CBZ and LTG+GPT, p < 0.01. 
3.2.4.2.2 Inter-event intervals 
Changes in the frequency of IDs is a rather crude measure, therefore changes in IEIs were 
also explored. Whilst IEIs are the reciprocal measure of frequency this type of measure 
provides more information as to the spread of seizures over time. For example, frequency of 
IDs may suggest three IDs occurred over 45 minutes in vitro, but whether these three IDs 
occurred in the last 20 minutes of recording or equally spread over 45 minutes is not 
captured. This information is provided by exploring IEIs. 
In terms of IEI between IDs, a mixed model ANOVA demonstrated there was a significant 
difference between the response to different AED combinations in different brain slices 
preparations, F (10, 112) = 2.51, p < 0.01 (see figure 3-9). Specifically, post hoc analysis 
showed sucrose slices (3.28 ± 0.15 seconds Log10) had significantly longer IEIs following 
VPA application, in comparison to standard slices (2.78 ± 0.12 seconds Log10), p < 0.05. 
Additionally, sucrose slices also had significantly longer IEIs (3.48 ± 0.12 seconds Log10) 
following CBD+CBZ application, in comparison to standard slices (2.47 ± 0.14 second 
Log10), p < 0.01. These results suggest IDs displayed in sucrose slices were better 
controlled by AED combinations VPA+CBZ and CBD+CBZ. 
There was also a main effect of drug combination F (5, 56) = 3.53, p < 0.01. Post hoc 
analysis showed irrespective of brain slice preparation method, CBD+CBZ combination 
displayed significantly lower IEIs in comparison to CBZ+ZNS, p < 0.05, suggesting 
CBD+CBZ was not as an effective AED combination in comparison to CBZ+ZNS. 
3.2.4.2.3 Duration 
In terms of durations of IDs, a mixed model ANOVA demonstrated there was no significant 
difference in the response to AED combinations in both brain slice preparations, F (10, 126) 
= 1.64, p > 0.05 (see figure 3-10). There was a main effect of drug combination, F (5, 63) = 
2.36, p < 0.0.5. Post hoc analysis showed, irrespective of brain slice preparation, durations of 
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IDs following LTG+GPT application were longer in comparison to CBZ+ZNS and TGB+CBZ, 
p < 0.05. 
3.2.4.2.4 Power 
As the greatest power of IDs was concentrated at the lower frequency ranges, analysis of 
AED effects was conducted on SW (0.7-1.9 Hz) and delta (2-4 Hz) ranges, but a full 
breakdown of AED effects on the power of IDs at different frequency bands, please see 
Appendix 6.  
With regards to the power of IDs at SW (0.7-1.9 Hz) frequencies, a mixed model ANOVA, 
demonstrated there was no significant difference between method of brain slice preparation 
and power of IDs with different AED combinations, p > 0.05 (see figure 3-11). Irrespective of 
brain slice preparation, there was a significant main effect of AED combination F (5, 58) = 
3.39, p < 0.01.  
In terms of power of IDs at delta (2- 4Hz) frequencies, a mixed model ANOVA demonstrated 
there was no significant role for method of brain slice preparation and power of IDs with 
different AED combinations, p > 0.05 (see figure 3-12). There was a main effect of brain slice 
preparation method F (1, 58) = 25.05, p < 0.05. Post-hoc analysis showed, specifically, 
irrespective of drug combination the power of sucrose slice IDs at the delta frequency was 
significantly lower in comparison to standard slices, p < 0.05. There was also a main effect of 
pooled drug combinations, F (5, 58) = 5.13, p < 0.01. Post-hoc analysis showed, irrespective 
of brain slice preparation method, TGB+CBZ reduced the power of IDs significantly more 
than CBD+CBZ, LTG+GPT, p < 0.01.and CBZ+ZNS 
 
  
85 
 
 
Figure 3-8. The effects of AEDs on the frequency of IDs in two brain slice preparations. A. The effects of TGB+CBZ on frequency of IDs 
in two slice preparations B. The effects of VPA+CBZ on frequency of IDs in two slice preparations C. The effects of CBZ+ZNS on frequency of 
IDs in two slice preparations D. The effects of CBZ+GPT on frequency of IDs in two slice preparations E. The effects of LTG+GPT on 
frequency of IDs in two slices preparations F. The effects of CBD+CBZ on frequency of IDs in two slice preparations. 
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Figure 3-9. The effects of AEDs on the IEIs between IDs in two brain slice preparations. A. The effects of TGB+CBZ on IEIs between IDs 
in two slice preparations B. The effects of VPA+CBZ on IEIs between IDs in two slice preparations C. The effects of CBZ+ZNS on IEIs between 
IDs in two slice preparations D. The effects of CBZ+GPT on IEIs between IDs in two slice preparations E. The effects of LTG+GPT on IEIs 
between IDs in two slices preparations F. The effects of CBD+CBZ on IEIs between IDs in two slice preparations. 
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Figure 3-10. The effects of AEDs on the duration IDs in two brain slice preparations. A. The effects of TGB+CBZ on the duration of IDs in 
two slice preparations B. The effects of VPA+CBZ on the duration of IDs in two slice preparations C. The effects of CBZ+ZNS on the duration of 
IDs in two slice preparations D. The effects of CBZ+GPT on the duration of IDs in two slice preparations E. The effects of LTG+GPT on the 
duration of IDs in two slices preparations F. The effects of CBD+CBZ on the duration of IDs in two slice preparations. 
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Figure 3-11. The effects of AEDs on the SW (0.7-1.9Hz) power of IDs in two brain slice preparations. A. The effects of TGB+CBZ on the 
SW (0.7-1.9 Hz) power of IDs in two slice preparations B. The effects of VPA+CBZ on the SW (0.7-1.9 Hz) power of IDs in two slice 
preparations C. The effects of CBZ+ZNS on the SW (0.7-1.9 Hz) power of IDs in two slice preparations D. The effects of CBZ+GPT on the SW 
(0.7-1.9 Hz) power of IDs in two slice preparations E. The effects of LTG+GPT on the SW (0.7-1.9 Hz) power of IDs in two slices preparations 
F. The effects of CBD+CBZ on the SW (0.7-1.9 Hz) power of IDs in two slice preparations. 
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Figure 3-12. The effects of AEDs on the delta (2-4 Hz) power of IDs in two brain slice preparations. A. The effects of TGB+CBZ on the 
delta (2-4 Hz) power of IDs in two slice preparations B. The effects of VPA+CBZ on the delta (2-4 Hz) power of IDs in two slice preparations C. 
The effects of CBZ+ZNS on the delta (2-4 Hz) power of IDs in two slice preparations D. The effects of CBZ+GPT on the delta (2-4 Hz) power of 
IDs in two slice preparations E. The effects of LTG+GPT on the delta (2-4 Hz) power of IDs in two slices preparations F. The effects of 
CBD+CBZ on the delta (2-4 Hz) power of IDs in two slice preparations.  
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3.2.4.2.5 Predictive power of different ID parameters 
The analyses of AED effects on different parameters of IDs in the two brain slice 
preparations is complex. Only the IEI parameter was able to discriminate AED efficacy 
between the two slice preparation methods. Sucrose slices were shown to respond better to 
VPA and CBD+CBZ. However, all parameters consistently showed, irrespective of brain slice 
preparation, TGB+CBZ were the most effective AED combinations whereas LTG+GPT and 
CBD+CBZ were the least effective.   
To assess which parameter held the most predictive power of slice preparation a logistic 
regression was conducted. The regression model contained four predictor variables of slice 
preparation: percentage change from 0[Mg]2+ aCSF to application of two AEDs in the 
frequency of IDs, percentage change of the IEI between IDs, percentage change in the 
duration of IDs and percentage change in the power of IDs at the SW frequency range.  The 
full model containing all predictors was not statically significant, χ² (9, n= 67) = 13.23, p > 
0.05, indicating the model was not able to distinguish between different brain slice 
preparations (see figure 3-13). The model as a whole explained between 17.9% (Cox and 
Snell R square) and 23.9 % (Nagelkerke R squared) of the variance in brain slice preparation 
methods, and correctly classified 73.1 % of cases. Although this analysis was unable to 
highlight which out the four parameters hold the most predictive power, it is evident from 
analyses investigating the efficacy of AEDs in different brain slice preparations that IEI and 
duration parameters hold a great deal of predictive power and shall therefore be the 
continued primary parameters of investigation. 
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Figure 3-13. The percentage change of ID parameters with application of AEDs in two 
brain slice preparations. 
 
3.2.5 The role of LTP in the resistance to AEDs in sucrose slices 
From the analyses presented thus far, it is evident that sucrose prepared slices are less 
excitable in comparison to standard prepared slices, and show little or no difference in the 
response and resistance to many combination AEDs. Given that sucrose slices have a better 
preserved inhibitory network and consequently better control over network activity, it would 
be expected that these slices show significantly less resistance. What is the mechanism 
behind this degree of persistent resistance in sucrose prepared slices? We have shown that 
sucrose slices display a greater latency to first ID time period compared to standard slices, 
the period of time when LTP processes are activated.  
Brief, controlled periods of Ca2+ elevations occur during physiological processes associated 
with plasticity changes of LTP in learning and memory (Gnegy, 2000; Malenka & Nicoll, 
1999; Tzounopoulos & Stackman, 2003; West et al., 2001). However, at the other of the 
spectrum, pathological uncontrolled and irreversible elevations in Ca2+ lead to neuronal 
death. The middle ground, appears to be a characterised by a less severe epileptogenic 
injury whereby exposure to prolonged but reversible elevations in Ca2+ trigger pathological 
plasticity changes, leading to chronic epilepsy and DRE (DeLorenzo et al., 2005). 
To test the hypothesis that sucrose slice AED resistance was due to longer duration of 
exposure to LTP inducing 0[Mg]2+ aCSF, sucrose slices were incubated with the protein 
synthesis inhibitor, cycloheximide, for 30 minutes prior to 0[Mg]2+ aCSF application. 
Application of cycloheximide would be expected to inhibit the expression of LTP, and 
consequently reduce synaptic strength. 
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As demonstrated in figure 3-14, there were no significant differences in the number of 
cycloheximide treated slices which displayed IDs in 0[Mg]2+ aCSF, in comparison to sucrose 
perfused slices, p > 0.05. On the other hand, cycloheximide slices (6910.2 ± 676.70 
seconds) showed a significantly longer latency to first ID, in comparison to sucrose slices 
(4753.8 ± 476.55 seconds)., p < 0.01. 
Figure 3-14. Excitability of sucrose perfused and cycloheximide treated slices. A. 
Percentage of cycloheximide treated and sucrose perfused slices that displayed IDs. B. 
Latency to first ID in in cycloheximide treated and sucrose perfused slices. 
 
Differences in ID parameters between cycloheximide treated and sucrose slices in 0[Mg]2+ 
aCSF were assessed. As shown in figure 3-15, an independent-sample t-test showed there 
no significant differences between the duration of IDs in cycloheximide treated (95.53 ± 9.03 
seconds) and sucrose slices (87.45 ± 7.21 seconds), t (33) = 0.69, p > 0.05. A Mann-
Whitney- U test revealed no significant difference in the IEI between IDs in cycloheximide 
treated (1000.5 seconds ± 264.94) and sucrose slices (1074.8 ± 159.18 seconds), U = 84.00, 
Z = -1.16, p > 0.05. 
 
Figure 3-15. ID parameters of cycloheximide treated and sucrose perfused slices in 
0[Mg]2+ aCSF. A. The duration of IDs in cycloheximide treated and sucrose perfused slices. 
B. The IEIs between IDs in cycloheximide treated seconds and sucrose perfused slices.  
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To assess the effects of LTP inhibition on AED resistance, CBZ+ZNS, LTG+GPT and 
CBD+CBZ were applied to cycloheximide treated slices and sucrose perfused slices. These 
drug combinations were chosen based on the premise that they displayed the highest levels 
of resistance in sucrose slices. The differences in duration was not considered as part of this 
analysis as very few cycloheximide slices showed IDs following AED applications. 
As illustrated in figure 3-16, a chi-square test for independence indicated no significant 
association between the percentage of cycloheximide treated and sucrose slices with 
resistance to CBZ+ZNS, χ² (1, n = 13) = 1.04, p > 0.05. There was a significant difference 
between the percentage of cycloheximide treated (20 %) and sucrose slices (83.33 %) with 
resistance to LTG+GPT, χ² (1, n = 11) = 4.41, p < 0.05. There was no significant association 
between the percentage of cycloheximide treated and sucrose slices with resistance to 
CBD+CBZ, χ² (1, n = 12) = 0.11, p > 0.05. 
 
Figure 3-16. The resistance of cycloheximide treated and sucrose slices to AEDs. 
Significantly more sucrose slices than cycloheximide treated slices showed resistance to 
LTG+GPT AEDs. 
 
As demonstrated in figure 3-17, a mixed model ANOVA demonstrated, irrespective of drug 
combination, the IEIs of cycloheximide treated slices were significantly higher than sucrose 
slices overall, p < 0.05. There was no significant interaction effect between cycloheximide 
treated and sucrose slices with different drug combinations, p > 0.05. 
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Figure 3-17. The effect of AEDs on the IEIs between IDs in cycloheximide treated and 
sucrose slices. A. The effects of CBZ (50 µM) and ZNS (100 µM) on IEIs between IDs in 
cycloheximide treated and sucrose slices. B. The effects of LTG (20 µM) and GPT (20 µM) 
on IEIs between IDs in cycloheximide treated and sucrose slices. The effects of CBD (30 µM) 
and CBZ (50 µM) on IEIs between IDs in cycloheximide treated and sucrose slices. 
 
As differences in the resistance of AEDs between cycloheximide treated and sucrose slices 
were only evident in one out of three AED combinations, and in latencies to first ID analysis, 
it was attempted to further test the role LTP in sucrose slice AED resistance by treating slices 
with a different LTP inhibitor, GF109203X, which inhibits PKC. However, this treatment 
considerably inhibited the induction of IDs, as only 2 out of 20 slices consistently displayed 
more than one IDs after prolonged exposure to 0[Mg]2+. Only 4 out of 20 slices (20 %) 
displayed more than one ID, but these IDs occurred inconsistently with very long IEIs. As 
illustrated in figure 3-18, the latency to first seizure or total time recorded in 0[Mg]2+ without 
an ID was significantly longer in slices pre-treated with GF109203X (10,441.75 ± 698.47 
seconds) in comparison to cycloheximide treated slices (6910.20 ± 676.70 seconds), t (33) = 
3.49, p < 0.01. These results suggest PKC plays a role in the induction of IDs. 
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Figure 3- 18. The excitability of GF109203X treated slices. A. A representative trace 
illustrating the long latency to first ID in GF109203X treated slices. The first ID occurred at 
9145 seconds followed by another ID 5380 seconds later, as indicated by the asterisks. 
Scale: 500 μV x 2000 seconds. B. Bar graph showing the average latency to first ID or 
average length of time without an ID in cycloheximide and GF109203X treated slices. 
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3.3 Discussion 
The current investigation demonstrated standard prepared slices are more excitable in 
comparison to sucrose prepared slices, probably as a result of a better preserved inhibitory 
network. Irrespective of preparation method, CBD+CBZ and LTG+GPT were the least 
effective AED combinations and TGB+CBZ were the most effective. There is little difference 
between the two brain slice preparations in terms of resistance and efficacy of combination 
AEDs. This is of particular interest given the preservation of the inhibitory network, one may 
expect resistance to be lower in sucrose slices, but given the increased latency to first ID, it 
is likely enhanced LTP processes in these slices bring levels of resistance to similar standard 
as seen in standard prepared slices. LTP processes were shown to play a potential role in 
the resistance toward AEDs. 
Previous studies exploring the effects of AEDs on IDs induced in vitro, have demonstrated a 
unifying sensitivity to a large range of AEDs (Armand et al., 1998b; Drier & Heinemann, 
1990; Zhang et al., 1995). This overwhelming deficiency in the ability to differentiate between 
the effectiveness of AEDs in vitro, has promoted the existence of ‘me too’ drugs, which are 
capable to treating seizures for some patients, but do not improve prognosis for those 
patients with DRE. Furthermore, by not being able to identify better drugs for sufferers of 
DRE, the possibility of understanding the mechanisms underlying this severe form of 
epilepsy remains to be elucidated.  
In our laboratory comparisons between standard and modified slice preparation protocols 
have illustrated improvements to motor cortex and hippocampal slice viability when prepared 
with modified sucrose aCSF. Additionally, we have demonstrated oscillatory activity stability 
is significantly improved with modified methods of brain slice preparations, allowing accurate 
characterisation of pharmacological effects in vitro (Modebadze, 2014; Prokic, 2012). It is 
important to question how improved brain slice preparations effects investigations of AED 
discovery and efficacy, and whether improved preparations can enrich the ability to 
differentiate between effective and non-effective AEDs.  
3.3.1 The excitability of slices from different brain slice preparations 
The current study demonstrated the presence of enhanced excitability in standard prepared 
brain slices in comparison to sucrose prepared slices. This was evident as a higher 
percentage of standard slices displayed IDs with shorter latencies to first ID, in comparison to 
sucrose slices. Additionally, analysis of ID parameters in 0[Mg]2+ aCSF supported these 
findings by showing sucrose prepared slices were the least excitable. 
Previous research by Kuenzi et al. (2000) compared the effects of slices prepared from 
standard and sucrose based aCSF on hippocampal synaptic plasticity, and demonstrated the 
amount of induced LTP was significantly reduced in sucrose prepared slices. LTP induction 
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critically depends on the depolarisation of pyramidal cell in the hippocampus, but stimulus-
response relationships suggested the sucrose preparation did not affect excitatory synaptic 
transmission. Moreover, this LTP deficit in sucrose slices was reversed by blocking GABAA 
receptor activity with picrotoxin, thus suggesting sucrose aCSF better preserves inhibitory 
transmission.  
Based on these findings, we collaborated with colleagues at Newcastle University to conduct 
PV interneuron staining in both standard and sucrose prepared slices, before and after ID 
activity. This investigation led to the finding that PV interneurons are better preserved in 
sucrose slices in comparison to standard slices. Additionally, it was found that the presence 
of IDs reduced the number of PV interneurons in both types of slices. These findings suggest 
the reason for enhanced excitability in standard prepared slices is due to poor preservation 
of the inhibitory network. 
Interneurons have profound effects on the excitability of slices, and abnormalities in the 
GABAergic circuitry of animals and humans has been proposed to underlie the hyper-
excitability seen in epilepsy (de Lanerolle et al., 1989; Kumar & Buckmaster, 2006; Peterson 
& Ribak, 1989). Moreover, levels of inhibition in vitro and in vivo are not consistent 
(Buckmaster & Schwartzkroin, 1995). Whilst such differences can to some extent can be 
accounted for by the loss of inhibitory axon collaterals during the slicing procedure, it is 
important for in vitro slice preparation methods to be optimised to reduce variance between 
in vitro and in vivo environments, in order to investigate AED effects as accurately as 
possible.  
3.3.2 The efficacy of different AED combinations in different brain slice preparations 
Comparative investigations into the resistance of the two brain slice preparations, to several 
combinations of AEDs, showed there were minimal differences between standard and 
sucrose slices in terms of percentage of slices that were resistant to two AEDs.  
Investigations of resistance to specific AED combinations in the different preparations were 
assessed using two definitions of resistance. Analysis of resistance according to the first 
definition (continued presence of IDs following application of two AEDs) highlighted standard 
slices show greater resistance to CBD+CBZ in comparison to sucrose slices. The second 
definition (less than 50 % reduction in seizure frequency following the application of two 
AEDs) did not highlight any differences between the two brain slice preparations in response 
to different combination AEDs. 
The majority of combination AEDs here act in mechanistically similar ways, either by acting 
at Na+ or Ca2+ channels, or both (see section 1.5). The exceptions being TGB acts to 
enhance GABA transmission (Dalby & Nielsen, 1997; Jackson et al., 1999; Thompson & 
Gahwiler, 1992), and the mechanisms of CBD remain ambiguous but it has been suggested 
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to affect: the equilibrative nucleoside transporter, the orphan G-protein-couple receptor 
GPR55, the 5HT1a receptor, the α1 and α3 glycine receptors and the transient receptor 
potential of Ankyrin type I channel (see Devinsky et al., 2014 for a review).  
A higher percentage of sucrose slices displayed greater resistance to TGB+CBZ, in 
comparison to standard slices. This is surprising, as we have demonstrated sucrose slices 
better preserve the inhibitory network, therefore we would expect drugs such as TGB which 
enhance inhibition to work better in such slices. One explanation for these unexpected 
results may explained by variances in the damage of inhibitory networks in standard 
prepared slices. Histological investigations of PV interneurons found, some standard 
prepared slices had a more intact inhibitory network in comparison to other standard 
prepared slices.  
Additionally, it is likely that that the effects of changes to inhibitory networks are not as simple 
to decipher as expected, and the interplay of changes to excitation also need to be 
congruently evaluated. Sucrose slices showed longer latencies to first IDs in comparison 
standard prepared slices, and were more likely to have been exposed to greater NMDA 
activation which plays an important role in LTP expression. This enhanced exposure to 
excitation may have resulted in a higher resistance to TGB+CBZ. If this is the case, one may 
question why is resistance not consistently seen in sucrose slices with other AEDs? As 
demonstrated TGB+CBZ are particularly effective AEDs, irrespective of slice preparation, in 
comparison to other AEDs, and it may be this superiority that leads to such results.  
The debate over precedence of changes in excitation and inhibition accounting for DRE 
(Galarreta & Hestrin, 1998; Pavlov et al., 2013; Margineanu & Klitgaard, 2009; Sayin et al., 
2003; Woodhall et al., 2005), is a long standing one, which has demonstrated valid points for 
both sides of the debate. Additionally, other mechanisms of DRE such as inflammation and 
glia-induced hyperexcitability may also be of importance (Devinsky et al., 2013). 
Further in-depth analyses of AED effects on different parameters (e.g. frequency of IDs, IEIs 
between IDs, duration of IDs and power of IDs) in different brain slice preparation methods, 
further demonstrated little difference between sucrose and standard prepared slice. 
Irrespective of different brain slice preparation effects, analysis of these different parameters 
further showed the CBD+CBZ and LTG+GPT were the least effective AED combinations and 
TGB+CBZ was the most effective AED combination. Power analyses did not show 
preparation specific AED effects but did demonstrate the power of IDs in sucrose slices 
overall was smaller in comparison to standard slice IDs. 
The quantitative characterisation of AED effects can be rather complex and many 
researchers often use frequency of IDs and latency to first ID, as is often done in clinical 
settings (Brodie et al., 1999b; Buchanan, 1994; de Silva et al., 1996; Sivenius et al., 1994). 
However, there is a need to consider other parameters (Baker et al., 1991; Yonekawa et al., 
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1995) and in vitro and in vivo techniques offer the ability to extract information on other ID 
parameters. In this investigation, largely consistent findings between analyses of different 
parameters have been demonstrated and whilst this is reassuring, it is important to recognise 
which parameters provide the most insight and predictive power. Regression analyses 
conducted failed to highlight which out the four parameters considered held the most 
predictive power, but analyses investigating AED efficacy in different brain slice preparations 
suggested IEI and duration of IDs would be the most informative. 
3.3.3 The role of LTP in the resistance of sucrose perfused slices 
Overall there was no significant difference between sucrose and standard prepared slices. 
Given that the inhibitory network is better preserved in sucrose slices in comparison to 
standard slices, it is intriguing as to why the level of resistance in sucrose slices persists. 
Although Knuezi et al (1995) demonstrated LTP is reduced in sucrose slices, here it is 
evident that latency to first ID is significantly longer. Therefore, one must consider the 
possibility that this increased length of time exposed to excitatory and LTP inducing agents, 
results in this increased resistance.  
The induction of certain forms of LTP fundamentally relies on the activation of postsynaptic 
NMDA receptors, as illustrated in figure 3-18. Glutamatergic activation of postsynaptic AMPA 
receptors allows intracellular entry of Na+ and K+ ions and glutamatergic activation of 
postsynaptic NMDA receptors promotes influx of Ca2+ and Na+ ions once the Mg2+ block has 
been removed. Metabotropic glutamate receptors have also been shown to enhance LTP via 
activation of protein kinase C (PKC) (McGuinness et al., 1991).  
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Figure 3- 18. Schematic representation of LTP induced cellular signal transduction 
pathways. Adapted from Kandel et al. (2012).  
 
The critical rise in intracellular Ca2+ as a result of NMDA receptor activation, triggers LTP 
through a wide range of cellular signal transduction pathways. There are a bewildering 
number of protein kinases (e.g. PKC, cyclic adenosine 3’,5’- monophosphate (cAMP), 
tyrosine kinase, Src and mitogen-activated protein kinase (MAPK)) involved in LTP (for a 
review see Lynch, 2004). Despite this number of protein kinases involved in LTP, 
overwhelming evidence has a suggested an important role of Ca2+ activated α-calcium-
calmodulin-dependent protein kinase II (CamKII) in initiating LTP effects.  
CamKII is one the most abundant proteins in neurons and is expressed pre- and post-
synaptically, but expression has been found to be higher in postsynaptic cells where it would 
be ideally located to respond to changes in calcium concentration (Flink & Meyer, 2002; 
Lynch, 2004). Activation of CamKII leads to AMPA receptor phosphorylation which ultimately 
increases AMPA receptor conductance (Barria et al., 1997). CamKII activity continues long 
after Ca2+ signals have returned to baseline, because when CamKII is autophosphorylated at 
Th286 activity is no longer Ca2+ dependent (Lisman, 1994). When the kinase is mutated 
(threonine replaced with alanine) autophosphorylation is prevented and LTP is impaired 
(Giese et al., 1998). Moreover, CamKII displays pre- and postsynaptic effects (Lynch, 2004; 
Malenka & Nicoll, 1999). Presynaptically CamKII has been shown to increase 
phosphorylation of synapsin I and MAP2 (Fukunga et al., 1996). Postsynaptically, CamKII 
inhibitors have been demonstrated to inhibit LTP (Malenka et al., 1989; Malinow et al., 1989). 
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To test the hypothesis that sucrose slice AED resistance was due to longer duration of 
exposure to LTP inducing 0[Mg]2+ aCSF, sucrose slices were incubated with the protein 
synthesis inhibitor, cycloheximide, for 30 minutes prior to 0[Mg]2+ aCSF application. No 
differences between the percentage of cycloheximide treated and sucrose slices that 
displayed IDs were observed, but there were differences in the latency to first ID. The latency 
to first ID was considerably longer in cycloheximide treated slices. There were no significant 
differences between cycloheximide treated and sucrose slices, in terms of IEIs between IDs 
and duration of IDs in 0[Mg]2+ aCSF. These findings suggest that LTP is likely play a role in 
bootstrapping the generation of IDs, as latency to first ID significantly increases when LTP is 
blocked, and IDs do not occur in the presence of GF109203X. Complimentary to these 
findings, chronic pilocarpine epilepsy studies have demonstrated NMDA receptor inhibition 
with MK-801 prevented the development of epilepsy (Rice & DeLorenzo, 1998). In order for 
these conclusions to be firmly presented, further investigation showing the links between 
NMDA receptors and LTP must be made. 
There were also no significant differences in terms of percentage of slices that showed 
resistance to two out of three AED combinations. However, significantly more sucrose slices 
showed resistance to the LTG+GPT combination in comparison to cycloheximide treated 
slices. Analysis of AED effects on IEIs between IDs in cycloheximide treated and sucrose 
slices, further supported the finding of heightened resistance of sucrose slice to the 
LTG+GPT combination. As cycloheximide treated slices were especially sensitive, to the 
‘weakest’ AEDs, LTG+GPT, these findings further support the notion that LTP is crucial in the 
establishment of IDs and in the generation of drug resistance.  
Overall, cycloheximide treated slices consistently show a much lower resistance to 
combination AEDs (no more than 20 %), in comparison to non-cycloheximide treated slices 
of different preparations. These findings coupled with the fact that ID initiation is substantially 
blocked by the PKC inhibitor, GF109203X, suggests LTP is likely to be involved in seizure 
initiation and resistance.    
3.4 Conclusion 
The current study investigated the excitability of standard and sucrose prepared slices. It has 
previously been demonstrated that differences remain between these two preparations in 
terms of slice viability, oscillatory stability and induction of LTP. The investigation concluded 
standard prepared slices are much more excitable than sucrose prepared slices, and 
immunohistochemistry follow-up investigations suggested this enhanced excitability may due 
to a poorly preserved inhibitory network in standard slices in comparison to sucrose slices.  
As many studies using standard prepared slices in acute models have demonstrated 
sensitivity to a wide range of AEDs, we further investigated differences between the two 
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slices preparations to see if differentiations in AEDs could be better identified in sucrose 
slices, and potentially serve as a better model for assessing drugs targeting DRE. The 
analysis of several ID parameters, led to the conclusion that there is little difference between 
sucrose and standard slices in terms of resistance to AEDs. This could possibly be due to 
extended latency to first ID in sucrose slices, as longer exposure to excitation and LTP 
inducing 0[Mg]2+ aCSF induces more damage in sucrose slices and therefore brings the level 
of resistance to AEDs seen in these slices to the same as standard slices. Investigation with 
the protein synthesis blocker, cycloheximide, provided evidence to support this hypothesis as 
cycloheximide treated slices showed a longer latency to first ID and were less resistant to 
combination AEDs in comparison to sucrose slices. Additionally, initiation of IDs was blocked 
in slices treated with the PKC inhibitor, GF109203X. These findings demonstrate the likely 
role of LTP in ID generation and AED resistance.  
Finally, many researchers have highlighted the need to consider assessing AED resistance 
using different parameters. In this study we concluded IEIs between IDs and duration of IDs 
held the most predictive power in determining differences between different slices 
preparations. Even though there were no overtly obvious differences in resistance to AEDs in 
standard and sucrose slices, sucrose slices evidently better preserve the neuronal networks, 
which lead to more accurate findings, which has important applications for studies of chronic 
epilepsy. 
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Chapter 4 The effects of antiepileptic drugs in layer II of medial 
entorhinal cortex during epileptogenesis compared to resected 
epileptic human tissue 
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4.1 Introduction 
4.1.1 Antiepileptic drug effects in acute and chronic models of epilepsy 
The discovery of AEDs originally occurred by serendipity, and later the need for preclinical 
testing of potential AEDs became apparent, hence the common use of pentylenetrazole 
(PTZ) and maximal electric shock (MES) screening models. The MES model induces 
seizures by corneal or transauricular electrical stimulation, whereas the PTZ model induces 
seizures by systematically administering PTZ.  Many AEDs focus on restoring, to some 
extent, the excitation-inhibition balance (Klitgaard, 2005). However, these acute models 
suffer from several limitations. For example, the MES model has been criticised for being 
particularly sensitive to drugs which work, at least in part, by blocking Na+ channels 
(Meldrum, 1997). Additionally, these models yield false negative results as the MES model is 
not sensitive to drugs such as LEV and TGB which primarily act through Na+ independent 
mechanism (Loscher & Schmidt, 1994). The PTZ model has also been criticised for similar 
reasons. For example, because PTZ acts as a GABA antagonist, this model suggests VGB 
and TGB are effective anticonvulsants, but conversely have been shown to be ineffective 
and even pro-convulsive in some epileptic human patients (Loscher, 2002; Meldrum, 1997).  
In a similar fashion to these acute in vivo models of seizures, in vitro models of seizures (e.g. 
0[Mg]2+, 4-AP) have also have often found sensitivity to a wide range of AEDs (e.g. CBZ, 
VPA, PHT, BZDs and barbiturates) (Drier & Heinemann, 1990; Zhang et al., 1995), which 
promote the development of ‘me too’ drugs and do not offer insight into the mechanisms of 
drug resistance or effective treatment as described in section 3.1. 
Acute models have led to development of a wide range of AEDs, but these drugs often 
interfere with normal physiology and therefore result in poor efficacy and safety profiles. 
Moreover, these models ignore the complex underlying pathophysiology of epilepsy, 
therefore the prognosis for drug responsive epileptic patients is poor as AEDs do not alter 
the progression or underlying pathology of epilepsy (Shinnar & Berg, 1996). Furthermore, 
prognosis for DRE sufferers is even more unsatisfactory, as available AEDs fail to exert 
antiepileptic effects, and a lack of understanding over the mechanisms that lead to resistance 
makes overcoming such circumstances with better treatments unlikely. It has been 
suggested that once a better understanding of the mechanisms underlying drug resistance in 
epilepsy has been developed, more effective drugs that halt, or even reverse, the process of 
epileptogenesis can be developed (Loscher, 2002). Several AEDs have been tested in 
clinical trials for the potential to alter epileptogenesis, and have failed to do so (Temkin, 
2001; Temkin et al., 1990), therefore the use of chronic animal models of epilepsy is even 
more relevant in order to identify truly AEDs. 
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Chronic models of epilepsy have transformed the development and testing of AEDs by 
improving treatment outcome predictions and providing better insight into epileptogenesis 
and DRE mechanisms. One AED that clearly illustrated this point is the identification of LEV 
as an AED. LEV does not show antiepileptic potential in models with normal animals, but 
shows a potent antiepileptic effect in chronic epileptic models (Klitgaard, 2001; Klitgaard et 
al., 1998; Loscher & Honack, 1993). Moreover, LEV has mechanistic actions that are rather 
different from classic AEDs which generally target Na+, Ca2+ and GABA transmission. 
Specifically, LEV has been shown to inhibit high-voltage activate Ca2+ currents 
(Niespodziany et al., 2001) and suppress inhibitory effects of allosteric modulators of GABA 
and glycine currents, including zinc and β-carbolines (Rigo et al., 2002). LEV has also been 
shown to interact with the synaptic vesicle protein 2A (SVA2A) (Bajjalieh et al., 1994; Lynch 
et al., 2004). SV2A modulates presynaptic neurotransmission by regulating exocytosis of 
neurotransmitter vesicles. In support, mice lacking SVA2A develop a strong seizure 
phenotype and usually die within 3 weeks of birth (Lynch et al., 2004).  
Another example demonstrating the benefits of chronic models of epilepsy includes the 
prediction made by the kindling model of epilepsy suggesting clinical failure of NMDA 
antagonists as an AED, which was suggested by the MES model to be effective (Loscher, 
1998; Loscher & Honack, 1991). Additionally, the AEDs diazepam and PHT, have shown 
opposite effects of superiority as AEDs in acute and chronic models of kindling, with PHT 
being more effective in the acute model and diazepam being more effective in the chronic 
model (Pinel, 1983). Although this study has been criticised as acute and chronic models 
were induced on the same animals, therefore varying levels of tolerance may have been 
developed, thus confounding the results (Loscher, 2002). Drugs that are effective in the 
amygdala kindled model have been suggested to be useful in treating complex partial 
seizures in humans (Loscher et al., 1986; McNamara, 1984), however the mechanism 
through which certain AEDs aid control of certain types of seizures is less clear. 
An acute, in vivo study using pilocarpine further demonstrated superiority over classical MES 
screening models. Following pre-treatment with AEDs pilocarpine was administered and the 
protective effects were measured by incidence of seizures. Turski (1987) demonstrated, 
clonazepam (CLO), PHB, VPA and trimethadione (TMD) effectively prevented the incidence 
of seizure following pilocarpine administration, suggesting the potentiation of GABA was the 
superimposing mechanism providing protection. However, a similar study has suggested 
these drugs are not effective at halting pilocarpine induced effects (Morrisett et al., 1987). 
These contrasting results may have occurred as a result in different treatment protocols 
(concentration of AEDs and pilocarpine) and time post pilocarpine treatment animals were 
observed for. For example, Morrisett et al (1987) showed VPA pre-treatment resulted in a 
longer latency to SE but is unable to stop SE from occurring. 
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Turski (1987) further showed the AEDs, DPH and CBZ had no effect on preventing the 
incidence of seizures. Similar findings have been found in the kainate model, in vitro (Clifford 
et al., 1982) and in vivo (Fuller & Olney, 1981; Kleinrok et al., 1980).  In contrast, MES and 
PTZ models suggests these drugs are effective (Czuczwar et al., 1982; Turski, 1987). 
Moreover, ESM and acetazolamide (ACT) significantly exacerbated seizure incidence and 
brain damage. Other acute pilocarpine studies have demonstrated certain combinations of 
AEDs (e.g. diazepam and PHB/PHT) work well in reducing pilocarpine induced effects 
(Lemos & Cavalheiro, 1995). 
Studies investigating AED effects in the latent period of chronic KA and pilocarpine models 
have shown protective effects, in terms of reduced morphological effects and incidence of 
SRS, of VPA (Bolanos et al., 1998), GPT(Cilio et al., 2001) and LEV (Margineanu et al., 
2008) but not VGB (Pitkanen et al., 1999). In contrast there a relatively few studies which 
investigated AED effects in the chronic phase of pilocarpine and kainate models. This is 
surprising as some have recognised different mechanisms underlying epileptogenesis and 
maintenance of SRS, therefore drugs which target prevention of epileptogenesis and drugs 
which target prevention of SRS may be different (Leite et al., 2002; Silver et al., 1991; 
Shinnar and Berg, 1996; Loscher, 1998).  
One in vivo study conducted by Klein et al. (2015) investigating AED effects in chronic 
epilepsy in the KA model found that six AEDs suppressed secondary generalised convulsive 
seizures, but focal non convulsive seizures were resistant to CBZ and PHT but not VPA, 
LEV, PHB and diazepam. These findings support a similar study conducted by Riban et al. 
(2002). This study went on to investigate resistance of focal seizures in responders and non-
responders, and found non-responders were likely to be resistant to more than one AED. 
From these findings it was suggested this mouse model of KA induced epilepsy is resistant 
to AEDs which modulate VGSCs, in a similar fashion to the 6-Hz mouse model of difficult to 
treat partial seizures (Barton et al., 2001; Bankstahl et al., 2013), but was sensitive to drugs 
with GABAergic mechanisms.  
Whilst the study by Klein et al. (2015) suggests the KA model of chronic epilepsy was useful 
in the testing of DRE, it suffers from several limitations. Firstly, resistance was seen only in 
non-convulsive focal seizures, not in secondarily convulsive seizures that are often seen in 
patients of DRE to a devastating degree. Secondly, this studied identified resistance in terms 
of response to singly administered AEDs, whereas the definition of DRE clearly identifies a 
failure to respond to two or more AEDs (Berg et al., 2001; Cowan 2002; Kwan & Brodie, 
2006). Finally, the presence of high frequency electrographic seizures may be regarded as a 
strength for assessing AEDs, but it could be questioned whether such a severe seizure state 
is accurately imitating the human condition and variances are likely to result in differences of 
AED response too. As with many in vivo studies, in this study there also lies the possibility 
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that differences between responders and non-responders could stem from subtle differences 
associated with injection site of KA. 
Overall, it is evident that because chronic models of epilepsy are more prototypical of 
underlying pathophysiology of epilepsy in comparison to acute models, they are 
consequently better equipped to make accurate predictions and test the efficacy of AEDs. 
Having said this, relatively few studies have explored how response to AEDs change over 
the course of epileptogenesis or directly addressed whether the nature of epileptogenesis is 
continuous or not. Moreover, while several different studies have explored AED efficacy at 
different stages of the chronic KA model of epilepsy, relatively few have been carried out on 
the pilocarpine model. Additionally, studies investigating AED effects during different stages 
of epileptogenesis often suffer from limitations such as employing high severity models and 
classifying resistance based on the response to individual AEDs rather than combinations of 
AEDs. For these outlined reasons it is the primary aim the current study to investigate the 
efficacy of combinations of AEDs during epileptogenesis of the refined Li-pilocarpine model, 
in the MEC. 
4.1.2 Antiepileptic drug effects in human patients 
One of the fundamental aims of research with chronic animal models of TLE, is to identify 
mechanisms and drugs which effectively prevent epilepsy in humans. However, it has been 
demonstrated that there are marked differences that exist between different chronic models 
of epilepsy in terms of underlying pathophysiology and response to different AEDs. Whilst 
the amygdala-kindling model has been suggested to be useful for assessing DRE (Loscher, 
1997), current knowledge makes it difficult to identify which model is the most appropriate for 
studying epilepsy. However, as epilepsy generally has multi-factorial aetiologies many 
models are likely to be relevant and results from different models should all be considered to 
avoid false negative or positive predictions (Loscher, 2002).  
Treiman (1987) assessed the findings of 20 randomised, double-blind, controlled clinical 
trials assessing AED effects in severely afflicted medically intractable patients. It was found 
that there were no significant differences in the efficacy of AEDs tested, but all worked 
significantly better than placebo, and combinations of AEDs worked better than 
administration of single AEDs in some studies. 
Other clinical studies have attempted to use AEDs early on to prevent epileptogenesis, in a 
similar fashion to some acute animal models tested in vivo. Typically in these trials, at risk 
individuals are identified and treatment is started 12 hours-1 month post injury. Participants 
are monitored for 6 months to 3 years for seizure occurrence, and some include a period of 
monitoring after the drug has been stopped, this is when the antiepileptogenesis effect can 
be examined. 
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These studies have generally shown PHT (Temkin et al., 1990; Young et al., 1983), PHB 
(Manaka, 1992), CBZ (Glotzner et al., 1983), VPA (Temkin et al., 1999), Mg2+ (Temkin et al., 
2007) cannot reliably prevent or suppress epileptic seizures after traumatic brain injury. The 
findings contrast in vivo investigations on AEDs administered during the latent period which 
have shown VPA protects against spontaneous seizures (Bolanos et al., 1998). 
Besides these negative results, these studies have also been illustrated to have substantial 
limitations. For example, some studies were not blinded, studies had short periods of 
observation after the drug was stopped, monitoring of compliance or test drug concentrations 
were not carried out and EEG monitoring of subclinical seizures was not evaluated. 
Moreover, as drugs were administered early on it is difficult to differentiate effects of seizure 
suppression and antiepileptogenesis effects. Most of the drugs tested were older generation 
AEDs, therefore the need to test second generation AEDs in laboratories and, if successful, 
in clinical trials needs to be evaluated (Temkin, 2009). 
Only a few studies have assessed whether drugs which are ineffective in in the treatment of 
epileptic patients, are also ineffective epileptic human resected tissue in vitro. Whilst it may 
seem more important to evaluate mechanistic actions showing why AEDs do not work in 
patients, through in vitro investigation, this consistency issue is an important one that needs 
to be addressed in order understand the limits of in vitro experimentation. In vitro studies 
exploring AED effects in human resected epileptic tissue have demonstrated 0[Mg]2+ aCSF 
induced IDs are not very sensitive to CBZ, but are sensitive to VGB (Musshoff et al., 1997; 
Musshoff et al., 2000). In support, Kohling et al. (1998) illustrated CBZ and PHT fail to 
suppress epileptiform activity. However, it is important to note epileptiform activity in these 
studies were more representative of LRDs and IIDs, which have been shown to behave in 
more resistant ways in comparison to IDs in rodent tissue (Drier & Heineman, 1990; 
Sokolova et al., 1998; Zhang et al., 1995). 
Epilepsy is a disease which functionally arises from excessive neuronal excitation, therefore 
in vivo and in vitro methods are the ‘gold standard’ scientific approach for investigating 
mechanisms of pharmaco-resistance (Jones et al., 2016). Our laboratory is one of a 
prestigious few that has access to studying resected epileptic tissue in vitro. As explained by 
Jones et al. (2016) in vitro work with human tissue involves a fair share of complexities 
surrounding the collection, preparation and storage of human tissue. Additional complexities 
surround the ability to induce ictal-like events in this type of tissue. However, there is a 
pressing need for the investigation of AEDs in human tissue and comparison to animal 
models of epilepsy, which would provide insights into how to improve animal models and 
mechanisms of resistance. Based on the issue outlined, it is the secondary aim of this study 
to compare AED effects in the resected epileptic human tissue and epileptic rodent tissue 
from refined Li-pilocarpine model. 
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4.2 Results 
4.2.1 Neuronal network excitability and the efficacy of AEDs in MEC layer II during 
epileptogenesis 
4.2.1.1 Excitability of layer II of the MEC during epileptogenesis compared to controls 
Sucrose perfused transverse hippocampal-entorhinal slices were prepared after SE induction 
using the Li-pilocarpine model at four stages of epileptogenesis: 24hrs, 1 week, 5 weeks and 
12 weeks+. Slices were also prepared from aged-matched controls. Epileptogenesis was 
initiated using the refined Li-pilocarpine model 1-3 days post weaning (postnatal day 21 - 24) 
(see section 2.2.1 for more details). 
To induce IDs, a 0[Mg]2+ aCSF perfusate was applied to all slices. To investigate differences 
in excitability a between-subjects ANOVA was conducted, which showed no significant 
interaction effect between status (SE/control) and age (24 hrs/1 week/5 weeks/12 weeks+), p 
> 0.05 (see figure 4-1A and table 4.1). There was a significant main effect of status F (1, 59) 
= 6.75, p < 0.05. Specifically, post-hoc analysis demonstrated a higher percentage of SE 
slices (48.60 %) showed IDs in comparison to controls (34.31%), p < 0.05. There was no 
significant main effect of age, p > 0.05. 
To investigate differences in excitability between epileptic and control slices, in terms of 
latency to first seizure, a between-subjects ANOVA was conducted. Again, there was no 
significant interaction between status and age, p > 0.05 (see figure 4-1B and table 4.1). 
There was a main effect of status, F (1, 151) = 103.65, p < 0.01. Post-hoc analysis showed 
latency to first seizure was significantly shorter in SE slices (63.11 ± 3.26 ranked seconds) 
irrespective of stage of epileptogenesis, in comparison to control slices (128.95 ± 5.60 
ranked seconds), p < 0.01. This analysis was conducted on ranked data, to avoid 
inaccuracies as a result of violations of the normality assumption. 
 
Table 4.1. The percentage of slices with IDs and latency to first ID in SE and control 
slices at different stages of epileptogenesis. 
  
24hrs 1week 5weeks 12weeks+ 
Percentage control 30.56  40  47.92  18.75  
 
SE 53.57  47.73  48.04  45.05  
Latency control 4801.50 (± 523.62) 8310.92 (± 1118.78) 8086.40 (± 1033.69) 7173.13 (± 678.05) 
 
SE 2795.10 (± 250.60) 2505.53 (± 238.81) 2980.50 (± 288.71) 3290.49 (± 231.63) 
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Figure 4-1. The excitability of layer II MEC in control and epileptic slices at different 
stages of epileptogenesis. A. The percentage of control and epileptic slices which showed 
IDs. B. Latency to first seizure in control and epileptic slices. 
 
There are clear differences between epileptic and control slices at all stages of 
epileptogenesis. Once IDs had been initiated, they could reliably last for 2.5 hours at all 
stages. The next section assesses AED effects in epileptic slices during epileptogenesis. The 
comparison of AED effects in epileptic and control slices during epileptogenesis was not 
carried out. Not only was it difficult to induce IDs in control tissue, making the ethics behind 
using such a large number of animals questionable, but the IEIs between IDs in control 
tissue was often very long and extremely variable. 
To gain further insight into excitability changes, we explored ID parameter changes in 0[Mg]2+ 
aCSF during different stages of epileptogenesis. A one-way between subjects ANOVA 
showed there were significant differences in the IEIs between IDs at different stages of 
epileptogenesis, F (3, 111) = 8.78, p < 0.01. Post-hoc analysis showed IEIs at 24hrs post SE 
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induction (1055.51 ± 133.73 seconds) was significantly greater in comparison to 1 week 
(465.35 ± 60.84 seconds), 5 weeks (552.48 ± 85.58 seconds) and 12 weeks+ post SE 
(449.55 ± 68.51 seconds), p < 0.01, as illustrated in figure 4-2. 
To explore the effects of durations of IDs in 0[Mg]2+ aCSF, at different stages of 
epileptogenesis, a one-way between subjects ANOVA was conducted on raw data. There 
were significant differences in the durations of IDs at different stages of epileptogenesis, F 
(3, 115) = 5.26, p < 0.01. Post-hoc analysis showed the durations of IDs at 5 weeks post SE 
(81.04 ± 3.72 seconds) were significantly longer in comparison to durations of IDs at 24hrs 
(63.19 ± 2.90 seconds), 1 week (64.05 ± 2.90 seconds) and 12 weeks+ post SE (66.98 ± 
4.41 seconds), p < 0.05. 
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Figure 4-2. ID parameter changes in 0[Mg]2+ aCSF during epileptogenesis. A. A bar 
graph demonstrating the average IEI between IDs at different stages of epileptogenesis. B. 
Bar graph demonstrating average duration of IDs at different stages of epileptogenesis.  
 
4.2.1.2 The effects of AEDs on ID parameters during epileptogenesis 
To provide further insight into changes in efficacy of AEDs during epileptogenesis, a mixed 
model ANOVA was conducted to investigate changes of IEI with different drug combinations 
at different stages of epileptogenesis. A box cox transformation was applied to the data to 
overcome violations of normality (see Appendix 7 for raw data). The box cox transformation 
is an algorithm applied to non-normally distributed data to identify the ideal transformation to 
be applied to the data in order to normalise it. A value of lambda (-2 to +2) which minimises 
standard deviation is calculated. Different transformations are applied depending on the 
value of lambda, as shown in table 4.2. 
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Table 4.2. Different data transformations according to the box-cox transformation 
lambda value 
λ Transformation 
-2 Y-2 = 1/Y2 
-1 Y-1 = 1/Y1 
-0.5 Y-0.5 = 1/(Sqrt(Y)) 
0 log(Y) 
0.5 Y0.5 = Sqrt(Y) 
1 Y1 = Y 
2 Y2 
 
 
There was no significant interaction effect between stage of epileptogenesis and drug 
combination p > 0.05, indicating there was no superiority of AED efficacy, in terms of IEI 
changes, at different stages of epileptogenesis.  
There was a main effect of drugs (i.e. from 0[Mg]2+, to first AED and second AED) F (2, 182) 
= 69.83, p < 0.01. Post hoc analysis showed IEIs were significantly shorter in 0[Mg]2+ aCSF, 
compared to first application AEDs and second application of AEDs. Additionally, IEIs of first 
application of AEDs were significantly shorter than second applications of AEDs, p < 0.01, 
irrespective of specific drug combination and stage of epileptogenesis. As illustrated in figure 
4-3 all AEDs had were effective in increasing IEIs between IDs at every stage of 
epileptogenesis. 
There was no significant main effect of stage of epileptogenesis on IEIs, p > 0.05, indicating 
efficacy of AEDs did not change during epileptogenesis in terms of IEIs. There was a 
significant main effect of drug combination, F (10, 182) = 2.15, p < 0.05. Post-hoc analysis 
showed, irrespective of stage of epileptogenesis, application of the TGB+CBZ combination 
produced significantly greater increases in IEIs between IDs, in comparison to LTG+GPT and 
CBD+CBZ, p < 0.05, suggesting AEDs of GABAergic mechanisms are more effective in the 
refined Li-pilocarpine model of epilepsy. 
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Figure 4-3. The effects of AEDs on IEIs during epileptogenesis. A. The effect of TGB+CBZ on IEIs at different stages of epileptogenesis. B. 
The effect of VPA+CBZ on IEIs at different stages of epileptogenesis C. The effect of CBZ+ZNS on IEIs at different stages of epileptogenesis D. 
The effect of CBZ+GPT on IEIs at different stages of epileptogenesis D. The effect of LTG+GPT on IEIs at different stages of epileptogenesis F. 
The effect of CBD+CBZ on IEIs at different stages of epileptogenesis. There was no superiority of specific AEDs at specific stages of 
epileptogenesis. Irrespective of stage of epileptogenesis TGB+CBZ had the greatest effect at increasing IEIs.
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Exploring AED effects on other parameters, a mixed model ANOVA was conducted to 
investigate the effects of combination AEDs on the duration of IDs during different stages of 
epileptogenesis. Although, normality was significantly skewed according to the Shapiro 
Wilk’s test and Kolmogorov-Smirnov test, a box cox transformation did not significantly 
improve the distribution of data. Additionally, examination of the histograms did not show 
large variations from normal distribution, therefore the following analysis has been carried out 
raw data. Moreover, the Box’s test of equality of covariance (p > 0.05) on raw data indicated, 
this assumption had not been violated, therefore the analysis was accurate and reliable. 
The mixed model ANOVA analysis demonstrated there was no significant interaction, 
between stage of epileptogenesis and drug combination on the duration of IDs, p > 0.05 (see 
figure 4-4). There was no main effect of stage of epileptogenesis on duration of IDs, p > 0.05. 
There was a significant main effect of drug application, F (2, 52) =3.64, p < 0.05. Post hoc 
analysis illustrated the pooled durations of IDs in 0[Mg]2+ aCSF were significantly longer in 
comparison to the pooled durations of IDs after first and seconds application of AEDs, p < 
0.05. There were no significant differences in the pooled durations of IDs from first to second 
application of AEDs, p > 0.05. There was a significant main effect of drug combination on the 
duration of IDs, F (10, 52) = 2.79, p < 0.01. Post-hoc analysis however failed to illustrate 
significant differences between different drug combinations, p > 0.05. 
 
 
116 
 
 
Figure 4-4. The effects of AEDs on the duration of IDs during epileptogenesis. A. The effect of TGB+CBZ on the duration of IDs at different 
stages of epileptogenesis. B. The effect of VPA+CBZ on the duration IDs at different stages of epileptogenesis C. The effect of CBZ+ZNS on the 
duration of IDs at different stages of epileptogenesis D. The effect of CBZ+GPT on the duration of IDs at different stages of epileptogenesis D. The 
effect of LTG+GPT on the duration of IDs at different stages of epileptogenesis F. The effect of CBD+CBZ on the duration of IDs at different stages 
of epileptogenesis. There was no superior effect of specific AEDs on the duration of IDs at different stages of epileptogenesis.
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4.2.1.3 Resistance to combination AEDs in MEC layer II during epileptogenesis 
As explained in chapter 3 (section 3.2.4.1) resistance to combination AEDs can be analysed 
using two definitions of resistance. To test the association between different stages of 
epileptogenesis (24 hrs, 1 week, 5 weeks and 12 weeks) and pooled resistance to combination 
AEDs (0 = not resistant, 1 = resistant), a chi-square test of independence was conducted. 
Figure 4-5A illustrates pooled data showing the percentage of slices that showed resistance 
to combination AEDs at 24 hrs post SE (33.3 %), 1 week post SE (27.5%), 5 weeks post SE 
(19.6 %) and 12 weeks+ post SE (19.6 %). There is no significant association between different 
stages of epileptogenesis and resistance to combination AEDs χ² (3, n = 120) = 4.41, p > 0.05.  
The following analysis investigated if there were differences in resistance to specific AEDs at 
different stages of epileptogenesis using the first definition of resistance (continued presence 
of IDs) (see figure 4-5B). A chi square test of independence was conducted for each stage of 
epileptogenesis. There were no significant association between resistance and different AED 
combinations at 24 hrs post SE induction, χ² (5, n = 30) = 10.25, p > 0.05. There was a 
significant association between resistance and AED combination at 1 week post SE 
induction, χ² (5, n = 31) = 14.71, p < 0.05. Post-hoc inspection of adjusted residuals showed 
100% of slices responded to TGB+CBZ (adjusted residual = > +/-1.96). There was a 
significant association between resistance and AED combinations at 5 weeks post SE 
induction, χ² (5, n = 31) =13.92, p < 0.05. Post hoc inspection of adjusted residuals showed 
CBZ+ZNS significantly contributed to this association, as 66.7 % of slices were resistant. 
LTG+GPT also contributed significantly to this association as 80 % of slices were resistant to 
these AEDs. CBD+CBZ was also maximally effective at this stage of epileptogenesis, as 
100% of slices were susceptible. This finding is consistent with analysis of the ID IEIs. These 
results suggest CBD+CBZ is most effective during the latter latent period, and may be 
influential as a tool for preventing epileptogenesis. There was no significant association 
between resistance and AED combinations during chronic epilepsy (12 weeks+ post SE 
induction), χ² (5, n = 28) = 4.48, p > 0.05. 
The final analysis investigated if there were differences in resistance to specific AEDs at 
different stages of epileptogenesis using the second definition of resistance (< 50 % 
reduction of IDs = resistant) (see figure 4-5C). There was a significant association between 
resistance and different AED combinations at 24 hours post SE induction χ² (5, n = 29) = 
12.41, p < 0.05. Post hoc inspection of adjusted residuals showed CBD+CBZ significantly 
contributed to this association as 80 % of slices were resistant. There was a significant 
association between resistance and different AED combinations at 1 week post SE induction 
χ² (5, n = 30) = 11.67, p < 0.05. Post hoc inspection of adjusted residuals failed to show 
significant contribution, but 80 % of slices showed resistance toward LTG+GPT and 
CBD+CBZ. Additionally, the majority of slices were responsive (not resistant) towards 
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VPA+CBZ (80 %) and TGB+CBZ (100 %). There was a significant association between 
resistance and different AED combinations at 5 weeks post SE induction χ² (5, n = 30) = 
12.86, p < 0.05. Post hoc inspection of adjusted residuals showed LTG+GPT significantly 
contributed to this association as 80 % of slices were resistant. Also of interest, was the fact 
that 100% of slices were not resistant towards CBD+CBZ and TGB+CBZ. There was no 
significant association between resistance and AED combinations during chronic epilepsy 
(12 weeks+ post SE induction), χ² (5, n = 29) = 4.62, p > 0.05. 
Comparisons of the analyses of resistance to combination AEDs during epileptogenesis 
suggests, similar results can be produced, although the latter definition (< 50 % reduction of 
IDs = resistant) is more sensitive to identifying differences in resistance. Both analyses 
highlight that CBD becomes more effective as epileptogenesis progresses, with optimal 
response being seen at 5 weeks post SE. Additionally, TGB+CBZ is very effective at all 
stages of epileptogenesis, whereas LTG+GPT appears to be the least potent combination 
AEDs. 
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Figure 4-5. Resistance to AEDs during epileptogenesis. A. Pooled data showing the 
percentage of slices that showed resistance to combination AEDs at 24 hrs post SE, 1 week 
post SE, 5 weeks post SE and 12 weeks+ post SE. B. Percentage of slices that showed 
resistance to AED combinations at different stages of epileptogenesis. C. Percentage of 
slices that showed resistance (<50 % reduction of IDs) to AED combinations at different 
stages of epileptogenesis. 
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4.2.2 Comparisons to the Piriform and Entorhinal cortices 
4.2.2.1 Differences in the excitability of the PC and EC 
Epilepsy is a complex disorder and the EC is not the only site reported to show early 
dysfunction. As highlighted in section 1.1.1 one of the main cortical inputs to the MEC comes 
from the piriform cortex (Agster & Burwell, 2009), and also happens to be another site which 
shows early signs of dysfunction following SE (Gavrilovici et al., 2012; Loscher & Ebert, 
1996; Raccine et al., 1988). Similar investigations into the excitability and efficacy of AEDs of 
the piriform cortex have also been conducted in our laboratory by Jane Pennifold (Pennifold, 
2016). A summary of our combined work showing differences in excitability and resistance 
between the EC and PC can be found in figure 4-6. It is important to acknowledge that these 
results were obtained from different animals whereby EC slices were prepared using a 
sucrose based aCSF and PC slices were prepared using a choline based aCSF. Different 
solutions were utilised to optimise viability of slices for the two different areas in vitro, and so 
loose rather than direct comparisons shall be made between the two brain areas to avoid 
conclusions being hindered by confounding variables associated with differing homeostatic 
environments. 
To investigate excitability in the PC, in terms of percentage of slices that displayed IDs, a 
between-subjects ANOVA was conducted. There was no significant interaction between 
status (control/ SE) and stage of epileptogenesis, therefore excitability did not significantly 
differ as epileptogenesis progressed, p > 0.05 (see figure 4-6). There was a main effect of 
status F (1, 128) = 4.19, p < 0.05. Post-hoc analysis indicated, irrespective of stage of 
epileptogenesis, more SE slices displayed IDs so were more excitable in comparison to 
control slices, p < 0.05. These PC results are similar to those of EC, whereby significant 
differences in percentage of slices that displayed IDs were found between SE and control 
slices, but excitability did not alter between SE and control according to stage of 
epileptogenesis (see figure 4-1A or 4-6B for comparison). Comparison of figure 4-6A and 4-
6B also illustrate the EC is not as excitable as the PC in controls and SE slices. 
To investigate excitability in the PC, in terms of latency to first seizure, a between-subjects 
ANOVA was conducted. There was a significant interaction between status (control/ SE) and 
stage of epileptogenesis, F (3, 328) = 3.49, p < 0.05. Post-hoc analysis showed latency to 
first ID was significantly shorter in SE slices at 5 weeks post SE, in comparison to controls, p 
< 0.01. Whilst no overall significant interaction between status and stage of epileptogenesis 
was found in the EC, it was evident there were significant differences between SE and 
control slices at every stage of epileptogenesis (see figure 4-1B or 4-6D for comparison). 
Comparison of figure 4-6C and 4-6D show overall the latency to first seizure is greater in EC 
compared to the PC for control and SE slices, thus showing the EC slices are not as 
excitable. 
121 
 
 
Figure 4-6. The excitability of the PC and EC in control and epileptic animal during epileptogenesis. A. The percentage of control and SE 
slices that showed IDs in the PC at different stages of epileptogenesis. B. The percentage of control and SE slices that showed IDs in the EC at 
different stages of epileptogenesis. C. The latency to first seizure in control and SE slices of the PC at different stages of epileptogenesis. D. The 
latency to first seizure in control and SE slices in the EC during different stages of epileptogenesis.
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4.2.2.2 Resistance to combination AEDs during epileptogenesis in the EC and PC 
To test the association between different stages of epileptogenesis (24 hrs, 1 week, 5 weeks 
and 12 weeks) in PC SE slices and pooled resistance (continuation of IDs following the 
application of 2 AEDs) to combination AEDs (0 = not resistant, 1 = resistant), a chi-square 
test of independence was conducted. There was a significant association between different 
stages of epileptogenesis and resistance to combination AEDs χ² (3, n = 191) = 33.65, p < 
0.01. Post-hoc inspection of the adjusted residuals showed 24 hr SE slices significantly 
contributed to the association having the most slices with resistance (40.4 %). SE slices at 5 
weeks (15.7 %) and 12 weeks+ (13.5 %) post SE induction also significantly contributed to 
the association. Whilst differences in pooled resistance can be seen the PC SE slices this 
difference is not evident in the EC. Further comparison of figure 4-7A and 4-7B also shows 
pooled resistance in both the PC and EC decreases as epileptogenesis progresses but more 
so in the PC than EC. 
A chi square test of independence was conducted for each stage of epileptogenesis to 
assess if there were differences in resistance to specific AEDs in PC slices. From the four 
chi-square tests, there was a significant association between resistance and AED 
combinations at 5 weeks post SE, χ² (5, n = 48) = 22.59, p < 0.01. Post-hoc inspection of the 
adjusted residuals showed VPA+CBZ, LTG+GPT and TGB+CBZ significantly contributed to 
the association. PC slices at 5 weeks post SE showed the greatest resistance to TGB+CBZ 
(50 %) and no resistance toward VPA+CBZ and LTG+GPT. Interestingly in comparison the 
EC showed greater resistance to LGT+GPT and CBZ+ZNS at 5 weeks. Additionally, 
differences in resistance to specific AED combinations can also be seen at 1 week post SE 
in EC slices. Further comparison of figure 4-7C and 4-7D, highlights that resistance dips in 
both the EC and PC at 5 weeks post SE. 
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Figure 4-7. Resistance to combination AEDs during epileptogenesis in the piriform and entorhinal cortex. A. Pooled resistance to 
combination AEDs in the PC at different stages of epileptogenesis. B. Pooled resistance to combination AEDs in the EC at different stages of 
epileptogenesis. C. Resistance to specific combination AEDs in the PC at different stages of epileptogenesis. D. Resistance to specific combination 
AEDs in the EC at different stages of epileptogenesis.
124 
 
 
4.2.3 Effects of combination AEDs in resected human tissue 
Results presented thus far have illustrated slices in which the epileptogenesis process has 
been initiated are overall more excitable in comparison to control slices. Whilst AED 
combinations do not show variable efficacy at different stage of epileptogenesis, TGB+CBZ 
is the most effective AED combination in the EC overall, whilst the converse relationship is 
shown in the PC. Similarly, LTG+GPT is the least potent AED combination in the EC, but the 
more effective in the PC. CBD+CBZ has shown greater potency with development of 
epilepsy in both the EC and PC.   
The secondary aim of this study was to compare AED effects in the resected epileptic human 
tissue and epileptic rodent tissue from refined Li-pilocarpine model, in the hope to better 
understand mechanisms of resistance and improve models of epilepsy by identifying 
similarities and differences in response to AEDs. Table 4.3 summarises the types of resected 
human tissue used in these investigations (n slices: temporal lobe = 9, frontal lobe = 3, motor 
cortex = 1). 
 
Table 4.3. Summary of human resected tissue used in investigation comparing the 
efficacy of combination AEDs in human and animal models of temporal lobe epilepsy. 
Patient Human tissue with induced IDs 
1 Motor cortex 
2 Temporal gyrus and amygdala 
3 Sensory motor cortex 
4 Medial temporal gyrus and amygdala 
5 Inferior frontal gyrus 
6 Left parietal gyrus 
7 Sensory motor cortex 
8 Temporal lobe 
9 Medial temporal gyrus 
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4.2.3.1 Excitability of resected human tissue 
To investigate differences in excitability between epileptic rodent and human tissue, in terms 
of percentage of slices that showed IDs, a Mann-Whitney-U test was conducted. There were 
significant differences between epileptic rodent and human tissue, U = 20.50, z = -2.09, p < 
0.05. A higher percentage of epileptic human tissue slices (76.78 ± 11.06 %) displayed IDs in 
comparison to chronically epileptic rodent tissue (45.05 ± 3.35 %), as illustrated in figure 4-
8C. 
There were significant differences between rodent and human tissue, in terms of latency to 
first seizure, U = 19.00, z = -3.58, p < 0.01. The latency to first ID was significantly longer in 
the epileptic rodent EC (3290.45 ± 235.28 seconds) in comparison to human TLE tissue 
(1283.88 ± 365.12 seconds), as illustrated in figure 4-8D.
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Figure 4-8. The excitability of epileptic rodent and human tissue. A. Evoked ID in human 
epileptic temporal neocortex. B. Evoked IIDs in human epileptic temporal neocortex C. The 
percentage of epileptic rodent and human tissue which displayed IDs. D. The latency to first 
ID in epileptic rodent and human tissue. 
 
To further explore differences in excitability, differences between rodent and human tissue 
were compared in terms of IEIs between IDs in 0[Mg]2+ aCSF for rodent tissue and in 0[Mg]2+ 
and high K+ or KA (300-400 nM) aCSF for human tissue. There were significant differences 
between the IEIs of rodent and human tissue in ID inducing mediums, U = 52.00, z = -2.11, p 
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< 0.05. The IEIs between IDs was significantly longer in human tissue (918.47 ± 223.59 
seconds) in comparison to rodent tissue (449.55 ± 223.59 seconds).  
Further analysis on ID parameters, included exploring differences of the durations of IDs in 
ID inducing mediums. As illustrated in figure 4-9, there were no significant differences in 
terms of the duration of IDs in rodent and human tissue, U = 82.50, z = -1.12, p > 0.05. 
 
 
Figure 4-9. Characteristic of ID parameters in epileptic rodent and human tissue. A. 
Average IEIs between IDs in epileptic rodent (449.55 ± 223.59 seconds) and human tissue in 
ID inducing mediums. B. Average durations of ID in epileptic rodent and human tissue in ID 
inducing mediums. 
 
4.2.3.2 Efficacy of AEDs in resected human tissue 
Due to the limited sample size on which different AEDs were tested in resected human 
tissue, meaningful statistical analysis could not be conducted. Nevertheless, the effects of 
AEDs on the IEIs between IDs are illustrated in figure 4-10. In comparison to epileptic rodent 
tissue, which did show some degree of resistance to AEDs, human resection of temporal 
lobe areas (e.g. amygdala, medial temporal gyrus) were all sensitive to all combination 
AEDs, in vitro. There was evidence of some resistance to VPA and CBD alone, but these 
experiments would need to be repeated to confirm this inference.  
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Figure 4-10. The effects of AEDs on the IEIs between IDs in resected epileptic human temporal lobe tissue. A. The effect of TGB+CBZ on 
IEIs on resected human TLE tissue. B. The effect of VPA+CBZ on IEIs on resected human TLE tissue C. The effect of CBZ+ZNS on IEIs resected 
human TLE tissue D. The effect of CBZ+GPT on IEIs resected human TLE tissue E. The effect of LTG+GPT on IEIs resected human TLE tissue F. 
The effect of CBD+CBZ on IEIs resected human TLE tissue. 
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4.2.3.3 Excitability of different brain regions from human resected tissue 
This section explores differences in excitability in human epileptic tissue resected from three 
different brains areas: the temporal lobe, the frontal cortex and the motor cortex. Although 
data from all three is presented, differences in excitability will only be statistically analysed 
between the temporal lobe and frontal cortex, as the sample size of motor cortex slices was 
limited.  
As illustrated in figure 4-11A, epileptic resected tissue from the temporal lobe region of the 
human brain had the greatest excitability as 76.79 % of slices displayed IDs, followed by 
motor cortex slices and frontal lobe slices. To compare differences in latency to first ID in 
human resections from different brain areas a Kruskal-Wallis analysis was carried out. As 
illustrated in figure 4-11B, there were no significant differences in latency to first ID, in 
resected tissue from the temporal lobe, frontal cortex and motor cortex, p > 0.05. 
Figure 4-11. The excitability of human epileptic tissue from three different brain 
regions. A. Percentage of slices which display IDs from temporal lobe, frontal cortex and 
motor cortex brain regions. B. Latency to first ID in human epileptic tissue from temporal 
lobe, frontal cortex and motor cortex brain regions. 
 
In terms of ID parameters, a Mann-Whitney-U test showed there were no significant 
differences in the IEIs between IDs in tissue resected from temporal lobe and frontal cortex 
areas, U = 8.00, z = - 0.82, p > 0.05. Additionally, there were no significant differences 
between the durations of IDs from epileptic human tissue resected from the temporal lobe 
and frontal cortex, U = 11.00, z = -0.20, p > 0.05 (see figure 4-12). 
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Figure 4-12. Characteristics of ID parameters in 3 different brain regions of the human 
epileptic brain. A. The IEIs between IDs in the epileptic resected temporal lobe, frontal lobe 
and motor cortex regions. B. The duration of IDs in epileptic resected temporal, frontal lobe 
and motor cortex regions. 
 
4.3 Discussion 
The current study investigated changes in excitability and the efficacy of combination AEDs 
during epileptogenesis in an animal model of epilepsy and in resected tissue from human 
epileptic patients. Slices prepared from animals who had undergone the refine Li-pilocarpine 
model of epilepsy were significantly more excitable in comparison to controls. Findings 
suggest immediate network changes. All combination AEDs were effective in reducing IDs at 
every stage of epileptogenesis, but TGB+CBZ were the most effective and LTG+GPT were 
the least effective overall. Resistance to AEDs was between 20-33% across all stages of 
epileptogenesis, and resistance to CBD+CBZ decreased as epileptogenesis progressed. 
Excitability in resected human tissue showed tissue from temporal lobe regions were more 
excitable in comparison to the motor cortex and frontal lobe regions. However, resected 
tissue required more excitation in order to induce IDs in comparison to epileptic rodent 
tissue. Preliminary investigations of AED efficacy illustrated all combination AEDs were 
effective in reducing IDs, with some resistance toward VPA and CBD. Overall, it is evident 
epilepsy induces subtle changes in network dynamics that increase excitability in the 
temporal lobe and other brain regions in rodent models and resected human tissue. 
Acute in vivo (e.g. MES and PTZ) and in vitro (e.g. 0[Mg]2+, 4- AP,) studies provided a great 
initial step in the screening of AEDs for epilepsy treatment. However, these studies suffer 
from several limitations. As a result chronic models of epilepsy have been employed and 
have transformed the development and testing of AEDs by improving treatment outcome 
predictions and providing better insight into epileptogenesis and mechanisms of DRE. 
Chronic models have identified AEDs with unique mechanisms such as LEV (Bajjalieh et al., 
1994; Lynch et al., 2004). Chronic models have further enabled exploration of the protective 
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effects of AEDs at different stages of epileptogenesis (Bolanos et al., 1998; Margineanu et 
al., 2008; Morrisett et al., 1987; Turski, 1987).  
Whilst several different studies have explored AED efficacy at different stages of the chronic 
KA model of epilepsy, relatively few have been carried out on the pilocarpine model. 
Additionally, studies investigating AED effects during different stages of epileptogenesis 
often suffer from limitations such as employing high severity models and classifying 
resistance based on the response to individual AEDs rather than combinations of AEDs. For 
these outlined reasons it was the primary aim the current study to investigate the efficacy of 
combinations of AEDs during epileptogenesis of the refined Li-pilocarpine model, in layer II of 
the MEC.  
One of the fundamental aims of research with chronic animal models of TLE, is to identify 
mechanisms and drugs which effectively prevent epilepsy in humans. However, it has been 
demonstrated that there are marked differences that exist between different chronic models 
of epilepsy in terms of underlying pathophysiology and response to different AEDs. For 
example, clinical studies have shown VPA cannot prevent or suppress epileptic seizures 
after traumatic brain injury (Temkin et al., 1999), but in vivo investigations on AEDs 
administered during the latent period have shown VPA protects against spontaneous 
seizures (Bolanos et al., 1998). 
Evidently there is a need to also investigate AEDs in human tissue in comparison to animal 
models of epilepsy, to provide insights into how to improve animal models and better 
understand mechanisms of resistance. Therefore the secondary aim of this study was to 
compare excitability and AED effects in the resected epileptic human tissue to epileptic 
rodent tissue from refined Li-pilocarpine model. 
4.3.1 Excitability and efficacy of AEDs in layer II MEC during epileptogenesis  
The current study demonstrated enhanced excitability of slices that had undergone the 
refined Li-Pilocarpine model of epilepsy. Irrespective of the stage of epileptogenesis, 
significantly more SE slices displayed IDs in 0[Mg]2+ aCSF, with shorter latencies to first ID in 
comparison to their control counterparts. Further investigation of ID parameter characteristics 
during epileptogenesis, showed the IEI’s between IDs was the longest slices 24 hours post 
SE induction, and therefore these slices were not as excitable in comparison to slices from 
later stages of epileptogenesis. These results suggest there is an active process underlying 
the suppression of ictogenesis at this early stage of epileptogenesis. Elevation in inhibition 
has been suggested to be a compensatory response of brain in attempt to decrease seizure 
propensity (Fritschy et al., 1999). Moreover, other ID parameters such as duration are largely 
unaltered at different stages of epileptogenesis suggesting compensation mechanisms are 
specific to ID triggering mechanisms rather than the nature of the intrinsic discharge itself. 
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In terms of evaluating whether epileptogenesis is a continuous process or not, these findings 
show support for the step-function hypotheses of epileptogenesis. The step-function 
hypothesis suggests the mechanisms responsible for seizure generation are mature at the 
time of the first seizure, after the latent period. On the other hand, the continuous-function 
hypothesis suggests the mechanisms responsible for seizure generation are not complete at 
the time of the first seizure, and seizure frequency increases as epileptogenesis progresses 
(Dudek & Staley, 2012). Evidently, fundamental network changes occur imminently after from 
the Li-Pilocarpine model of epilepsy has been carried out. These network changes increase 
the excitability of networks and promotes the generation of IDs, thus supporting the step-
function hypothesis. However, this step difference appears after SE induction rather than 
after the latent period.  
Investigations of the efficacy of AEDs during epileptogenesis illustrated that all combinations 
of AEDs significantly increased the intervals between IDs, and there was no superiority of 
certain AED combinations at different stages of epileptogenesis. Irrespective of stage of 
epileptogenesis, TGB+CBZ increased IEI’s between IDs significantly more than LTG+GPT 
and CBD+CBZ. Combination AEDs also reduced duration of IDs overall. These findings 
suggest AEDs with GABAergic mechanisms are more effective in this refined Li-Pilocarpine 
model of epilepsy. 
In support of these findings, many experimental and clinical studies have demonstrated 
GABA has an important role in the mechanism and treatment of epilepsy (Trieman, 2001). 
For example, GABAergic abnormalities have been observed in genetic (Roberts et al., 1985) 
and acquired models of epilepsy (Esclapez & Trottier, 1989; Houser et al., 1986). GABA 
agonists have been shown to suppress seizures (Vicini et al., 1987; Rogers et al., 1994), and 
conversely GABA antagonists have been shown to induce seizures (Jones & Lambert, 
1990a, b). Moreover, in human TLE patients, GABAA receptors have been shown to be 
reduced (McDonald et al., 1991).  
Others have suggested that this excitation-inhibition imbalance occurs as a result of the 
disconnection of inhibitory and excitatory neurons, as proposed by dormant interneuron 
hypothesis (Sloviter, 1987). In support, some studies which have found that inhibition is not 
completely impaired by chronic epilepsy, but more likely to be overshadowed by abnormal 
enhanced excitation (Mody & Heinmann, 1987; Tolner et al., 2007). On the contrary, Kumar 
& Buckmaster (2006) demonstrated chronic epileptic adult rats show a significant loss of 
GABAergic neurons in the EC and gephyrin-positive puncta in EC layers I and II. 
Additionally, excitatory synaptic drive to nearby surviving interneurons appeared to be intact, 
suggesting hyper-excitability is not due to dormancy but an actual loss of inhibitory input.  
It is clear that disrupting the equilibrium between excitation and inhibition in the brain is likely 
to induce seizures, however, epilepsy is much more mechanistically complex. This is evident 
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as AED discovery thus far has typically targeted reducing excitation or enhancing inhibition, 
which has offered control over seizures for some but not all patients. Additionally, enhancing 
GABAergic inhibition can be pro-epileptic in some circumstances too (e.g. absence seizures) 
(Loscher, 2002). Abnormal enhancement of GABAergic inhibition has been observed in a 
number of studies (Klassen et al., 2006; Naylor et al., 2005; Zhan & Nadler, 2009). Whilst 
this elevation in inhibition has been suggested to be a compensatory response of brain in 
attempt to decrease seizure propensity (Fritschy et al., 1999) others have reported 
abnormally enhanced inhibition, paradoxically, promotes seizures. For example, Cope et al. 
(2009) showed in a genetic model of absence epilepsy, GAT-1 deficiency lead to enhanced 
levels of GABAA inhibition.  
Whilst enhancements in inhibition have been linked to the initiation of seizures, on the other 
side of the paradox, a lack of excitation leading to hyopfunctional networks has also been 
suggested to promote seizures (Duncan et al., 2008; Turrigiano, 2012). One mechanism 
through which this has been suggested to occur is through homeostatic synaptic scaling 
(Turrigiano et al., 1998 Turrigiano et al., 2008). Neuronal networks must maintain stability in 
the face of plastic challenges such as changes in the cell size or synapse number or 
strength, that alter excitability and stability. Synaptic scaling is a form of homeostatic 
plasticity, whereby perturbing network activity generates compensatory changes in synaptic 
strength to maintain balance. For example, neurons can detect changes in their own firing 
rates through calcium-dependent sensors that regulate receptor trafficking to increase or 
decrease accumulation of glutamate receptors at synaptic sites through a range of signalling 
pathways (Turrigiano, 2012). According to this research a lack of excitation in hypofunctional 
networks, could generate seizures themselves through synaptic scaling whereby a shift in 
the activity set point occurs. 
Moreover, it important to consider the interactions of excitation and inhibition. For example, 
severe myoclonic epilepsy is characterised by mutations of VGSCs which impair sodium 
current and action potential firing in hippocampal inhibitory interneurons without detectable 
changes in pyramidal neurons. As a result, AEDs such as PHT and CBZ which block sodium 
channels, act in pro-epileptic ways (Oakley et al 2011; Rogawski & Loscher, 2004). 
Additionally, numerous studies have demonstrated the ability of glutamate in modulating 
inhibition (Belan & Kostyuk, 2001) which can have enhancing and inhibiting effects 
depending on the type of receptors (NMDA, KAR and mGluRs), sensitivity and location (pre- 
or postsynaptic) of receptors. 
Overall, the emphasis of the excitation-inhibition imbalance in epilepsy is of limited value, as 
this over simplistic view, of a clearly multi-factorial disease, ignores the mechanisms that 
render an epileptic brain resistance to AEDs (Margineanu & Klitgaard, 2009). Conversely, 
however, assessing the myriad of genetic, developmental and acquired factors that influence 
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the interplay between synaptic reorganisations leading to excitation-inhibition derangement, it 
is important to generate a cohesive understanding by asking crucial question to ensure 
development of knowledge and not just information (Sloviter, 2004). 
The measurement of resistance to AEDs in clinical studies as well as physiological in vivo/ in 
vitro investigations have often been flawed. The current study explored how resistance to 
different combination AEDs changed during epileptogenesis according to two measurements 
of resistance. Findings based on the first definition (continued presence of IDs following 
application of two AEDs) of resistance showed there were no stage dependent effects and 
resistance was demonstrated in 20 - 33% of slices through epileptogenesis. Resistance was 
interestingly the highest in the least excitable slices at 24 hours post SE induction. 
Thereafter, resistance decreased during the latent period before beginning to slightly rise in 
chronic epilepsy. A more definitive increase in resistance may have been observed in chronic 
epilepsy, had more time been left between confirmation of epileptic status through the PSBB 
task and experimentation. As shown in chapter 3, LTP plays a significant role in the 
resistance to AEDs in acute models, as sucrose slices had longer latencies to first ID and 
therefore longer exposure to the excitatory, LTP inducing 0[Mg]2+ aCSF. The reinforced 
network thereafter demonstrated slightly more resistance to AEDs in comparison to standard 
prepared slices. Complimentary to these findings, chronic pilocarpine epilepsy studies have 
demonstrated NMDA receptor inhibition with MK-801 prevented the development of epilepsy 
(Rice & DeLorenzo, 1998). Future investigation of how the length of time spent in the chronic 
epileptic state without treatment influences resistance to AEDs will determine the role of LTP 
in chronic epilepsy. 
There were very few differences between the two analyses of resistance for specific AED 
combinations at different stages of epileptogenesis. Overall, some level of resistance was 
maintained for most drug combinations. Both analyses demonstrated TGB+CBZ was highly 
effective at abolishing IDs at all stages of epileptogenesis in comparison to other drug 
combinations. This finding correlate with other analyses of ID parameters. Specifically, 
TGB+CBZ was shown to increase IEIs between IDs at every stage of epileptogenesis. 
According to the second definition of resistance (< 50% reduction in ID frequency) the 
CBD+CBZ combination becomes more effective as epileptogenesis progresses. However, 
the analyses based on the first definition of resistance suggests the CBD+CBZ combination 
is maximally effective at 5 weeks post SE, suggesting it may be influential as a tool for 
preventing epileptogenesis. This definition of resistance allows us to pinpoint with greater 
accuracy when CBD+CBZ would be most effective, hence allowed the differentiation 
between therapies that target disease prevention and disease modification (Sloviter & 
Bumanglag, 2013).  
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4.3.2 Excitability and resistance to AEDs in the PC and EC 
Connections between the PC and EC are well characterised (Agster & Burwell, 2009). The 
PC is a three layered cortical structure and has been shown to be an easily excitable, 
seizure-prone region (Hoffman & Haberly, 1991; Loscher & Ebert, 1996; Raccine et al., 
1988). Similar investigations into the excitability of the PC and efficacy of AEDs during 
epileptogenesis, carried out by Pennifold (2016), allowed the comparison of the PC and EC 
areas in this refined Li-Pilocarpine model of epilepsy and in controls. These investigations 
suggested the PC is highly excitable in normal and pathological conditions, in comparison to 
the EC.  
It is important to acknowledge that these results were obtained from different animals 
whereby EC slices were prepared using a sucrose based aCSF and PC slices were prepared 
using a choline based aCSF. Different solutions were utilised to optimise viability of slices for 
the two different areas in vitro. However, experimental observations of hippocampal slices 
prepared using choline based aCSF showed a tendency for increased spontaneous 
epileptiform activity, hence these results could be an effect of the different solutions used. On 
the other hand, Hamidi et al. (2014) demonstrated when the connectivity between the PC 
and EC is preserved the duration of IDs in the two areas is reduced. This view that 
interconnectivity hampers ictogenesis is supported by evidence from Barbarosie and Avoli 
(1997) who found IDs could not be recorded in the EC when connected to the hippocampus. 
In contrast, the studies carried out on the EC here were done in combined EC-hippocampal 
slices, whereby IDs could still be induced in the EC. Nevertheless, it would be of interest to 
further investigate how excitability changes during epileptogenesis when the PC and EC 
areas are connected.  
Investigation of PC drug resistance showed resistance was greatest at 24hrs post SE and 
more likely to show resistance in comparison to the EC at this stage. There were no further 
differences in resistance at other stages of epileptogenesis, but resistance did appear to be 
the lowest at 5 weeks post SE.  
It is of particular interest that resistance to combination AEDs was lower 5 weeks post SE in 
PC and EC slices, as this time point coincides with the final developmental stage of 
adolescence whereby the immature brain is transformed into adult form. The mechanism 
responsible for this transition is synaptic pruning (Selemon, 2013) and reorganisation of 
connections have been shown to be activity dependent (Changeux & Danchin, 1976; Shatz, 
1990). As a result of these developmental processes the balance of excitation and inhibition 
are altered in favour of inhibition (Bourgeois & Rakic, 1993; Rakic et al., 1986) as excitatory 
synapses are selectively degenerated but inhibitory synapses are spared. Additionally, D2 
dopamine receptors on interneurons undergo maturation, leading stimulation to result in 
excitation of interneurons, thus promoting inhibition (Tseng & O’Donnell, 2007). These 
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developmental processes in which inhibition is enhanced may explain why resistance to 
AEDs may be reduced at 5 weeks post SE. Moreover, perturbations in this developmental 
refinement such as the presence of seizures or underlying excitability lead to the survival of 
too many excitatory synapses during synaptic pruning resulting in a chronically unstable and 
excitable network. In support of this view, Zhou et al. (2009) demonstrated the LGI1 gene 
regulates glutamatergic pruning pre-and post-synaptically, and in mice expressing a mutated  
PC slices at 5 weeks post SE showed the greatest resistance to TGB+CBZ and no 
resistance toward VPA+CBZ and LTG+GPT. Interestingly in comparison the EC showed 
greater resistance to LGT+GPT and CBZ+ZNS at 5 weeks post SE. Moreover, CBD+CBZ 
and TGB+CBZ are particularly effective combinations of AEDs in both areas of the brain. 
TGB enhances GABA transmission by blocking reuptake of GABA into neurons and glia 
(Trieman, 2001). The mechanisms of CBD remain ambiguous but it has been suggested to 
affect: the equilibrative nucleoside transporter, the orphan G-protein-couple receptor GPR55, 
the 5HT1a receptor, the α1 and α3 glycine receptors and the transient receptor potential of 
Ankyrin type I channel (see Devinsky et al., 2014 for a review). Further investigation, into 
network changes that promote the efficacy of these drugs would provide better insight into 
the mechanisms of epileptogenesis and DRE.  
4.3.3 Excitability and efficacy of AEDs in resected human tissue 
4.3.3.1 Excitability in resected temporal lobe tissue 
Investigations of the excitability of epileptic resected human tissue and rodent tissue of the 
temporal lobe regions, illustrated significantly more human tissue slices showed IDs in 
comparison to rodent tissue. Additionally, human tissue slices had shorter latencies to first 
ID. However, it is important to acknowledge that the human tissue we received was highly 
variable from patient to patient and even slice to slice. In some slices IDs were easily 
induced with just a 0[Mg]2+ aCSF perfusate, in most other slices this would not be enough 
drive to induce IDs in the network and harsher solutions such as 0[Mg]2+/high K+ aCSF 
and/or 200- 400 nM kainate would be required in order to induce IDs. Therefore, these 
comparisons suggest human tissue is much more excitable than epileptic rodent tissue, but 
these findings should be treated with caution given the complexities surrounding the 
induction of IDs in resected human tissue. 
Comparisons of ID parameter characteristics showed human tissue showed longer IEIs 
between IDs in comparison to rodent tissue. There were no differences in the two types of 
tissue with regard to the durations of IDs. These findings taken together with the fact most 
human tissue slices required harsher inducing ID inducing solutions, suggest in vitro this 
tissue is not as excitable as chronic epileptic rodent tissue. 
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As reviewed by Köhling and Avoli (2006), many studies of resected human tissue require 
pro-convulsant agents such as GABA antagonists and 4-AP and/or alterations to the aCSF 
concentrations of Na+, K+ and Mg2+, in order to observe epileptiform-like activity in vitro. On 
the other hand, recent observations of spontaneous pathological activity have been reported 
(Cunningham et al., 2012; Huberfield et al., 2007; Roopun et al., 2010). It has been 
suggested increases in the reporting of spontaneous activity could be a result of improved 
slice preparation methods, such as the replacement of sodium chloride with sucrose or 
choline and the addition of several antioxidants (Jones et al., 2016). These improved slicing 
methods were adopted within our laboratory, and whilst spontaneous IIDs and HFOs were 
regularly present, spontaneous IDs very rarely occur. Other factors that may have 
contributed to this lack of spontaneous ictal activity include: variations in surgical technique, 
variations in the brain area the sample is taken from and time taken to transport and slice the 
sample. Having said this, spontaneous ictal events are only very occasionally evident in 
chronic epileptic rodent tissue in our recordings. It is important to acknowledge that in vitro 
preparation represent a reduced system of the intact brain, therefore it is not unusual 
characteristic to require electrical or chemical stimulation in order to induce IDs. 
Comparisons of ‘control’ and epileptic human tissue have shown no epileptiform activity can 
be induced in control tissue, but can be observed in epileptic tissue (Jones et al., 2016). 
These findings are representative of the excitability differences in EC control and epileptic 
tissue described here. The key point to take away from this study, however, is that human 
TLE tissue required more excitation than chronic epileptic rodent tissue. Further exploration 
of the functional implications of morphological changes may provide insights as to why more 
excitation was required.  
Earlier studies investigating the functional implications of morphological changes 
demonstrated cell dispersion and recurrent sprouting lead to circuitry changes which promote 
seizure activity (Houser, 1990). Additionally, using organotypic cultured slices, Hocke et al. 
(2007) conducted histological examinations and showed hippocampal cell loss associated 
with TLE.  
Investigations of the electrophysiological properties of neurons in human epilepsy have 
shown parameters of intrinsic neuronal excitability appear to be rather normal. For example, 
action potential discharges, voltage-gated Na+, K+ and Ca2+ currents appear to be remarkably 
similar to those found in rodent tissue (Beck et al., 1996; Isokawa et al., 1991; Strowbridge et 
al., 1992).  
Whilst intrinsic cellular properties appear rather ‘normal’, synaptic mechanisms have been 
shown to be more abnormal. For example, NMDA-dependent activity has been shown to be 
considerably prolonged, and was correlated to a loss of spine density (Isokawa & Levesque, 
1991; Isokawa et al., 1997). Additionally, Mathern et al. (1997) demonstrated increased 
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NMDAR2 hybridization in the DG and increased AMPA GluR3 mRNA densities in the 
hippocampus of epileptic patients. The number of GABAA receptors is been shown to be 
reduced in hippocampal resected tissue (McDonald et al., 1991; Johnson et al., 1992; Olsen 
et al., 1992; Wolf et al., 1994), but this is most likely a secondary change associated with cell 
loss. Paradoxically, however, others have found mechanisms of synchronous activity relies 
on GABAA receptor activation in Taylor’s type focal cortical dysplastic (FCD) tissue 
(D’Antuono et al., 2004). FCD is characterised by disruption of cortical lamination and large 
balloon cells. The ability of GABA to cause extracellular increase in K+ and the decreased 
ability of GABAB agonist, baclofen, to control release of GABA from interneurons, was 
suggested to be the mechanisms through which GABA mediated synchronisation occurred. 
Investigating the functional implications of synaptic abnormalities on plasticity, Wilson et al. 
(1998) showed short-term plasticity in disturbed in sclerotic epileptic tissue in comparison 
non-sclerotic tissue. Specifically, paired-pulse depression was increased in the performant 
path and decreased in associational pathways. This increased inhibition in the performant 
pathway, maybe a compensatory mechanism aimed at protecting against seizures, whereas 
reduced inhibition in associated areas may support seizure initiation. Furthermore, in vitro 
investigations have demonstrated, LTP induced by high-frequency stimulation or forskolin 
(increases intracellular cAMP) is dramatically reduced in sclerotic tissue, in comparison to 
non-sclerotic tissue from TLE patients (Beck et al., 2000). The level of damage and 
reorganisation within epileptic tissue increases variability in findings. In support, it has been 
shown epileptiform activity can easily be induced in sclerotic tissue (10mM K+) in comparison 
to non-sclerotic tissue (12mM K+) (Gabriel et al., 2004).  
Many KA and pilocarpine models of epilepsy have been criticised on the basis that they 
produce severe widespread brain damage that does not accurately reproduce that human 
pathology (Sloviter & Bumanglag, 2013). One of the main advantages to the refined Li-
Pilocarpine model of epilepsy used within our laboratory is the reduction in severity. The 
model induces subtle alterations in network dynamics, without significant loss of neuronal 
network function (Modebadze et al., 2016). The results presented in chapter 3 of different 
slice preparations and previous epileptic human tissue studies have shown epileptiform 
activity is more difficult to induce in tissue that is less damaged. Despite some discrepancy 
between the induction in epileptiform activity between rodent and human tissue here, which 
could partially be attributed to tissue removal procedures, it is clear the refined Li-pilocarpine 
model of epilepsy can provide fruitful insights into the mechanisms of epilepsy.  
4.3.3.2 AED efficacy in temporal lobe resected tissue 
All six combination AEDs were demonstrated to increase IEIs in resected temporal lobe 
human tissue. There appeared to be some resistance to VPA and CBD alone, but results 
would need to be replicated with larger samples in order to draw firm conclusions from these 
139 
 
findings. These preliminary findings suggest AEDs that are potentially ineffective in treating 
TLE in patients, maybe effective in vitro.  
In contrast, others have shown resistance to CBZ and PHT (Kohling et al., 1998; Musshoff et 
al., 1997), however these studies explored AED effects on IID and LRD type epileptiform 
activity, which is typically shorter in duration in comparison to IDs and not representative of 
behavioural convulsions observed in patients. The current study assessed the effects of 
AEDs on longer duration IDs. 
As highlighted, the in vitro brain slice preparation represents a reduced system. As a result of 
severed connections represented in this preparation the mechanisms of drug resistant 
present in patients, may not be replicable in vitro. On the other hand, these results are 
preliminary and as some resistance was shown toward VPA and CBD results from larger 
samples may reveal different insights.  
4.3.3.3 Excitability in resected tissue from different brain regions 
Investigations of the excitability of epileptic human tissue of different brain areas, showed 
more temporal lobe slices showed IDs in comparison to motor cortex and frontal lobe slices. 
There were no differences in the latency to first ID. These results suggest of the three 
epileptic regions examined the temporal lobe is the most excitable. In terms of ID parameters 
IEIs between IDs and the duration of IDs were the shortest in the motor cortex, followed by 
the temporal lobe and finally the frontal lobe slices.  
These findings are supported by statistics which show temporal lobe epilepsy is the most 
common form (41% of cases) (Curia et al., 2014). Additionally, studies have shown the 
intrinsic cellular characteristics of temporal lobe areas, give rise to their participation in 
epileptogenesis (Jones & Heinemann, 1988). It is likely that these characteristics are similar 
in resected human tissue too.  
4.3.4 Conclusion 
The current study investigated changes in excitability and the efficacy of combination AEDs 
during epileptogenesis in an animal model of epilepsy and in resected tissue from human 
epileptic patients. Irrespective of stage of epileptogenesis slices prepared from animals who 
had undergone the refine Li-pilocarpine model of epilepsy were significantly more excitable in 
comparison to controls. Findings demonstrate immediate network changes. All combination 
AEDs were effective in reducing IDs at every stage of epileptogenesis, but TGB+CBZ were 
the most effective and LTG+GPT were the least effective overall. These findings suggest 
AEDs of GABAergic mechanisms are particularly effective. However, the focus on targeting 
inhibition or excitation in AED therapy should be avoided as it has not been fruitful thus far. 
Alternative mechanisms are considered in chapter 5. Resistance to AEDs was between 20-
33% across all stages of epileptogenesis. There was some evidence of variation to specific 
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combination of AEDs at different stages. For example, CBD+CBZ was shown to be 
particularly effective as epileptogenesis progressed, with the optimal efficacy at 5 weeks post 
SE, suggesting a therapeutic role in the prevention of epileptogenesis perhaps.  
Comparisons of the PC and EC areas demonstrated that the PC in control and epileptic 
animals was more excitable than the EC. Both regions showed a dip in resistance during the 
latent period (5 weeks post SE) of epileptogenesis, when developmental synaptic pruning 
processes and maturation of receptors are likely to enhance AED effects. Both the PC and 
EC responded well to CBD+CBZ and TGB+CBZ in chronic epilepsy. 
Investigations of excitability in resected human tissue showed tissue from temporal lobe 
regions were more excitable in comparison to the motor cortex and frontal lobe regions. 
However, resected tissue required more excitation in order to induce IDs in comparison to 
epileptic rodent tissue. This discrepancy could be attributed to the likelihood that damage 
within human tissue is likely to be subtle (Gabriel et al., 2004). One of the main criticisms of 
many kainate and pilocarpine models is that they are often severe and do not imitate human 
pathology, however the refined Li-pilocarpine model used within our laboratory has been 
demonstrated to show subtle alterations in network dynamics, without significant loss of 
neuronal network function (Modebadze et al., 2016). Preliminary investigations of AED 
efficacy illustrated all combination AEDs were effective in reducing IDs, with some resistance 
toward VPA and CBD. 
Overall, it is evident epilepsy induces subtle changes in network dynamics that increase 
excitability in the temporal lobe and other brain regions in rodent models and resected 
human tissue. Although, AED efficacy on the whole has shown to be effective in vitro 
preparations of rodent and human tissue, it is important to remember this preparation is 
representative of a reduced system. Nevertheless, subtle changes in AED efficacy during 
epileptogenesis can be seen, the mechanisms for which can be further explored. 
 
 
 
 
 
 
 
 
 
141 
 
 
Chapter 5 Mechanisms underlying NMDA induced network 
alterations during epileptogenesis in layer II of the MEC. 
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5.1 Introduction  
The typical time course of epileptogenesis is characterised by initial neuronal insult followed 
by a seizure free latent period and finally the presence of spontaneous recurring seizures 
(SRS) (Dudek & Staley, 2012; Sloviter & Bumanglag, 2013). The latent period has been 
regarded as the pre-epileptic state during which a cascade of molecular and structural 
mechanisms are activated, leading to the promotion of SRS.  
Studies exploring epileptogenic mechanisms have typically focused on the imbalance 
between excitation and inhibition leading to the disruption of the brain’s equilibrium and 
resulting in the epileptic seizures. This approach has been illustrated to be of limited value in 
understanding seizures and DRE (Margineanu & Klitgaard, 2009). 
Alternatively, the drug-transporter (Loscher & Potschka, 2002; Sisodiya, 2003) and drug-
target hypotheses (Remy et al., 2003; Loup et al., 2000) suggest alterations to drug-
transporter proteins which transport drugs across the BBB and alterations to drug targets 
themselves may result in resistance to AEDs. Whilst these maybe somewhat relevant 
explanations, they do not account for all possibilities of drug resistance (Baltes et al., 2007), 
therefore other possibilities, such as the involvement of inflammatory processes, functional 
glia and altered intracellular communication should be also explored (Margineanu & 
Klitgaard, 2009).  
5.1.1 Excitatory modulation of inhibition 
Despite inhibitory neurons comprising of just 10-25% of the neuronal networks (Markram et 
al., 2004), they play a critical role in the modification of neuronal activity. Inhibitory neurons 
have been shown to be important in the development of cortical circuitry (Allendoerfer & 
Shatz, 1994), and in the plasticity of excitatory synapses (McBain & Fisahn, 2001). Several 
neurotransmitters, such as dopamine (Zhou & Hablitz, 1999b), serotonin (Zhou & Hablitz, 
1999a), GABA (Jarolimek & Misgeld, 1997) and glutamate (Satake et al., 2000) have been 
suggested to modulate presynaptic GABA release from interneurons.  
Glutamate receptors have been well documented to be involved in plasticity associated with 
LTP and epilepsy, therefore understanding the mechanisms behind excitatory modulation of 
inhibition can also provide insights into how LTP and epilepsy can be manipulated (Belan & 
Kostyuk, 2002). Numerous studies have demonstrated the ability of glutamate in modulating 
inhibition (see Belan & Kostyuk, 2002 for a review).  
A study by Xue et al. (2011) explored how NMDA receptor activation influences GABAergic 
transmission. It was initially demonstrated NMDA application elicits an inward current and 
phasic synaptic activity in CA1 pyramidal cells. There were two types of NMDA-induced 
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responses one with characterised by small amplitude changes (common type I) and another 
of larger amplitude changes (less common type II). To assess whether NMDA increases 
EPSCs or IPSCs the GABAA receptor antagonist, SR-95531, was applied and abolished 
NMDA-induced increases in phasic synaptic activity, thus confirming NMDA receptor 
activation increases the frequency of IPSCs. Variations to the duration of NMDA application 
demonstrated a biphasic increase in amplitude, suggesting the presence of two components 
to NMDA induced responses. The frequency of IPSCs induced by NMDA peaked at a 
duration of 3 seconds.  
Further investigations included exploring whether changes to the frequency and amplitude 
were attributed to an increase in presynaptic GABAergic interneurons firing or postsynaptic 
pyramidal GABAA receptor sensitivity. Puff application of TTX abolished NMDA-induced 
synaptic activities in pyramidal neurons, suggesting presynaptic GABAergic interneurons 
increase firing with NMDA application. Additionally, recording from GABAergic interneurons 
indicated NMDA application activates NMDA receptors located at the soma/dendrites of 
interneurons. Induced activity comprised of either an intense discharge of action potentials 
during the rising phase of depolarisations or in spontaneously firing interneurons, action 
potentials initially increased and then ceased when the depolarising action reached a plateau 
(see top traces in figure 5-1A and B). These two differential responses in interneurons to 
NMDA application possibly explains initial differences in type I and type II NMDA induced 
amplitude changes in pyramidal neurons, respectively. Different interneuron responses 
occurred as a result of differential expression of voltage-gated calcium channels (VGCCs), 
which mediate GABA release. Interneurons with P/Q type VGCCs were involved in type I 
responses, whereas interneurons with N-type VGCCs were involved in type II responses. 
Intracellular pyramidal cell loading of the NMDA antagonist, MK-801 demonstrated 
postsynaptic NMDA receptors are also involved in NMDA induced IPSCs. Finally, the 
possibility that postsynaptic activation leads to recruitment of NO as a retrograde messenger 
was tested, using the NO scavenger, PTIO. PTIO reversibly inhibited NMDA induced IPSCs. 
These findings indicate a mechanisms of feedback inhibition, to prevent over-excitation. 
Overall, these findings suggest NMDA receptor activation enhances GABAA inhibition 
between hippocampal interneurons and pyramidal cells, through two distinct mechanisms. 
Firstly, through activation of NMDA receptors in presynaptic interneurons and secondly 
through postsynaptic pyramidal NMDA receptor activation. This latter mechanism recruits 
retrograde messenger NO pathways to enhance GABA release from interneurons. As 
depicted in figure 5-1, activation of postsynaptic NMDA receptors leads to an influx of Ca2+ 
which phosphorylates protein kinase C (PKC) to activate NO synthase. NO then diffuses to 
presynaptic interneuron sites, where it is absorbed by the haem group of guanylate cyclase. 
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Guanylate cyclase reacts with GTP to produce cGMP which increases transmitter release 
and decreases transmitter reuptake.  
NO is produced by a group of isoenzymes, the nitric oxide synthases (NOS), which converts 
L-arginine to citrulline. The three isoenzymes are: endothelial (eNOS), inducible (iNOS) and 
neuronal (nNOS). For activation eNOS and nNOS require the formation of Ca2+ calmodulin 
complexes, whereas iNOS is synthesised following inflammatory stimulation and is 
commonly expressed in astrocytes and microglia. Agents such as heme, tetrahydrobiopterin, 
Flavin adenosine dinucleotide, Flavin mononucleotide and reduced nicotinamide-adenine 
dinucleotide phosphate are required for the catalytic activity of all NOS isoenzymes. As 
mentioned one way in which NO mediates cell signalling is through activation of cGMP, but 
another way involves post-translational modifications including nitrotyrosination and S-
nitrosylation (Banach et al., 2011). 
The role of NO in modulating neurotransmitter release at excitatory synapses is well 
documented (see Garthwaite, 2008 for review). For example, during activation of 
hippocampal pyramidal cell muscarinic receptors retrograde signalling by NO, controls 
cannabinoid receptor (CB1R) dependent depolarisation-induced suppression of inhibition 
(Makara et al., 2007). On the other hand, others have shown inhibitory enhancing effects of 
NO signalling pathways in other brain regions (Nugent et al., 2009; Yang & Cox, 2007). 
Additionally, NO has also been implicated in LTP, as stimulation of glutamatergic afferents 
activates Ca2+ influx through NMDA receptors and promotes NO production which acts as a 
retrograde messenger to enhance glutamate release (Haley et al., 1992).  
NMDA receptors have been extensively documented to play a central role in LTP at 
glutamatergic synapses, but the role of NMDA receptors in the LTP of inhibitory circuits has 
only more recently been elucidated. Expressions of NMDA receptor subunits varies 
according to types of interneurons (e.g. PV interneurons, somatostatin interneurons, etc.) 
(Moreau & Kullmann, 2013). Additionally, at presynaptic locations NMDA molecular 
mechanisms (e.g. BDNF, NO, glutamate) of GABAergic synaptic plasticity also vary (Castillo 
et al., 2011). These different variations contribute to the effective routing of activity in healthy 
inhibitory circuits. 
The NMDA receptor mediated influence over inhibition is very complex and in a similar 
fashion of mGluRs and KARs, has different models of action dependent on locations and 
sensitivity NMDA receptor subunits on different types on interneurons (Castillo et al., 2011; 
Moreau & Kullmann, 2013; Tang et al., 2006) and pre- and post-synaptic locations of NMDA 
receptors (Xue et al., 2011). To add another layer of complexity, the intracellular signalling 
pathways NMDA receptors activate, e.g. NO, also have numerous effects.  
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Figure 5-1. A representation of NMDA receptor activation enhancing GABAergic 
transmission onto hippocampal pyramidal cells through pre- and postsynaptic 
mechanisms (adapted from Xue et al., 2011). A. Presynaptic activation of NMDA receptors 
on interneurons with higher expression P/Q type VCCs (top trace), leads to a NMDA induced 
type I response (smaller amplitude) of sIPSCs in pyramidal cells (bottom trace). B. 
Presynaptic activation of NMDA receptors on interneurons with higher expression of N- type 
VCCs (top trace), leads to a NMDA induced type II response (larger amplitude) of sIPSCs in 
pyramidal cells (bottom trace). C. Postsynaptic activation of NMDA receptors on pyramidal 
cells, enhances GABA release from presynaptic terminals of interneurons through 
recruitment of retrograde messenger NO.C. Schematic representation of the retrograde 
messenger action of NO (adapted from Hölscher, 1997). 
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5.1.2 Changes in NMDA receptors during epileptogenesis 
The involvement of NMDA receptors is critical in LTP and as evidenced in section 5.1.2 also 
plays a significant role in the intricate control of neuronal excitation by modulating inhibition 
through a variety of mechanisms. Interestingly, pathological LTP mechanisms have been 
suggested as an explanation of epileptogenesis and DRE.  
In contrast to AMPA and KA subtypes of glutamate receptors, NMDA receptors are also 
permeable to Ca2+ ions in addition to Na+ and K+ ions. Furthermore, NMDA receptors have 
slower kinetics which is attributed to a higher affinity for glutamate (Conti & Weinberg, 1999). 
Under normal physiological conditions brief controlled elevations in Ca2+ transmitted via 
NMDA receptors, trigger LTP through a wide range of signal transduction pathways (e.g. 
PKC, cyclic adenosine 3’,5’- monophosphate (cAMP), tyrosine kinase, Src and mitogen-
activated protein kinase (MAPK) (for a review see Lynch, 2004). These plasticity induced 
structural and electrophysiological changes are fundamental to learning and memory 
(Malenka & Nicoll, 1999; Gnegy, 2000; West et al., 2001; Tzounopoulos & Stackman, 2003). 
The Ca2+ hypothesis of epileptogenesis proposes the neuronal effects of Ca2+ lie on a 
continuum. One end of the spectrum is characterised by brief increases in Ca2+ associated 
with physiological effects of learning and memory. The middle ground is characterised by a 
reversible but prolonged and sub-lethal elevation in intracellular Ca2+ that trigger pathological 
plasticity of epileptogenesis. Finally, the extreme end of the spectrum is characterised by 
irreversible elevation in Ca2+ and neuronal death (DeLorenzo et al., 2005).  
In terms of Ca2+ effects during epileptogenesis, it has been postulated that during initial CNS 
insult, sub-lethal increases in Ca2+ that do not cause cell death are experienced. During the 
latent period persistent elevations in Ca2+ initiate pathological LTP. Finally during chronic 
epilepsy persistent elevations in Ca2+ maintains SRS (DeLorenzo et al., 1998; Rice & 
DeLorenzo, 1998; Pal et al., 2000, 2001; Sun et al., 2002, 2004).  
Pathological plasticity induces a wide range of changes including a reduction in GABA 
transmission proposed to be a result of GABAA receptor internalisation (Blair et al., 2004) and 
an upregulation in NMDA receptor function and/ or expression at postsynaptic sites (Avanzini 
& Franceschetti, 2003; Dalby & Mody, 2001; Morimoto et al., 2004). Additionally, presynaptic 
NMDA receptor alterations have been demonstrated in chronic epilepsy. Presynaptic 
regulation of glutamate release is powerfully controlled by heteroreceptors and 
autoreceptors. Heteroreceptors regulate the syntheses and/or release of mediators other 
than their own ligand and are effected by GABAB, adenosine and muscarinic receptors. 
Autoreceptors are sensitive to the neurotransmitters released by the neurons in which it 
resides and is effected by mGluRs, KARs and NMDA receptors. Yang et al. (2006) 
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demonstrated in the layer V of the EC there is a developmental decrease in NR2B 
autoreceptor function, however in chronically epileptic animals this is reversed as sEPSCs 
were sensitive to the NR2B antagonist, Ro 25-6981.These results suggest enhanced NR2B 
activity which may occur through upregulation or redistribution of receptors. This enhanced 
NR2B activity represents a recapitulation of earlier development. Similarly, others have 
suggested epileptic network resemble earlier development (Cohen et al., 2003).  
Additionally, others have also reported evidence for enhanced NR2B expression in human 
and animal models of epilepsy (DeFazio & Hablitz, 2000; Mathern et al., 1999; Ying et al., 
2004). For example, epileptiform discharges from patients with cortical dysplasia have been 
shown to be suppressed with the NR2B antagonist, ifenprodil (Moddel et al., 2005). In the 
freeze-lesion induced animal model, ifenprodil also increases the threshold for evoking 
discharges (DeFazio & Hablitz, 2000). 
Under normal physiological conditions the NMDA receptor subunit NR2A, is three times more 
likely to open in response to glutamate in comparison to NR2B. On the other hand, when 
NR2B receptors do open they stay open for twice as long in comparison to NR2A. Whilst 
NR2A is insensitive to different glutamate concentrations, NR2B responds in a graded 
fashion in response to different glutamate concentrations. The activity of NR2A is also 
insensitive to location of the synapse, whereas NR2B receptors located closest to release 
site were opened three times as often as NR2B receptors located further away. As 
mentioned NR2B receptors normally get displaced by NR2A receptors during development 
and this coincides with a reduction in spontaneous activity, but Santucci and Raghavachari 
(2008) also suggested NR2B receptors become preferentially located extrasynaptically, 
where higher concentrations of glutamate are required for them to open. The possible 
functions of this extrasynaptic NR2B receptor locations was suggested to detect events that 
cause large amounts of glutamate to be released or detect glutamate release by astrocytes 
which may play a role in synchronisation. Finally, both NR2B and NR2A receptors could both 
drive CamKII autophosphorylation required for LTP but NR2B was more reliably involved. 
Given that research by Yang et al (2006) and others have shown an upregulation in NR2B 
expression in epilepsy coupled with the variable electrophysiological profile and involvement 
in LTP it seems likely that the altered NR2A to NR2B ratio can play an influential role in the 
maintenance of seizures.  
Dravid et al (2007) investigated the potencies of structurally distinct NMDA channel blockers 
at recombinant NMDA receptors (NR1+NR2A/NR2B/NR2C/NR2D), the results from which 
suggest MK801 would serve a good probe to investigate the changes of NMDA subunit 
receptor changes and the influence on the generation and maintenance of seizures in 
epilepsy. Dravid et al. (2007) specifically showed that inhibitory potency varied with 
stereochemistry of channel blockers and NMDA receptor subunit composition. At pH 7.6 
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MK801 inhibitory potency was similar for all four NR2 subunits, but potency of (-) MK801 was 
more variable. At NR2A subunits (+) MK801 was 23 times more potent than (-) MK801. For 
NR2B, NR2C and NR2D subunits (+) MK801 was 3.6, 1.6 and 4.4 times, respectively, more 
potent than (-) MK801 at pH 7.6. Additionally, the potency of (+) MK801 and (-) MK801 is 
greater at NR2A when pH is reduced, but this shift in potency is not seen at NR2B subunits. 
Evidently Dravid et al. (2007) have demonstrated the robust nature of MK801 isomers on 
NR2 subunits, which could be useful to investigate the changes of NMDA subunit receptor 
changes and the influence on the generation and maintenance of seizures in epilepsy.  
Moreover, other studies have already begun to show the usefulness of MK801 as a tool in 
investigating NMDA receptor changes in epileptiform activity and behaviour, but the 
mechanisms underlying such changes remain to be elucidated. Moderate doses of the 
NMDA receptor antagonist MK801 have been shown to attenuate seizure activity (Avoli et 
al., 1996). On the other hand, low doses of NMDA receptor antagonist, MK-801, (0.1- 0.4 
mg/kg) has been widely reported to increase locomotion (Deutsche et al., 1997; Wu et al., 
2005; Wegnener et al., 2011) and epileptic activity (Stafstrom et al., 1997; Starr & Starr, 
1993).  
Whilst much research has focused using low dose MK801 to model schizophrenia (Tang et 
al., 2006), relatively few studies have focused on the mechanisms behind the biphasic 
MK801 effects on seizure activity. The mechanisms through which MK-801 worsens seizure 
activity has been suggested to be due disinhibitory effects in which MK-801 selectively 
inhibits NMDA receptors on interneurons (Stafstrom et al., 1997). Others have highlighted in 
normal tissue there appears to be substantial differences in the sensitivity to MK-801 which 
may correlate to anatomical localisations of different NMDA receptor subtypes and account 
for paradoxical effects of low doses of MK-801 (Tang et al., 2006). As NMDA receptors are 
altered in epileptogenesis, it can be hypothesised as the NMDA drive in epileptic networks 
change during epileptogenesis further differences in MK801 sensitivity maybe evident 
between control and epileptic tissue at different time points. 
Moreover, an alternative explanation of low dose MK801 seizure potentiating effects have 
been suggested to occur as a result of interdependence between D1 and NMDA receptors in 
the control of behaviour (Starr & Starr, 1993). Five subtypes of dopamine receptors (D1-D5) 
have been commonly described, all of which are G-protein-coupled transmembrane 
receptors. D1 receptors are the most abundant are found in the striatum, limbic areas, 
thalamus and hypothalamus. D2 receptors are the next most common are mainly found in 
the pituitary gland. Activation of D1 receptors increases intracellular cAMP, which activates 
protein kinase A (PKA) leading to phosphorylation of DARPP-32. DARPP-32 inhibits protein 
phosphatase-1 and calcineurin, thus promoting the action of protein kinases and favouring 
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protein phosphorylation which is an amplifying mechanism. Generally, D2 receptors oppose 
the actions of D1 receptors (Girault & Greengard, 2004). 
Activation of D1 receptors have been shown to accentuate pilocarpine-induced seizure 
activity (Burke et al., 1990). Also, in the study of dopamine receptors in Parkinson’s disease, 
MK801 has been shown to potentiate D1 stimulant induced increases in motor activity, but 
attenuates D2 agonist effects (Goodwin et al., 1992). Starr and Starr (1993), demonstrated 
both MK801 and the NO synthesis inhibitor, L-NAME, produced convulsant effects in synergy 
with D1 receptor agonist, SK&F38393. These results suggest that MK801 works in synergy 
with D1 receptors to activate NO signalling pathways leading to seizure activity. 
NO has been reported to significantly increase glutamate release at excitatory synapses 
(McNaught & Brown, 1998) and conversely decrease glutamate release (Sequeira et al., 
1997).  Biphasic effects of NO on glutamate release have been suggested to occur as a 
result in intracellular levels of cGMP (Ferrara and Sardo, 2004). Manipulations of NO have 
been shown to have pro and anticonvulsant effects. For example, demonstrating 
anticonvulsant effects, the NO precursor, L-arginine has effectively reduced susceptibility to 
seizures (Herberg et al., 1995; Prezgalinski et al., 1996), and NOS inhibitors have increased 
seizure susceptibility (Urbanska et al., 1996).The mechanisms through which this NO 
anticonvulsant effect occurs has been proposed to include: negative feedback on the NMDA 
receptor through competitive blockade of the recognition site (Manzoni et al., 1992), 
functional interaction with the redox modulatory site of NMDA receptors (reduction enhancing 
and oxidants depressing NMDA activity) (Lei et al., 1992; Sanchez et al., 2000) and NO 
induced enhancement of GABAergic transmission (Tsuda et al., 1997). Conversely 
proconvulsant effects of NO are related to changes in cerebral blood flow. For example, 
where vasodilation has been reduced with NOS inhibitors, seizures have been prevented or 
delayed (Bittermam & Bitterman, 1998). Similarly, KA inductions of seizure activity have been 
directly associated with increases in NOS activity (Yasuda et al., 2001). 
Overall, numerous investigations have demonstrated glutamate-receptors modulate 
GABAergic inhibition through a variety of mechanisms, which are complexly dependent and 
intertwined with spatial-temporal distribution patterns of extracellular glutamate 
concentrations and differential expressions of glutamate receptors on different types of 
neurons (Belan & Kostyuk, 2002). Undoubtedly, changes to different glutamate receptors will 
disrupt the excitability of networks. Whilst the expression of KARs increase as a result of 
axonal sprouting (Pinheiro & Mulle, 2008), axonal sprouting itself maybe a secondary 
mechanism. On the other hand, NMDA receptors have been extensively documented to be 
involved in seizure generation and LTP. Pre- and postsynaptic NMDA receptor activation of 
interneurons and pyramidal cells play an intricate role in regulating the excitation of neuronal 
networks. Numerous studies have also suggested NMDA receptors are altered significantly 
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over the course of epileptogenesis and MK801 could be a useful tool in investigating NMDA 
receptor changes during epileptogenesis. A prominent mechanism through which NMDA 
receptors exert control over excitability is via activation of NO signalling pathways which also 
has pro and anticonvulsant action and has been proposed to play a fundamental role in the 
development of epileptogenesis. The current study assessed how NMDA drive of inhibition 
changes during epileptogenesis in comparison to controls. Secondly the role of the NO 
pathway in mediating NMDA drive of inhibition during epileptogenesis was evaluated. 
 
5.2 Results 
5.2.1. NMDA drive of inhibition during epileptogenesis 
To explore NMDA drive of inhibition during epileptogenesis, transverse combined 
hippocampal-entorhinal slices were prepared from rats that had undergone the refined Li-
pilocarpine model at four different time points: 24 hours, 1 week, 5 weeks and 12 weeks+ 
post SE. Slices from age matched controls were also prepared. Slices were exposed to 
0[Mg]2+ aCSF for 25 minutes, after which a MK801 (+) MK801 maleate (Dizocipline)) dose 
response (0.001 – 30 μM) experiment was conducted to evaluate which concentrations 
promote or inhibit IDs in epileptic and control tissue in vitro.  
As illustrated in Figure 5-2 to 5-6, IDs could readily be evoked in control and epileptic slices 
at different stages of epileptogenesis with 0.1-0.3 μM MK801 application.  Statistical analysis 
of this data is represented in figure 5-7. Due to both independent and dependent variables 
being categorical in nature, analyses options were limited and therefore had to be made 
simpler.
151 
 
 
Figure 5-2. Ictal discharges at different MK801 concentrations in control and epileptic slices 24 hours post SE. A. Ictal discharges in a 60 g control rat 
evoked by different MK801 concentrations (0.001 – 30 μM) Scale: 500 μV x 1000secs. Red lines indicate the point of application. Red arrows indicate IDs. B. Ictal 
discharges evoked in a 24 hour SE rat by different MK801concentrations. Scale: 100 μV x 1000 secs. C. Comparison of the total number of IDs at different MK801 
concentrations in control (n = 12) and 24 hour SE rats (n = 12). D. Comparison of the percentage of slices which showed IDs with different MK801 concentrations 
in control and 24 hour SE rats. 
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Figure 5-3. Ictal discharges at different MK801 concentrations in control and epileptic slices 1 week post SE. A. Ictal discharges in a 85 g control rat 
evoked by different MK801 concentrations (0.001 – 30 μM) Scale: 100μV x 1000 secs. Red lines indicate the point of application. Red arrows indicate IDs. B. Ictal 
discharges evoked in a 1 week SE rat by different MK801 concentrations. Scale: 500 μV x 1000 secs. C. Comparison of the total number of IDs at different MK801 
concentrations in control (n = 12) and 1 week SE rats (n = 12). D. Comparison of the percentage of slices which showed IDs with different MK801 concentrations in 
control and 1 week SE rats. 
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Figure 5-4. Ictal discharges at different MK801 concentrations in control and epileptic slices 5 weeks post SE. A. Ictal discharges in a 290 g control 
rat evoked by different MK801 concentrations (0.001 - 30 μM) Scale: 200 μV x 1000 secs. Red lines indicate the point of application. Red arrows indicate IDs. B. 
Ictal discharges evoked in a 5 week SE rat by different MK801 concentrations. Scale: 500 μV x 1000 secs. C. Comparison of the total number of IDs at different 
MK801 concentrations in control (n = 12) and 5 week SE rats (n = 12). D. Comparison of the percentage of slices which showed IDs with different MK801 
concentrations in control and 5 week SE rats. 
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Figure 5-5. Ictal discharges at different MK801 concentrations in control and epileptic slices 12 weeks+ post SE. A. Ictal discharges in a 450 g control 
rat evoked by different MK801 concentrations (0.001 - 30 μM) Scale: 200 μV x 1000 secs. Red lines indicate the point of application. Red arrows indicate IDs. B. 
Ictal discharges evoked in a 12 weeks+ SE rat by different MK801 concentrations. Scale: 500 μV x 1000 secs. C. Comparison of the total number of IDs at 
different MK801 concentrations in control (n = 8) and 12 weeks+ SE rats (n = 12). D. Comparison of the percentage of slices which showed IDs with different 
MK801 concentrations in control and 12 weeks+ SE rats. 
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Figure 5-6. Excitability of control and epileptic slices with different MK801 concentrations at different stages of epileptogenesis. A. Total 
number of IDs at different MK801 concentrations in control slices at different developmental stages of epileptogenesis. B. Total number of IDs at different 
MK801 concentrations in epileptic slices at different developmental stages of epileptogenesis. C. Developmental changes in the percentage of control 
slices with IDs at different MK801 concentrations. D. Developmental changes in the percentage of epileptic slices with IDs at different MK801 
concentrations. 
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To statistically assess whether there were differences in the number of slices that showed 
IDs at different MK801 concentrations, two Friedman’s tests conducted on control and 
epileptic tissues. The results of the Freidman’s test of control slices showed, irrespective of 
age, there were significant differences in the number of control slices that showed IDs at 
different MK801 concentrations, χ² (6, n = 46) = 37.36, p < 0.01 (see Figure 5-7A). Control 
slices showed more IDs at concentrations of 0.1 μM and 0.3 μM MK801. Based on this 
information, post-hoc planned comparisons were carried out with Wilcoxon signed-rank tests, 
with a Bonferroni correction applied (p < 0.01). As shown in figure 5-7A there were significant 
differences between the number of control slices that showed IDs at 0.1 μM MK801 and 1 
μM (Z = - 3.21, p < 0.01), 10 μM (Z = - 3.16, p < 0.01), 30 μM (Z = - 3.74, p < 0.01) MK801 
concentrations. There were also significant differences between, 0.3 μM MK801 and 1 μM (Z 
= - 3.00, p < 0.01), 10 μM (Z = - 2.89, p < 0.01), 30 μM (Z = - 3.74, p < 0.01) MK801 
concentrations. The results show, irrespective of age 0.1- 0.3 μM MK801 were the optimal 
concentrations for evoking IDs in control tissue. 
Similarly, the results of the Freidman’s test of SE slices showed, there were significant 
differences in the number of SE slices that showed IDs at different MK801 concentrations, χ² 
(6, n = 46) = 37.36, p < 0.01 (see Figure 5-7B). SE slices showed higher number of IDs at 
0.3 μM MK801. Based on this information, post-hoc planned comparisons were carried out 
with Wilcoxon signed-rank tests with a Bonferroni correction applied (p < 0.01). As shown in 
figure 5-7B there were significant differences between the number of control slices that 
showed IDs at 0.1 μM MK801 and 30 μM MK801 (Z = -2.53, p < 0.01). There were also 
significant differences between, 0.3 μM MK801 and 1μM (Z = - 2.67, p < 0.01), 10 μM (Z = - 
3.60, p < 0.01), 30 μM (Z = - 3.74, p < 0.01) MK801 concentrations. The results show, 
irrespective of age 0.1- 0.3 μM MK801 were the optimal concentrations for evoking IDs in 
epileptic tissue. 
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Figure 5-7. Excitability of control and epileptic slices with different MK801 
concentrations. A. Percentage of excitable control slices (pooled ages) with different 
concentrations of MK801. B. Excitability of SE slices (pooled ages) with different 
concentrations of MK801. 
 
There was a trend for excitability (percentage of slices with IDs and accumulative number of 
IDs) with 0.1- 0.3 μM MK801 applications to gradually decrease in control animals post 80-90 
g. However, this trend was not present in tissue that had undergone the refined Li-pilocarpine 
model of epilepsy. As illustrated in figure 5-8 and summarised in table 5.1, excitability in SE 
slices remained high during the later latent period (5 weeks post SE) and during the chronic 
phases of epileptogenesis (12 week+ post SE). 
To investigate if there were significant differences in the percentage of slices with IDs with 
100 nM MK801 application in control and epileptic slices at different stages of 
epileptogenesis, a logistic regression analysis was conducted (see Figure 5-8A). The full 
model containing predictor variables, status and age was significant, χ² (7, N= 91) = 17.05, p 
< 0.05, indicating the model was able to distinguish between the presence and absence of 
IDs in slices at 100 nM MK801. The model explained between 17.1% (Cox & Snell R square) 
and 25.2 % (Nagelkerke R square) of the variance, and correctly classified 78 % of cases. 
Status, age and the status x age interaction effect did not make a unique significant 
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contribution to the model, p > 0.05. These results suggest there were no differences between 
the excitability of control and epileptic slices during epileptogenesis. 
To assess if there were significant differences in the percentage of slices with IDs with 0.3 
μM MK801 application in control and epileptic slices at different stages of epileptogenesis, a 
logistic regression analysis was conducted (see Figure 5-8B). The full model containing 
predictor variables, status and age was not significant, χ² (7, N= 91) = 12.51, p > 0.05, 
indicating the model was not able to distinguish between the presence and absence of IDs in 
slices at 0.3 μM MK801 (i.e. no better than chance). The model explained between 12.8 % 
(Cox & Snell R square) and 18.0 % (Nagelkerke R square) of the variance, and correctly 
classified 71.4 % of cases. Status, age and the status x age interaction effect did not make a 
unique significant contribution to the model, p > 0.05. These results suggest there were no 
differences between the excitability of control and epileptic slices during epileptogenesis. 
These results indicate there were no differences in excitability induced by 0.1- 0.3 μM MK801 
applications between control and epileptic slices at different stages of epileptogenesis. 
Nevertheless, there is a clear trend for excitability to decrease gradually in controls but not in 
epileptic slices with development (see Figure 5-8A and B). 
 
Table 5.1. Summary of excitability of control and SE slices with 0.1- 0.3 μM MK801 
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Figure 5-8. Excitability of control and epileptic slices at 0.1 and 0.3μM MK801. A. Percentage of slices with IDs with 0.1 μM MK801 in control 
and epileptic slices at different stages of epileptogenesis. B. Percentage of slices with IDs with 0.3 μM MK801 in control and epileptic slices at 
different stages of epileptogenesis.  
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It could be argued that the presence of IDs present in these experiments, was not due to 
MK801 application and instead occurred as a result of 0[Mg]2+ aCSF. However, it is clearly 
illustrated in figures 5-2 to 5-5 that IDs occurred prominently during application of 0.1- 0.3 μM 
MK801. Moreover, examination of the latency to first ID in control and epileptic slices, with 
and without MK801 application showed large differences, suggesting bursts of ictal activity 
was due to the application of MK801, as demonstrated in figure 5-9.  
A between-subjects ANOVA showed there were significant differences between pooled 
control slices with and without MK801 application (0.001- 30 μM) in the latency to first 
seizure F (1, 57) = 26.29, p < 0.01 (see Figure 5-9A). Post-hoc analysis showed control 
slices without MK801 has a longer latency to first ID (7149.88 ± 500.92 seconds) in 
comparison to control slices with MK801 (3602.76 ± 203.17 seconds). There was no 
interaction effect between MK801 application and age in control slices, p > 0.05 (see Figure 
5-9B).  
Further ANOVA analysis showed there were significant differences in the latencies to first ID 
in epileptic slices with and without MK801 application, F (1, 130) = 18.41, p < 0.01 (see 
Figure 5-9A). Post-hoc analysis showed SE slices without MK801 showed shorter latencies 
to first ID (2890.36 ± 128.31 seconds) in comparison to SE slices with MK801 (4871.90 ± 
536.67 seconds). There was no interaction effect between MK801 application and age in 
epileptic slices, p > 0.05 (see Figure 5-9C). 
Looking at figure 5-9B and 5-9C, it would appear that MK801 is more pro-convulsant in 
controls and more anticonvulsant in epileptic slices. To test this hypothesis, a between 
subjects ANOVA was conducted, but there was no significant interaction between MK801 
application, SE status and age F (3, 187) = 2.22, p = 0.09.  
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Figure 5-9. Latencies to first IDs in control and epileptic tissue, without and with 
MK801 application (0.001- 30μM). A. Latency to first ID in control and epileptic tissue with 
and without MK801 application B. Latency to first ID in control tissue, at different ages, 
without and with MK801 application. C. Latency to first ID in epileptic tissue, at different ages, 
without and with MK801 application. 
 
5.2.2. Role of NO pathway in the NMDA drive of inhibition 
As demonstrated in section 5.2.1 the NMDA receptor antagonist, MK801, was capable of 
evoking IDs in control and epileptic tissue. This trend decreased with development in controls 
but not epileptic tissue. Here, the role of NO mediating MK801 induced IDs is evaluated. 
Epileptic slices were exposed to 0[Mg]2+ aCSF and the nitric oxide synthase inhibitor, 7-
nitroinadazole (7-NI) (200 μM), after which MK801 concentrations (0.03 – 10 μM) were 
applied to evaluate whether IDs still precipitated. 
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To investigate whether there were significant differences in the percentage of SE slices that 
showed IDs at 0.1 μM MK801 in 0[Mg]2+ aCSF or 0[Mg]2+ and 7-NI aCSF, a logistic 
regression analysis was conducted (see Table 5.2 for summary). The full model containing 
predictor variables condition (in 0[Mg]2+ aCSF or 0[Mg]2+ and 7-NI aCSF) and age was not 
significant χ² (7, 92) = 3.31, p > 0.05, indicating the model was not able to distinguish 
between the presence and absence of IDs in slices at 0.1μM MK801 (i.e. no better than 
chance). The model explained between 3.5 % (Cox & Snell R square) and 5.5 % 
(Nagelkerke R square) of the variance, and correctly classified 79.3 % of cases. Condition, 
age and the status x age interaction effect did not make a unique significant contribution to 
the model, p > 0.05. These results suggest application of the NO synthase inhibitor, 7-NI, did 
not affect the percentage of slices with IDs induced by 0.1 μM MK801 at different stages of 
epileptogenesis (see figures 5-10 and 5-11). 
To investigate whether there were significant differences in the percentage of SE slices that 
showed IDs at 0.3 μM MK801 in 0[Mg]2+ aCSF or 0[Mg]2+ and 7-NI aCSF, a logistic 
regression analysis was conducted. The full model containing predictor variables condition 
(in 0[Mg]2+ aCSF or 0[Mg]2+ and 7-NI aCSF) and age was not significant χ² (7, 92) = 7.96, p > 
0.05, indicating the model was not able to distinguish between the presence and absence of 
IDs in slices at 0.3 μM MK801 (i.e. no better than chance). The model explained between 8.3 
% (Cox & Snell R square) and 12.8 % (Nagelkerke R square) of the variance, and correctly 
classified 78.3% of cases. Condition, age and the status x age interaction effect did not make 
a unique significant contribution to the model, p > 0.05. These results suggest application of 
the NO synthase inhibitor, 7-NI, did not affect the percentage of slices with IDs induced by 
0.3 μM MK801 at different stages of epileptogenesis (see figure 5-10 and 5-11). 
 
Table 5.2. Percentage of SE slices with IDs with and without 7-nitraindazole 
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Figure 5-10. Percentage of slices with IDs at different MK801 concentrations in 7-nitraindazole (200 μM) and/or 0[Mg]2+ aCSF during 
epileptogenesis. A. Percentage 24 hours SE slices with IDs at different MK801 concentrations in 7-NI and/or 0[Mg]2+. B. Percentage 1 week SE 
slices with IDs at different MK801 concentrations in 7-NI and/or 0[Mg]2+. C. Percentage 5 week SE slices with IDs at different MK801 concentrations 
in 7-NI and/or 0[Mg]2+. D. Percentage 12 weeks+ SE slices with IDs at different MK801 concentrations in 7-NI and/or 0[Mg]2+.
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Figure 5-11. The effects of 7-nitraindazole on MK801 ID inducing effects during 
epileptogenesis. A. Percentage of SE slices with IDs at difference MK801 concentrations, 
during epileptogenesis. B. Percentage of SE slices with IDs at different MK801 
concentrations, during epileptogenesis after 7-NI exposure. 
 
 
 
 
 
 
 
165 
 
5.2.3. Changes in GABAergic events during epileptogenesis 
The findings presented thus far demonstrate that NMDA receptor activity deviates from 
normal physiological development during epileptogenesis. This is evident through a trend in 
which low MK801 concentrations (0.1- 0.3 μM) readily induces IDs throughout 
epileptogenesis, whereas in controls this excitability decreases. As illustrated in section 
5.2.2, these ID inducing effects of low MK801 concentrations are not mediated through the 
NO signalling pathway, as the NO synthase inhibitor, 7-nitraindazole failed to significantly 
reduce excitability. Here, the developmental changes of GABAergic events during 
epileptogenesis are explored further.  
Bazelot et al. (2010) demonstrated interneurons, but not pyramidal cells, were capable of 
evoking field potentials at monosynaptic latencies. These inhibitory fields were shown to be 
GABAergic in nature and originated from postsynaptic sites as they were suppressed by low 
external Cl-. Further electrode array investigation revealed events generated at dendritic sites 
had similar amplitudes to perisomatic events, but occurred less frequently. Based on this 
study, the alterations to GABAergic activity during epileptogenesis are explored here on a 
similar neuronal network level.  
In a similar fashion to Bazelot et al (2010), figure 5-12 illustrates slow field events are 
inhibitory in nature. Blocking of excitatory transmission with CNQX (20 μM) and AP5 (50 μM) 
reduced the frequency of events. Additional application of bicuculline (20 μM) suppressed 
slow extracellular events. Variable effects of amplitude were evident, but this experiment was 
only conducted in an 80 g and 250 g control rat for confirmatory purposes. 
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Figure 5-12. Extracellular events mediated by GABAA receptors in CA3 and layer II MEC. Ai. Extracellular CA3 trace showing spikes and 
extracellular field IPSPs (arrow) in the presence of KA (50 nM). Scale: 100 μV x 100ms. Aii. Extracellular CA3 trace showing spikes and 
extracellular field IPSPs in the presence of CNQX (20 μM) and AP5 (50 μM). Note reduction in frequency of field IPSPs. Aiii. Suppression of CA3 
field IPSPs in the presence of bicuculline (20 μM). Bi. Extracellular MEC trace showing spikes and extracellular field IPSPs (arrow) in the presence 
of KA (50 nM). Scale: 50 μV x 100 ms. Bii. Extracellular MEC trace showing spikes and extracellular field IPSPs in the presence of CNQX (20 μM) 
and AP5 (50 μM). Note reduction in frequency of field IPSPs. Biii. Suppression of MEC field IPSPs in the presence of bicuculline (20 μM). 
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Results presented in section 5.2.1 demonstrated clear difference in ID inducing effect of low 
concentration MK801 (0.1- 0.3 μM) in SE and control slices during the latent period. A 
summary of the effects of MK801 in field IPSPs (IEIs and amplitude) in controls and SE 
slices at 1 week and 5 weeks post SE induction is presented in Table 5.3.  
 
Table 5.3. The effects of MK801 on field IPSPs in control and SE slices  
 
 
To investigate differences in the inter-event-intervals (IEIs) between field IPSPs in SE and 
control slices at 1 week post SE a mixed-model ANOVA was conducted on ranked data, due 
to the low complexity and small sample size used. As illustrated in figure 5-13C, there were 
significant differences in the IEIs between field IPSPs in control and SE slices at 1 week post 
SE, F (1, 10) = 13.04, p < 0.01. The IEIs between field IPSPs in SE slices was significantly 
longer in comparison to control slices. These results suggest inhibition is reduced in SE 
slices during the early latent period. There was no significant effect of MK801 on the IEIs 
between field IPSPs, p > 0.05. There was also no interaction effect between the effect of 
MK801 and status of animals (control vs SE), p > 0.05. 
To investigate differences on the amplitude of field IPSPs in SE and control slices at 1 week 
post SE a mixed-model ANOVA was conducted on ranked data. As illustrated in figure 5-
13D, there was no significant differences in the amplitude of field IPSPs in control and SE 
slices at 1 week post SE, p > 0.05. There was also no significant effect of MK801 the 
amplitude of field IPSPs, p > 0.05. Finally, there was no significant interaction effect between 
effect of MK801 and status of animal (control vs SE), p > 0.05. 
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Figure 5-13. The effects of MK801 on field IPSPs in control and SE slices at 1 week post SE. Ai. Field IPSPs in an 80 g control slice in 0[Mg]2+ 
aCSF (Bandpass second order filter 1-300 Hz). Scale: 20 μV x 200 ms. Aii. The effect of MK801 (300 nM) on field IPSPs in 80 g control slice. Bi. 
Field IPSPs in a 1 week SE slice in 0[Mg]2+ aCSF. Bii. The effect of MK801 (300nM) on field IPSPs in a 1 week SE slice. C. The effects of MK801 
on the IEIs between field IPSPs in control (0[Mg]2+ aCSF: 328.83 ms ± 126.00, MK801: 294.37 ms ± 72.27) and 1 week SE slices(0[Mg]2+ aCSF: 
1062.66ms ± 348.77, MK801: 1801.33 ms ± 543.73). D. The effects of MK801 on the amplitude of field IPSPs in control (0[Mg]2+ aCSF: 91.70 μV ± 
4.85, MK801: 87.16 μV ± 2.58) and 1 week SE slices (0[Mg]2+ aCSF: 95.08 μV ± 16.88, MK801: 93.08 μV ± 15.31). 
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To investigate differences in the IEIs between field IPSPs in SE and control slices at 5 weeks 
post SE a mixed-model ANOVA was conducted on ranked data. As illustrated in figure 5-
14C, there were significant differences in the IEIs between field IPSPs in control and SE 
slices at 5 weeks post SE, F (1, 7) = 16.20, p < 0.01. The IEIs between field IPSPs were 
significantly longer in control slices compared to SE slices at 5 weeks post SE. These results 
suggest inhibition is enhanced in SE slices during the later latent period (5weeks) and 
contrast the results in figure 5-12 showing reduced inhibition in SE slices at 1 week post SE 
induction, and perhaps indicative of a compensatory mechanism. There was no significant 
effect of MK801 on the IEI’s between field IPSPs, p > 0.05. There was also no interaction 
effect between the effect of MK801 and status of animals (control vs SE), p > 0.05. Despite 
these results it is interesting that there is a trend for MK801 to reduce IEIs between field 
IPSPs in controls but not SE slices at 5 weeks post SE. 
To investigate differences on the amplitude of field IPSPs in SE and control slices at 5 weeks 
post SE a mixed-model ANOVA was conducted on ranked data. There was no significant 
differences in the amplitude of field IPSPs in control and SE slices at 5 weeks post SE, p > 
0.05. There was also no significant effect of MK801 the amplitude of field IPSPs, p > 0.05. 
Finally, there was no significant interaction effect between effect of MK801 and status of 
animal (control vs SE), p > 0.05. 
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Figure 5-14. The effects of MK801 on field IPSPs in control and SE slices at 5 weeks post SE. Ai. Field IPSPs in a 300 g control slice in 0[Mg]2+ 
aCSF. (Bandpass second order filter 1-300 Hz). Scale: 50 μV x 200 ms. Aii. The effect of MK801 (300 nM) on field IPSPs in 3000 g control slice. Bi. 
Field IPSPs in a 5 week SE slice in 0[Mg]2+ aCSF. Bii. The effect of MK801 (300 nM) on field IPSPs in a 5 week SE slice. C. The effects of MK801 on 
the IEIs between field IPSPs in control (0[Mg]2+ aCSF: 7032.68 ms ± 873.31, MK801: 4326.68 ms ± 1238.60) and 5 week SE slices (0[Mg]2+ aCSF: 
662.14 ms ± 118.33, MK801: 715.87 ms ± 185.23). D. The effects of MK801 on the amplitude of field IPSPs in control (0[Mg]2+ aCSF: 96.42 μV ± 
12.50, MK801: 92.58 μV ± 3.83) and 5 week SE slices (0[Mg]2+ aCSF: 106.11 μV ± 12.47, MK801: 118.67 μV ± 8.67). 
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5.3 Discussion 
The current study assessed how NMDA drive of inhibition changes during epileptogenesis in 
comparison to controls. Secondly the role of the NO pathway in mediating NMDA drive of 
inhibition during epileptogenesis was evaluated. Overall it was illustrated that IDs could be 
readily evoked by application of low concentrations of MK801 (0.1- 0.3 μM) in control and SE 
slices of all ages. There was a developmental trend for excitability in response to low 
concentrations of MK801 to decrease in controls and conversely excitability remained 
elevated in epileptic animals. Low dose MK801 ID inducing effects were not mediated by NO, 
as pre-treatment of slices with the NO synthase inhibitor, 7- nitroindazole, failed to exert any 
significant effects on IDs. Finally, MK801 did not exert any significant effects on field IPSPs, 
either. Overall, changes in NMDA receptor activity is evident during epileptogenesis but the 
mechanisms through which this alteration affects excitability remains to be elucidated as 
shall be discussed. 
5.3.1 Developmental NMDA drive of inhibition in controls and epileptic slices 
Numerous studies have demonstrated the ability of glutamate in modulating inhibition. 
Glutamate receptors have been well documented to be involved in plasticity associated with 
LTP and epilepsy, therefore understanding the mechanisms behind excitatory modulation of 
inhibition can also provide insights into how LTP and epilepsy can be manipulated (Belan & 
Kostyuk, 2002); Castillo et al., 2011; Moreau & Kullmann, 2013). 
Initial investigations of this study demonstrated IDs could be readily evoked by application of 
low concentrations of MK801 (0.1- 0.3 μM) in control and SE slices of all ages. This supports 
many studies which have illustrated low dose MK801 administration increases locomotion 
(Deutsche et al., 1997; Wu et al., 2005; Wegnener et al., 2011) and seizure activity (Starr & 
Starr, 1993).  
More interestingly, however, this study showed there was a developmental trend for 
excitability, in response to low concentrations of MK801, to decrease in controls and 
conversely remain elevated in epileptic animals. This supports studies which have 
demonstrated NMDA receptors are altered in epileptogenesis, either by changes in 
expression or by redistribution of receptors (Avanzini & Franceschetti, 2003; Dalby & Mody, 
2001; Morimoto et al., 2004; Yang et al., 2006). These findings further support the idea that 
epileptogenesis recapitulates earlier development (e.g. excitatory actions of GABA), when 
susceptibility to epileptogenesis is heightened (Cohen et al., 2003; Cossart et al., 2005). 
Moreover, Santucci and Raghavachari (2008) acknowledged during development NR2B 
receptors are displaced by NR2A receptors, which were suggested to be likely mediators of 
homeostatic stability of AMPA receptors. Additionally, the opening probabilities of NR2A and 
NR2B receptors were shown to be very different. Specifically, NR2B receptors opened for a 
172 
 
longer period of time but not as frequently in comparison to NR2A receptors. NR2B receptors 
are also sensitive to glutamate concentrations, reliably involved in LTP and are probably 
more extrasynaptically located following displacement by NR2A. As it has been suggested 
here and shown by others (Avanzini & Franceschetti, 2003; Dalby & Mody, 2001; Morimoto 
et al., 2004; Yang et al., 2006) the NR2B receptor does not undergo downregulation in 
epileptogenesis, therefore the enhanced excitability of networks and maintenance of seizures 
could be attributed to altered NR2B/NR2A ratio. Whether this alteration is a cause or effect of 
seizure activity remains to be established.  
As demonstrated by Siesjo et al. (1985) the induction of seizures reduces extracellular pH. 
This acidification was suggested to occur as a result of diffusion of lactic acid and fast 
transcellular Na+/H+ exchange. Dravid et al. (2007) showed NR2 subunits are differentially 
affected by pH changes. Lowering pH results in greater potency of (-) MK801 and (+) MK801 
at NNR2A receptors, thus more effectively reducing excitability. Changes in pH will affect the 
ionisation state of MK801 but protons can have a much larger effect as a multitude of amino 
acid residues, protein-associated lipids and carbohydrates can be ionised. It was suggested 
that this potency shift occurs as MK801 reacts to the ionisation state of the proton sensor. 
This was demonstrated through the increased potency of (-) MK801 and (+) MK801 at NR2A 
receptors in the presence of extracellular Zn2+ which increases proton affinity. This increased 
potency resembles activity at pH 6.9. On the other hand NR2B subunits are not associated 
with enhancements of MK801 potency, and the greater presence of these subunits receptors 
may enhance network excitability and LTP.  
Based on these studies it would be beneficial for future studies to confirm alterations of NR2 
subunits in this pilocarpine model of epilepsy. Others have suggested alterations in other 
NR2 subunits such as NR2A (Pratt et al., 1993) and NR2C (Bo et al., 2004) also occur as a 
result of epileptogenesis. It would be of further interest to explore the placement of 
NR1/NR2B receptors on different types of neurons (pyramidal cells, interneurons, astrocytes, 
etc). Do NR1/NR2B receptors remain as equally distributed over the synapse, as in the 
immature state or are the congregated extrasynaptically? Does conductivity of these 
receptors deviate from normal physiology in the epileptic state? These are important 
questions which can help develop a theory of how excitability and LTP are altered in epileptic 
pathology to promote recurring seizures. 
To some extent some of these questions have begun to be explored. For example, Woodhall 
et al., (2001) demonstrated NR2B containing receptors are present presynaptically at 
excitatory synapses in layer V of the EC, but not at those in layer II of the EC. Additionally, 
Ca2+ entry was shown to be the mechanism underlying facilitation of glutamate release by 
presynaptic NMDA receptors. It would be of interest to conduct similar experiments in 
epileptic animals for comparison.  Moreover, Frasca et al. (2011) investigated changes in 
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NR2B subunit phosphorylation, membrane localisation and cellular expression during 
epileptogenesis in the hippocampus. Expression of NR2B was activated in astrocytes and 
was increased at extrasynaptic and presynaptic neuronal compartments via redistribution. It 
was proposed the increased presence of NR2B containing receptors at extrasynaptic sites 
may modulate synaptic transmission by increasing synchronisation through slow inward 
currents and increased expression at presynaptic sites may lead to increased glutamate 
release from neurons and consequently contribute to hyper-excitation via over-activation of 
post synaptic glutamate receptors. Finally, blockade of NR2B with ifenprodil during 
epileptogenesis significantly reduced pyramidal cell loss in the hippocampus. Collectively 
these findings show NR2B changes during epileptogenesis contribute to enhanced 
excitotoxicity. Further supporting these findings, Muller et al. (2013) demonstrated chronic 
epilepsy leads to enhanced synaptic transmission and LTP, but unaltered LTD in the 
hippocampus through upregulation of NR2B but not NR2A. It was suggested that 
upregulation of NR2B may act as a compensatory mechanism that aims to reduce cognitive 
deterioration but actually leads to deleterious effects by yielding higher calcium influx. 
Interestingly in some cases NR2B up regulation has been associated with reduced 
hippocampal excitability (Gabriel et al., 2004; Kohling et al., 1995) thus further suggesting 
NR2B up regulation attempts to act as a form of seizure control. 
5.3.2 NO and the effects of NMDA receptor activation  
Having established NMDA activity is altered during epileptogenesis, it remained to be 
evaluated how subtle changes in NMDA activity can promote seizure activity. As suggested 
MK801 is a useful tool in this investigation given its variable activity at different NMDA 
subunit receptors and different concentrations. Whilst several studies have documented 
seizure inducing effects of MK801, the mechanisms through which this activity is initiated is 
largely unknown. However, suggestions as to the mechanistic action through which MK801 
induces IDs includes: selective inhibition of interneurons (Stafstrom et al., 1997), differences 
in anatomical localisations of NMDA receptor subtypes (Tang et al., 2006), and through NO 
signalling pathways. Star and Starr (1993) showed NO synthase inhibitor, L-NAME, was 
proconvulsant. However, NO itself has been shown to have opposing effects depending on 
its concentration and place of action. For example, NO can act to enhance inhibition (Nugent 
et al., 2009; Yang & Cox, 2007) and suppress inhibition (Makara et al., 2007) (see Ferraro & 
Sardo, 2004; Banach et al 2011 for reviews). Given the prominent neuromodulator role of NO 
in physiological and pathological conditions, the role of the NO pathway in mediating NMDA 
drive of inhibition during epileptogenesis was investigated further. 
Interestingly the current study showed that low concentration MK801 ID inducing effects 
were not mediated by NO, as pre-treatment of slices with the NO synthase inhibitor, 7-
nitraindazole, failed to significantly affect IDs. The most common inhibitors of NOS include: 
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N-nitro-L-arginine methyl ester (L-NAME), 7-NI, NG –nitro-L-arginine (NNA) and 1-[2-
(trifluoromethyl) phenyl] imidazole (TRIM). In support of the findings of this study, acute in 
vivo studies have shown 7-NI to be ineffective on altering seizure threshold in maximal 
electroshock (MES) models (25-50mg/kg) (Borowicz et al., 1997), amygdala kindled rats 
(100 mg/kg) (Borowicz et al., 2000a), PTZ models (30-50 mg/kg) (Borowicz et al., 2000b; 
Luszcki et al., 2007) and the KA model (50mg/kg) (Penix et al., 1994). However, when co-
administered with certain AEDs, 7-NI did show anticonvulsant effects.  
In contrast, other studies in the KA model have shown proconvulsant effects of 7-NI (20-60 
mg/kg) (Kirkby et al., 1996). Furthermore, other studies have shown proconvulsive effects of 
7-NI in the MES model (100-200 mg/kg) (88), PTZ model (50mg/kg) (Han et al., 2000), 
picrotoxin model (25-50 mg/kg) (Rajasekaran et al., 2003) and pilocarpine model (25-
100mg/kg) (Van Leeuwen et al., 1995). 
Moreover, in the pilocarpine model different NOS inhibitors have different effects. Starr and 
Starr (1993) showed L-NAME potentiated pilocarpine induced seizures, whereas Van 
Leeuwen et al. (1995) showed 7-NI exerted anticonvulsant effects. 7-NI has been identified 
as an inhibitor of nNOS (Babbedge et al., 1993; Moore et al., 1993), but could act as an 
inhibitor of constitutive NOS in vitro (Wolff & Gribin et al, 1994). L-NAME acts primarily on the 
eNOS isoform (Dwyer et al., 1991; Moncada et al., 1991) and is also an antagonist of 
muscarinic receptors (Buxton et al., 1993). It would be of interest to re-evaluate the role of 
the NO pathway in mediating NMDA drive of inhibition during epileptogenesis, with other 
NOS inhibitors, and even NO donors such as L-arginine as different results maybe yielded.  
5.3.3 The effects of MK801 on GABAergic activity during the latent period 
As this study showed, low dose MK801 ID inducing effects were not mediated by NO, the 
possibility that MK801 alters GABAergic activity was investigated. Bazelot et al. (2010) 
demonstrated interneurons, but not pyramidal cells, were capable of evoking field potentials 
at monosynaptic latencies. These inhibitory fields were shown to be GABAergic in nature and 
originated from postsynaptic sites as they were suppressed by low external Cl-. In a similar 
fashion, this study showed slow field events are inhibitory in nature. Field IPSPs are 
significantly reduced in SE slices during the early latent period in comparison to controls. 
These findings support numerous studies demonstrating attenuated inhibition in 
epileptogenesis (Gibbs et al., 1997; Kapur and Macdonald, 1997). MK801 did not exert any 
significant effects on field IPSPs in control or SE slices.  
GABA receptors undergo cell internalisation and insertion on a continual bases. 
Internalisation has been shown to occur via clathrin-dependent endocytosis (Connolly et al., 
1999; Kittler et al., 2000; Tehrani and Barnes, 1993, 1997), which can be initiated by PKC 
(Chapell et al., 1998) and BDNF (Cheng & Yeh, 2003; Jovanovic et al., 2004). Goodkin et al. 
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(2007) demonstrated GABAA receptor internalisation is accelerated by prolonged epileptiform 
activity resulting in reduced inhibition. Additionally, inhibition of neuronal activity reduced the 
rate of internalisation. Similar findings have been illustrated by Blair et al. (2004). Based on 
these results and other findings which have shown heightened activity of NMDA receptors 
during epileptogenesis, it was hypothesised that low concentrations of MK801 reduce 
inhibition, possibly through reduced internalisation, leading to increased interneuron 
inhibition, hence precipitating IDs. However, this study showed MK801 did not exert any 
differential effects on field IPSPs evoked by interneurons in controls and SE slices during the 
latent period, therefore this proposed MK801 ID inducing mechanisms is unlikely.  
5.3.4 Conclusion 
In conclusion, the current study demonstrated low concentrations of MK801 induced IDs in 
control and SE slices, emphasising previous demonstrations which show glutmatergic 
activation can have opposing effects depending on its concentration and place of action. 
Moreover, it was shown there was a developmental trend for excitability, in response to low 
concentrations of MK801, to decrease in controls and conversely remain elevated in epileptic 
animals. Again supporting previous evidence showing NMDA receptors are altered in 
epileptogenesis, either by changes in expression or by redistribution (Avanzini & 
Franceschetti, 2003; Dalby & Mody, 2001; Morimoto et al., 2004; Yang et al., 2006). Finally, 
this study investigated the NO and GABA mechanisms of MK801 ID inducing effects.  
Future studies further investigating how NR2 subunits are altered in epileptogenesis in terms 
of localisation on different neurons and electrophysiology would greatly improve our 
understanding of pathological LTP in epileptogenesis. Moreover, despite results suggesting 
NO and GABA are not involved in IDs induced by low concentrations of MK801, variable 
effects of different NOS inhibitors in the literature suggest other NOS inhibitors and even NO 
donors should be investigated throughout epileptogenesis in order to draw firmer 
conclusions.  
Moreover, whilst this study has focused on NMDA drive of inhibition, it has also been 
suggested that the interplay between different glutamate receptors (e.g. mGluRs, KARs and 
NMDA receptors), at different glutamate concentrations overall modulate inhibition (Belan & 
Kostyuk, 2002). The signalling mechanisms of different glutamate receptor subtypes may 
also interact. For example, it has been low concentrations of NO have been reported to 
activate BDNF (Xiong et al., 1999). NO also regulates neurotransmission of acetylcholine 
(Prast et al., 1998), noradrenaline, dopamine and serotonin (Feldman & Weidenfeld, 2004; 
Lorrain & Hull, 1993) in some brain areas. Evidently, there are a bewildering number of 
mechanistic possibilities with varying levels of complexity, which further need exploring in 
order to elucidate MK801 ID inducing effects in terms of excitatory regulation of inhibition 
during epileptogenesis. 
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6.1 Introduction 
A third of epilepsy patients are resistant to anti-epileptic drug (AED) treatment, leading to 
reduced quality of life, increased treatment costs and complexities surrounding polytherapy. 
It remains an important challenge of epilepsy research to understand the pathogenesis of 
TLE, in order to develop better treatments and alter the progression of the condition. The 
overall aim of this project was to explore dynamic network changes in the excitability and 
efficacy of AEDs in: acute models of epileptiform activity, chronic models of epileptogenesis 
and in resected human tissue, in vitro. Additionally, this project aimed to explore the 
underlying mechanisms of DRE. 
Several limitations of epilepsy research have prevented the development of better treatments 
and understanding of underlying mechanisms. Firstly, many acute and chronic models of 
epilepsy are extremely damaging and induce gross neuronal loss (e.g. via chemical insult or 
damaging slice preparatory methods), therefore do not accurately imitate the human 
condition (Modebadze et al., 2016; Sloviter & Bumanglag, 2013). Secondly, numerous AED 
screening models often only assess the effects of one AED, when the definition of DRE 
explicitly states DRE is a failure to respond to two or more drugs (Berg et al., 2001; Cowan, 
2002; Kwan & Brodie, 2006). Finally, studies aiming to explore the mechanisms behind 
epileptogenesis and DRE, have had a tendency to oversimplify complex pathology by 
proposing epilepsy is a mere imbalance between neuronal inhibition and excitation. This 
outlook has promoted the development of ‘me too’ drugs which do alter disease progression, 
which simply manage secondary effects by increasing inhibition or decreasing excitation. It is 
highly likely there are a variety of mechanisms underlying epileptogenesis and DRE, which 
are imperative to explore to improve prognosis for patients (Loscher & Schmidt, 2002; 
Margineanu & Klitgaard, 2009). 
6.2 The effects of brain slice preparations on excitability and efficacy of AEDs 
The initial investigation of this project exemplified the first of these limitations, by exploring 
the effects of two different brain slice preparations on the excitability and viability of layer II of 
the MEC. Standard prepared slices were much more excitable than sucrose prepared slices, 
and immunohistochemistry follow-up investigations suggested this enhanced excitability is 
due to a poorly preserved inhibitory network in standard slices in comparison to sucrose 
slices. Differences in oscillatory activity and intracellular properties have been previously 
demonstrated between standard and modified methods of brain slice preparations (Kuenzi et 
al., 2000; Modebadze, 2014; Prokic, 2012), but this is a novel demonstration of how brain 
slice preparation affects results when used in acute models of seizure-like events (SLEs). 
Additionally, this study showed there was little difference in response to combination AEDs in 
different brain slice preparations, but this could be due to increased latency to first seizure in 
sucrose prepared slices. LTP was suggested to play a role in the resistance to AEDs, as pre-
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treatment with the protein synthesis blocker, cycloheximide significantly increased latency to 
first seizure, and induction of IDs were almost completely blocked with the PKC inhibitor, 
GF109203X. These results suggest sucrose prepared slices better preserve the neuronal 
network in vitro, and serve as a better acute model for assessing AEDs and mechanisms of 
resistance.  
6.3 Excitability and efficacy of AEDs in the RISE model of epilepsy and in epileptic 
human tissue 
The next investigation of this project explored changes in neuronal network excitability and 
efficacy of combination AEDs during epileptogenesis (24hrs and 1, 5 and 12 weeks post 
status) in the refined Li-Pilocarpine (RISE) model and in resected tissue from human 
epileptic patients. Ictal-like discharges (IDs) were seen in significantly greater numbers of 
slices from RISE animals (range 45.05- 53.57 %) compared to age- matched controls (range 
18.75- 47.92 %). Additionally, RISE slices showed a consistently shorter latency to first 
seizure (LFS) across all time points (control LFS range 4801-8310s; RISE LFS range 2505-
3290 seconds). These findings demonstrated immediate network changes, as following SE 
induction immediate network excitability can be seen SE slices in comparison to controls. 
Investigations exploring the efficacy of different AED combinations during epileptogenesis 
showed that the TGB+CBZ combination was most effective in reducing measures of ictal 
activity whilst the combination of LTG+GPT was least effective. The resistance toward 
different drug combinations was also variable depending on the stage of epileptogenesis. 
Specifically, resistance to combination AEDs was the lowest at 5 weeks post SE. 
Nevertheless, resistance at this stage remained elevated towards CBZ+ZNS and LTG+GPT. 
Resistance remained between 20-33 % of slices at all stages of epileptogenesis. These 
findings suggest that vulnerable networks show underlying hyperexcitability even at stages 
when chronic behavioural seizures are not yet developed, and that the RISE model may 
provide insights into the variable efficacy of AEDs.  
It would be interest for future studies to further investigate antiepileptic potential of AEDs at 
different stages of epileptogenesis that do not work through classical mechanisms, such as 
LEV. On a related note, CBD has been shown to have antiepileptic potential, although the 
mechanism through which it has effect is debatable (Devinsky et al., 2014). Here, it was 
shown that although CBD is not the most effective AED it does become more efficient as 
epileptogenesis progresses. Developing a better understanding of CBD mechanisms, may 
provide better insights into underlying mechanisms of epilepsy. Furthermore, as evidenced in 
chapter 3 and by several others (Gabriel et al., 2004; Modebadze et al., 2016; Sloviter & 
Bumanglag, 2013), the level of damage imposed by models of epilepsy plays a vital 
consequential role in the outcomes and explanations of epilepsy research. Given the subtle 
network changes imposed by the RISE model in comparison it would be of interest to re-
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examine earlier in vivo studies by Turski et al. (1987) which explored protective effects of 
AEDs. 
Investigations of excitability in resected human tissue showed tissue from temporal lobe 
regions were more excitable in comparison to the motor cortex and frontal lobe regions. 
However, resected tissue required more excitation in order to induce IDs in comparison to 
epileptic rodent tissue. Preliminary investigations of AED efficacy illustrated all combination 
AEDs were effective in reducing IDs, with some resistance toward VPA and CBD. 
Discrepancies in excitability could be attributed to the likelihood that damage within human 
tissue is likely to be subtle, hence require more stimulation to induce ictal-like activity 
(Gabriel et al., 2004). One of the main criticisms of many kainate and pilocarpine models is 
that they are often severe and do not imitate human pathology, however the refined Li-
pilocarpine model used within our laboratory has been demonstrated to show subtle 
alterations in network dynamics, without significant loss of neuronal network function and 
therefore provides adequate imitations of the human condition in comparison to harsher 
models (Modebadze et al., 2016). Additionally, discrepancies in the excitability of rodent and 
human epileptic tissue could also be attributed to differences in the architecture of rodent and 
human brains. As Buzsaki (2002) discussed, the amplitude of LFPs in the hippocampus 
decrease from rodent to cat and from cat to primate as a result of changes in cellular spatial 
alignments caused by differences in brain size and the presence of gyri. Such circumstances 
are difficult to avoid, as the opportunity to investigate human resected tissue remains scarce, 
rodent models provide a reliable alternative to gain insight in pathological mechanisms. On 
the other hand, methodological advancements are continually being made and others have 
begun attempting to maximise the utility of valuable human tissue through organotypic 
cultures (see Jones et al., 2016 for a review), which could be of particular interest in 
investigating epileptic changes. 
6.4 The effects of the NO signalling pathway and GABA mediating latent period 
mechanistic alterations in epilepsy 
Studies conducted here on the RISE model of epilepsy clearly showed benefit of AEDs 
affecting GABAergic transmission. Much of epilepsy research has focused on the imbalance 
between excitation and inhibition leading to the disruption of the brain’s equilibrium and 
resulting in the epileptic seizures. This approach has only been partially fruitful, and this 
imbalance has been suggested to be a secondary effect of underlying pathological 
mechanisms (Loscher & Schmidt, 2002; Margineanu & Klitgaard, 2009). The final 
investigation of this project, explored how the NMDA drive of inhibition changes during 
epileptogenesis in comparison to controls. Secondly, the role of the NO pathway in mediating 
NMDA drive of inhibition during epileptogenesis was evaluated. Numerous studies have 
demonstrated glutamate-receptors modulate GABAergic inhibition through a variety of 
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mechanisms (Belan & Kostyuk, 2002). In particular, NMDA receptors have been extensively 
documented to be involved in seizure generation and LTP. Pre- and postsynaptic NMDA 
receptor activation of interneurons and pyramidal cells play an intricate role in regulating the 
excitation of neuronal networks. Many studies have also suggested NMDA receptors are 
altered significantly over the course of epileptogenesis. A prominent mechanism through 
which NMDA receptors exert control over excitability is via activation of NO signalling 
pathways which also has pro- and anticonvulsant action and has been proposed to play a 
fundamental role in the development of epileptogenesis.  
Low concentrations of MK801 (100-300nM) induced IDs in control and SE slices, thus 
supporting previous demonstrations which show glutamatergic activation can have opposing 
effects depending on its concentration and place of action. Moreover, it was shown there was 
a developmental trend for excitability, in response to low concentrations of MK801, to 
decrease in controls and conversely remain elevated in epileptic animals.  
During normal development NR2B receptors are displaced by NR2A receptors. These 
receptors have different characteristics as NR2B receptors remain open for longer but do not 
open as frequently as NR2A receptors. NR2B receptors are also sensitive to differences in 
glutamate concentrations and are more reliably involved in LTP (Santucci & Raghavachari, 
2008). Changes in pH that often occur with seizures (Siesjo et al., 1985) also affect the 
potency of MK801 at NR2 subunits differently. The potency of (+) MK801 is enhanced at 
NR2A but not NR2B receptors, hence NR2B receptors promote excitability (Dravid et al., 
2007). As it has been suggested in this study and shown by others (Avanzini & 
Franceschetti, 2003; Dalby & Mody, 2001; Morimoto et al., 2004; Yang et al., 2006) the 
NR2B receptor does not undergo downregulation in epileptogenesis, therefore the enhanced 
excitability of networks and maintenance of seizures could be attributed to altered 
NR2B/NR2A ratio.  
Further investigation into altered placement of NR2B receptors in relation to NR2A on 
different cells (e.g. pyramidal cells, interneurons and astrocytes) as well synaptic and 
extrasynaptic locations and altered conductivity of receptors in the epileptogenesis could aid 
the development of a theory explaining how excitability and LTP are altered in epileptic 
pathology to promote recurring seizures. To some extent, some studies have begun to 
explore these possibilities (Frasca et al., 2011; Muller et al., 2008; Woodhall et al., 2005). 
Finally, this study suggested NO and GABA are not involved in IDs induced by low 
concentrations of MK801. Pre-treatment of SE slices with the NOS inhibitor, 7-nitraindazole 
had no effect on IDs. Low concentrations of MK801 had no significant effects on the 
frequency and amplitude of field IPSPs in control and SE latent period slices.  However, 
variable effects of different NOS inhibitors in the literature suggest other NOS inhibitors and 
even NO donors should be investigated throughout epileptogenesis in order to draw firmer 
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conclusions. Future investigations could also further explore how interactions between 
different glutamate receptors affect inhibition (Belan & Kostyuk, 2001). Moreover, the 
signalling mechanisms of different glutamate receptor subtypes may also interact. For 
example, it has been low concentrations of NO have been reported to activate BDNF 
(Contestabile & Ciana, 2004; Xiong et al., 1999). NO also regulates neurotransmission of 
acetylcholine (Prast et al 1998), noradrenaline, dopamine and serotonin (Feldman & 
Weidenfeld, 2004; Lorrain & Hull, 1993) in some brain areas. These interactions should be 
further considered in order to elucidate MK801 ID inducing effects. 
6.5 Conclusion 
Overall, this project has demonstrated variable levels of damage imposed by brain slice 
preparatory methods influence the excitability and response to AEDs in acute models of 
seizures. Specifically, standard prepared slices are less resistant to AEDs in comparison to 
sucrose prepared slices, due to loss of inhibitory interneurons. Sucrose slice resistance 
towards AEDs in the 0[Mg]2+ aCSF model was suggested to occur as a result of LTP. 
Secondly, exploration of the excitability and efficacy of RISE model slices showed vulnerable 
networks show underlying hyperexcitability even at stages when chronic behavioural 
seizures are not yet developed, and that the RISE model may provide insights into the 
variable efficacy of AEDs. The RISE model was also an appropriate tool for comparative 
human tissue investigations. Finally, enhanced excitability with application of low 
concentration MK801 (100-300 nM) during the latent period, confirmed the importance of 
NMDA receptor changes during epileptogenesis. This was not mediated by the NO signalling 
pathway or changes in GABA. The future of epilepsy research would benefit in terms of the 
reliability of findings and explanations of epileptogenesis by using conservative acute and 
chronic models. Finally, further exploration of how pathological LTP effects inhibition could 
provide useful insights into the disease progression. 
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Appendix 3 
Raw data of the effects of AEDs on the frequency of IDs in 3 brain slice preparations presented in figure 3-8. 
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Appendix 4 
Raw data of the effects of AEDs on the IEIs between IDs in 3 brain slice preparations presented in figure 3-9. 
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Appendix 5 
Raw data of the effects of AEDs on the duration IDs in 3 brain slice preparations presented in figure 3-10. 
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Appendix 6 
Power of IDs at SW frequency  
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Power of IDs at delta frequency 
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Power of IDs at theta frequency 
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Power of IDs at beta frequency 
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Power of IDs at gamma frequency 
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Appendix 7 
Raw data of the effects of AEDs on IEIs during epileptogenesis represented in figure 4-4.
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